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Abstract
Anecdotal evidence indicated vaccine coverage disparities among foster-care (FCA) and
natural-home adolescents (NHA). Arkansas laws require 5 vaccines for school entry
(FVSE) to prevent 9 common childhood diseases. The study problem was that Pulaski
County, Arkansas adolescent birth cohort (PCABC) immunization rates were low
compared to U.S. adolescents for these FVSE. This study examined the extent to which
(1) PCABC immunization rates were significantly different from those estimated for U.S.
adolescents in 2006–2008, (2) NHA and FCA immunization rates were different in 2003–
2008; (3) sociodemographic variables mediate associations between home of residence
(HOR), NHA or FCA, and up to date (UTD) status for FVSE; and (4) vaccination game
theory (VGT) estimated deaths differ between individual-equilibrium and group-optimum
behaviors. The methodologies applied were direct standardization, χ2, multiple logistic
regressions, and VGT to analyze PCABC retrospective secondary data from the Arkansas
immunization registry. The results revealed that U.S. adjusted UTD coverage rates for
Hepatitis B, measles-mumps-rubella, and varicella were greater than those for PCABC.
Race-adjusted FCA immunization rates were 120% higher than for NHA. Race mediated
the association between HOR and UTD FVSE status, and African Americans had 80%
greater odds of being UTD with FVSE compared to Caucasians. Group-optimum
behavior was associated with fewer estimated deaths than individual equilibrium; thus, it
is protective against disease outbreaks. Positive social change may occur among the
PCABC when healthcare providers include these results in communications with parents
at FCA and NHA community health clinics. Parental vaccine acceptance for their
children may increase vaccinations and improve PCABC health and wellness.
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1
Chapter 1: Introduction to the Study
Introduction
This dissertation examined the association between adolescent home of residence
(HOR) and vaccination coverage uptake among the 1990 birth cohort in Pulaski County,
Arkansas (PCA). In this study, adolescent vaccination behavior and disparity in vaccine
coverage uptake were important and significant links in the resurgence and outbreaks of
previously controlled or eradicated childhood vaccine-preventable diseases (VPDs;
Centers for Disease Control and Prevention [CDC], 1999b; Immunization Action
Coalition [IAC], 2012). Immunization rates for adolescents aged 13 to 19 years were low
compared to childhood and adult immunization rates (CDC, 2008a; Mahon, Shea,
Dougherty, & Loughlin, 2008). Adolescent vaccine coverage uptakes were also below
coverage levels for those vaccines administered routinely in childhood (CDC, 2010a;
IAC, 2011). I used vaccination game theory (VGT) to further explore and identify risk
factors that influenced the five school-entry vaccine coverage uptakes among the 1990
birth cohort in PCA.
The five vaccines for school entry (FVSE) examined in this dissertation are
tetanus-diphtheria/tetanus-diphtheria-acellular pertussis (Td/Tdap), hepatitis B (Hep B),
measles-mumps-rubella (MMR), poliomyelitis (OPV/IPV), and varicella (VAR,
chickenpox). FVSE in Arkansas are required and mandated by Arkansas law (Arkansas
Department of Health [ADH], 2008; Jackson, 1969). The Arkansas immunization registry
(AIR) is the legal repository for reporting every administered vaccine from birth to age
22 years in Arkansas (ADH, 1995). Several counties in Arkansas reported that adolescent
vaccine-coverage levels, especially for the FVSE, tended to be lower than the national

2
average (Safi et al., 2012). For example, PCA evidence showed that adolescent vaccinecoverage levels for FVSE were lower than the national average. It was unclear whether
coverage levels were lower among certain groups of adolescents or whether they were
lower among all age groups.
Differences emerged in vaccine coverage among adolescents in previous studies.
For example, evidence suggested that children raised in nonparental-home settings were
less likely to be up-to-date (UTD) on their preventive healthcare services compared to
children in their natural home (Chu, Barker, & Smith, 2004; Darden, Gustafson, Nietert,
& Jacobson, 2011). Immunization coverage is one preventive-health service that differed
between foster-care and natural-home children (Chu et al., 2004; Darden et al., 2011).
This dissertation further examined the vaccine UTD status of adolescents in the 1990
PCA birth cohort from 1990 to 2008.
Increased numbers of cases of vaccine-preventable disease among adolescents in
Arkansas were a public health burden and concern. VPD outbreaks and resurgences in
Arkansas aligned with underimmunization and low-immunization coverage (Haselow,
2014). These VPD outbreaks among adolescents continued to increase in several counties
in Arkansas between 2012 and 2014 including Pulaski, Faulkner, Lonoke, Saline, and
White Counties (Haselow, 2014). In 2012, 248 pertussis cases emerged compared to 467
pertussis cases in 2013. Similarly, 237 VAR cases emerged in 2012 compared to 249
VAR cases in 2013 (Haselow, 2014). Thus, given the resurgence of previously controlled
(Chiappini, Stival, Galli, & Martino, 2013) or eradicated childhood diseases, it is
important to examine whether vaccination coverage levels for the FVSE are at or below
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coverage levels in PCA between two groups of adolescents: natural-home adolescents
(NHAs) and foster-care adolescents (FCAs).
This dissertation has five major sections. The first section includes the
background, purpose, significance, assumptions, delimitations, and social change
implications of this dissertation. The second section is the literature review, which
describes evidence from recent research studies on adolescent immunization coverage
and factors that influenced vaccine-coverage levels. The focus in Chapter 3 is the
dissertation methodology, whereas Chapter 4 presents data analysis and results. Finally,
Chapter 5 of this dissertation presents the implications of the findings as well as
recommendations.
Background
Measles-, mumps-, pertussis-, and VAR-outbreak resurgences continue to occur
every year in the United States (CDC, 1998a; 2011a, 2011d, 2012g, 2015; Cherry, 2013;
Gould et al., 2009; L. E. Lee et al., 2008; Lopez et al., 2006; Vitek, Aduddell, Brinton,
Hoffman, & Redd, 1999; Wheeler, 2012). Counties in the southern portion of the United
States have disproportionally high rates of VPD resurgence. Outbreaks of VPD
negatively impacted public health departments’ resources and contributed to societal
burdens (California Department of Public Health Immunization Branch, 2012; Wheeler et
al., 2004). Examples of societal burdens include economic stress from lost work
productivity, school absenteeism, hospitalization, and outbreak-investigation resources
and costs (Gould et al., 2009; Parker et al., 2006; Safi et al., 2012; Thompson et al., 2007;
Wheeler et al., 2004).
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Adolescent immunization rates are appropriate measures of societal burdens
(Byrd, Santibanez, & Chaves, 2011; Safi et al., 2012; Thompson et al., 2007). These
metrics emerge through declining shifts in public trust, parental attitudes toward
immunizations, and resurgence of VPD (Atwell et al., 2013; Darden et al., 2013; Dorell,
Jain, & Yankey, 2011). Although vaccines have contributed to an overall decline in
morbidity and mortality in society (CDC, 1998b, 1999b, 2007a), immunization rates
among adolescents in PCA are consistently below nationally established immunization
indicators (IAC, 2010; U.S. Department of Health and Human Services [USDHHS],
2010c).
The 1990 birth cohort PCA study determined differences among NHA and FCA
immunization rates for FVSE. Arkansas immunization laws (AILs) require adolescents to
complete all dose series of FVSE prior to age 18 years or before completing high school
(ADH, 1993, 2004a; Bugenske, Stokley, Kennedy, & Dorell, 2012). Evidence from peerreviewed research indicated that adolescents in their natural-home environments are more
likely to be UTD on their vaccination status compared to adolescents in foster care (Chu
et al., 2004; Darden et al., 2011). Thus, in Arkansas, where universal vaccination
coverage averaged lower than national coverage (CDC, 2011d), it was important to
determine whether disparities in vaccination coverage existed between NHA and FCA
children.
The importance of calculated differences in immunization rates between the two
groups established evidence for school-entry immunization-focused compliance
interventions. Access to health care, insurance status (Smith, Stevenson, & Chu, 2006),
immunization fragmentation of services, multiple providers, and sociodemographic
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factors contributed to differences that affected immunization coverage in both groups
(Smith, Singleton, & National Center for Immunization and Respiratory Diseases, 2011).
I calculated immunization rates for each group and compared results to identify any
differences in FVSE immunization rates and UTD status between NHA and FCA among
adolescents in PCA.
Arkansas Department of Health (ADH) and Advisory Committee on
Immunization Practices (ACIP) criteria established cohort immunization-coverage rates
for NHA and FCA. The Arkansas Department of Human Services (ADHS) required
immunization for all children in foster care as part of FCA-mandated medical care under
Medicaid regulations (ADHS, 2007, 2013). The criteria used to determine the percentage
of adolescents with complete vaccination UTD status for FVSE were based on Arkansas
Adolescent Immunization Rules and Regulations (see Appendix A, Table A1). Finally, I
compared the calculated immunization rates for the 1990 birth cohort for the FVSE to
U.S. national adjusted adolescent immunization rates for the same FVSE.
Purpose
This quantitative study had three main purposes. First was to examine differences
in vaccine coverage for FVSE between PCA and their corresponding birth cohort in the
United States. The second purpose was to examine differences in adolescent vaccine
coverage for FVSE between NHA and FCA. Third, I calculated the costs and risks
associated with vaccine payoff for the FVSE for individual and group behavior choices
for the 1990 birth cohort, modeled on VGT (Bauch & Earn, 2004). This study was one of
the few studies focused exclusively on an FCA and NHA birth cohort in PCA adolescent
immunization rates.
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Parental attitudes, environmental factors, social distancing, and clinical reasons
emerged as risk factors that adversely impacted immunization rates in this study. Parental
attitudes (Omer, Richards, Ward, & Bednarczyk, 2012; Opel et al., 2013) and clinical
reasons arose for adolescent disease prevention (CDC, 2009a). Adolescent immunization
behaviors related to social distancing (Reluga, 2010; Sawyer, Carbone, Searle, &
Robinson, 2007). Social-congregating impacted resurgence of VPDs including pertussis
(Wheeler et al., 2004) and VAR (Gould et al., 2009) in Arkansas. Understanding
immunization rates in a cohort supported compliance strategies to achieve 90% protective
coverage in herd immunity (CDC, 2009b; McElligott et al., 2012). It was important to
establish evidence to increase or maintain immunization rates required by Arkansas law
in compliance with public health and safety.
Arkansas vaccination-compliance expectation was that school administrators and
school nurses would gain an understanding of the magnitude of adolescent immunizationrate disparity in PCA. I analyzed 1990 birth cohort records in the Arkansas immunization
registry database (AIRD) quantitatively and established differences among the 1990
cohort immunization-rates uptake coverage and UTD status. The study design focused on
FVSE disparities among adolescents based on HOR—NHA and FCA—gender, race, and
ethnicity in the 1990 birth cohort for PCA. The positive social impact of improved
immunization coverage and UTD status were increased life expectancy (CDC, 1999c)
and reduced burden of hospitalization, disability, and deaths from VPD outbreak and
resurgence (Cooper, Larson, & Katz, 2008).
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Significance
The significance of this study was the ability to examine and establish differences
in adolescent vaccination-coverage level between two groups of adolescents—NHA and
FCA—living in PCA. Second, the study predicted estimated risks in payoff deaths
associated with vaccine behavior among NHAs and FCAs in the 1990 birth cohort in
PCA. Given evidence that vaccine coverage levels tend to be higher among NHAs
compared to FCAs (Smith, Santoli, Chu, Ochoa, & Rodewald, 2005), it was important to
examine whether this disparity also existed in PCA. Further analysis also explained
whether HOR was a driving force behind disparities in adolescent vaccine-coverage
levels for FVSE in PCA.
The importance of examining disparities in vaccination coverage between NHAs
and FCAs relates to primary prevention and the benefits of improved childhood and
adolescent wellness (CDC, 1999d, 1999g; Shefer et al., 1999; USDHHS, 2009).
Improvements in immunization coverage between NHAs and FCAs helps maintain good
health, extend life expectancy, and reduce risk and exposure to VPDs. School
absenteeism and poor student performance align with disease outbreaks (Davis, King,
Moag, Cummings, & Magder, 2008). Immunization rate, vaccine coverage, and UTD
status are national health indicators and surveillance tools for community health (CDC,
2006a; USDHHS, 2010d). Immunization UTD status is a preventive health behavior
(Bauch, Galvani, & Earn, 2003). Being current on vaccines aligns with the conduct of
other clinical preventive services in a community (USDHHS, 2009), and helps measure
the robustness of a preventive clinical healthcare system (Rodewald et al., 1999).
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Immunization UTD status was the main outcome variable in this analysis to establish
immunization rates among the 1990 birth cohort in PCA.
Problem Statement
The research problem was that reported immunization rates and uptake coverage
for the routinely required FVSE among adolescents in PCA were persistently low
compared to the U.S. average (CDC, 2012e). For example, PCA immunization rates were
20–40% lower compared to the U.S. national average for adolescents (CDC, 2010a).
Why this difference existed was uncertain, especially because FVSE were mandatory in
PCA. However, one reason this difference existed was adolescents’ home setting.
Differences in home setting partially explained this disparity (Zhao & Luman, 2010) in
that preventive health services differed between adolescents who lived in the natural-care
setting and those in foster care.
This study examined vaccine-coverage disparities between NHAs and FCAs.
Vaccine-coverage disparities among adolescents aligned with fragmentation of
immunization services (Darden et al., 2011). Adolescents who lived in stable parentalcare environments and had a single medical home (Smith, Santoli, et al., 2005) had less
fragmentation in immunization services (Darden et al., 2011). High-risk adolescents, such
as FCAs, often resided in group-home environments. These high-risk adolescents had
multiple providers and multiple facility types for their immunization services (Darden et
al., 2011; Smith et al., 2011). Adolescent group homes included behavior-treatment
facilities, juvenile correctional facilities, incarcerated housed adolescents, homes for
persons experiencing homelessness, and institutionalized juveniles (Smith et al., 2011). In
this study, FCAs were preidentified among the 1990 birth cohort for PCA.
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I calculated and reported the 1990 birth cohort immunization rates for PCA in this
study. Since 2006, Arkansas adolescents’ reported immunization rates have been 15–20%
lower than U.S. national averages for FVSE (CDC, 2012e). Adolescent immunization
rates of 90% or greater were essential to reduce risk of diseases (Glanz et al., 2010;
Healthy People 2010, 2011; USDHHS, 2010c). Community immunity was maintained
through immunization rates greater than 90% uptake coverage, as established in Healthy
People 2020 (McCauley, Stokley, Stevenson, & Fishbein, 2008; USDHHS, 2010a). I
compared calculated immunization rates for the 1990 PCA birth cohort to Healthy People
2020 immunization standards to determine compliance or disparity.
Research Questions and Hypotheses
RQ1: Are the calculated 2006–2008 adolescent percent vaccination uptake (VCU)
rates for FVSE among the 1990 birth cohort in PCA (PCABC) significantly
different from the reported FVSE 2006–2008 U.S. national adolescent estimated
immunization rates?
Ho1: There is no difference between the 2006–2008 PCABC calculated
percent VCU for the FVSE and the reported 2006–2008 U.S. adolescent
national immunization teen (NIS-Teen) estimated percent VCU for the FVSE.
Ha1: There is a difference between the 2006–2008 PCABC calculated percent
VCU for the FVSE and the reported 2006–2008 U.S. adolescent NIS-Teen
estimated percent VCU for the FVSE.
RQ2: Are there differences in percentage of FVSE vaccine coverage uptake
between NHA and FCA among adolescents in the 2003–2008 PCABC?
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Ho2: There is no significant difference in FVSE coverage uptake between the
HOR defined as NHA and FCA in the 2003–2008 PCABC.
Ha2: There is a significant difference in FVSE coverage uptake between the
HOR defined as NHA and FCA in the 2003–2008 PCABC.
RQ3: Is the association between HOR, defined as NHA and FCA, and UTD
FVSE coverage mediated through sociodemographic characteristics, which
include age, race, ethnicity, and gender in PCABC?
Ho3: The associations between HOR, defined as NHA or FCA, and UTD
FVSE in PCABC is not mediated through sociodemographic characteristics,
including age, race, ethnicity and gender.
Ha3: The associations between HOR, defined as NHA or FCA, and UTD
FVSE in PCABC is mediated through sociodemographic characteristics,
including age, race, ethnicity and gender.
RQ4: Will differences in individual vaccine payoff, measured by avoidance of
disease development as a result of vaccine receipt, affect group interest, measured
by deaths as a result of nonvaccination for the FVSE among the 1990 PCABC?
Ho4: Differences in individual vaccine payoff, measured by avoidance of
disease development as a result of vaccine receipt, will not affect group
interest, measured by deaths as a result of nonvaccination, for the FVSE
among the 1990 PCABC.
Ha4: Differences in individual vaccine payoff, measured by avoidance of
disease development as a result of vaccine receipt, will affect group interest,

11
measured by deaths as a result of nonvaccination, for the FVSE among the
1990 PCABC.
Theoretical Construct
Theory of games (TOG; von Neumann & Morgenstern, 1944), as used in this
study, enhanced understanding of how individual vaccine behavior affected the group
interest. I used the TOG to model individual decisions to receive vaccination and its
impact on the group interest. One feature of this vaccine-modeling construct was to
examine how the impact of vaccine uptake related to vaccine payoff deaths (Bauch et al.,
2003). The TOG (von Neumann & Morgenstern, 1944) and VGT application (Bauch et
al., 2003) offered important modeling for adolescent immunization actions, choices, or
behaviors to maximize or minimize payoffs (Jackson, Leyton-Brown, & Shoham, 2015).
The hallmark of the TOG (von Neumann & Morgenstern, 1944) and VGT application
(Bauch et al., 2003) was to use mathematical models to predict how an individual’s
decision to receive vaccine affected and compared to the outcome of group interests.
Appendix B contains tables with VGT equations and calculations. Immunization
acronyms are defined in Appendix C. In this study, 1990 PCABC immunization rates
predicted outcomes. In the 1990 birth cohort, mathematical models determined how
individuals’ self-interest decisions to vaccinate, called individual equilibrium in the
model, affected the group’s altruistic interest, and called group optimum. I calculated the
group interest as the cost of individuals who preemptively received vaccination and
measured the cost by the number of adolescents in the cohort who were expected to die
due to the failure of individuals to receive vaccination.
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Another important feature of the game-theory construct was its relationship to
community or herd immunity and the payoff from not receiving vaccination. If a
community had immunity as a population, then theoretically, the ability of that diseasecausing agent to cause disease diminished because the agent was no longer active or
present in the population (Baguelin et al., 2013). Community or herd immunity in a
community increased through population decisions to vaccinate (Barclay et al., 2014;
Domenech de Cellès, Riolo, Magpantay, Rohani, & King, 2014; Shim, Kochin, &
Galvani, 2010; Shim, Meyers, & Galvani, 2011), thereby improving disease prevention
and minimizing deaths associated with VPDs (Arinaminpathy et al., 2012; Blackwood,
Cummings, Broutin, Iamsirithaworn, & Rohani, 2013). Likewise, herd immunity could
impact an individual’s decision to receive vaccination. I examined this notion when I
applied the mathematical constructs in the data analysis derived from VGT.
Nature of the Study
This cross-sectional study used quantitative methods to examine differences in
adolescent vaccine coverage rates between NHAs and FCAs using the 1990 birth cohort
immunization records in PCA. Additionally, I modeled individual vaccine uptake
behaviors for the FVSE among NHAs and FCAs, and its impact on the group interest.
Definitions
The 1990 birth cohort defined all children born between January 1, 1990 and
December 31, 1990 in PCA. I subdivided this 1990 birth cohort into a control group,
NHA, and a research group, FCA. The NHAs were never under Arkansas child protective
services as wards of the State of Arkansas mandated by judicial court orders. FCAs were
wards of the State of Arkansas, mandated by judicial court orders until age 18. The age of
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18 years was a significant factor because this was the cut-off age for enrollment in fostercare services, graduation from high school, and adolescent status for immunization.
Age-appropriate vaccine status: The correct age in months or years at which a
specific vaccine must be administered (Dombkowski, Harrington, Hanauer, Kennedy, &
Clark, 2012; Schempf, Minkovitz, Strobino, & Guyer, 2007).
Arkansas immunization laws: Mandated age, grade, and specific types of vaccines
are defined in Table II of the Arkansas Immunization Rules and Regulations (AIRR)
established by Arkansas Board of Health (ADH, 2008).
Arkansas immunization registry (AIR): Mandated by AIL in 1995; AIR is the
legal repository for all reported and administered vaccines for all children in Arkansas
(Arkansas Legislative Branch [ALB], 1995a).
Five vaccines for school entry (FVSE): The FVSE were Td/Tdap, Hep B, MMR,
OPV/IPV, and VAR (ADH, 2008).
Foster-care adolescent (FCA): An adolescent up to age 18 years who does not
live in their natural or adoptive parents’ residence and is under court-ordered judicial
protective care, supported through ADHS control (ADHS, 2010).
Group optimum: The group optimum is the level of maximum vaccine coverage
that is best to protect the entire population against a VPD (Bauch et al., 2003).
Immunization disparity: Deficiency in a specific type and specific number of
doses for vaccines that fail to achieve 90% uptake of a routinely recommended vaccine
dose, established in Healthy People 2020 (USDHHS, 2010a).
Immunization rate: The proportion of vaccines in a dose series received by
children, as prescribed in ACIP immunization schedules (CDC, 2007b, 2012k).
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Individual equilibrium: Individual equilibrium focuses on maximizing selfinterest benefits from an outcome and minimizing the probability of the associated cost of
the outcome (Bauch & Earn, 2004; Bauch et al., 2003; von Neumann & Morgenstern,
1944).
Natural-home adolescent (NHA): Adolescents who live with their natural or
adoptive parents, have never been in child protective services, and attended public
schools from 1996 to 2008 in PCA (ADHS, 2010).
Payoffs: The benefit of receiving a vaccine, quantified by the number of deaths
prevented by vaccine receipt.
Routinely recommended vaccines: U.S. Food and Drug Administration licensed
vaccines recommended by ACIP (CDC, 1999c; CDC, 2007c).
Strategy: Strategies, which include vaccination, delayed vaccination, or no
vaccination, are deliberate choices, actions, behaviors, or decisions employed by
individuals or groups to achieve a desired outcome or payoff (Bauch et al., 2003; Chaves
et al., 2008; Meyer, Seward, Jumaan, & Wharton, 2000; Reluga & Galvani, 2011; Shim,
Chapman, & Galvani, 2010).
Up-to-date status (UTD): The current vaccination-series completion of actual
specific vaccine types and total number of doses in the series received at a given age and
calendar date. The UTD is important for vaccine-series next-dose administration, disease
exposure, and risk at time of an outbreak (Dombkowski, Lantz, & Freed, 2004b).
Vaccination status: The recommended specific vaccine type and total number of
doses received up to a particular given age (CDC, 2008b; Hinman, Orenstein, &
Schuchat, 2011).
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Assumptions
This study retained four assumptions based on Arkansas vaccine requirements:
•

Assumption 1: Each child received all age-appropriate vaccines, from birth to
age 18 years, and required vaccines during each school-grade milestone.
Children who received childhood doses could not have completed the vaccinedose series or received the booster dose. Adolescents refused vaccine and
immunization exemptions based on philosophical, religious, or personal
reasons (ADH, 2003; Arkansas State Board of Health, 2003).

•

Assumption 2: Students were 6 years old in the first grade in 1996 and
progressed regularly each year to the 12th grade. Further, Assumption 2
included that a fourth-grade student was 10 years old in 2000 and progressed
to seventh grade at the age of 13 in 2003.

•

Assumption 3: NHAs and FCAs progressed equally through similar public
school systems in PCA and graduated from high school in 2008.

•

Assumption 4: NHAs’ and FCAs’ school attendance data were collected by
October 15th each year from all school districts and systems in PCA. The
1990 cohort school-attendance data were reported annually to the Arkansas
Department of Education (ADE). For example, in 2002, PCA had 4,134
adolescents aged 12 in the sixth grade in all public schools. This study
examined the cohort as they progressed to the next grade until age 18 years as
a unit block (FCA enrollment appears in Appendix A, Table A5).
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Scope and Delimitations
The scope of this study was adolescent immunization status in a 1990 birth cohort
of all children born between January 1, 1990, and December 31, 1990, in PCA. The
study’s delimitation also includes all children who attended public schools from
kindergarten through 12th grade between 1996 and 2008 (ADE, 2009). Delimitations in
this study included those aged 13 to 18 years, defined as adolescence, the population size
of the study population, school attendance, parental control, and geography in PCA. I
subdivided the age of adolescents in the 1990 birth cohort into the control group, NHA,
and the study group, FCA. The delimitation focus was adolescents who were 13 years old
in 2003 and born in PCA. The focus followed each year for vaccines received and
reported to the AIR until age 18 years, in 2008 or upon graduation.
The study population size and study population denominator consisted of five
inclusion criteria in the 1990 birth cohort. These criteria were (a) FCAs enrolled under
ADHS control under judicial court orders; (b) NHAs who lived with their parents; (c)
types of vaccines, all five vaccines with number of doses with documented records in the
AIR; (d) attended public schools in PCA; and (e) in the geographic contiguous borders
and zip codes in PCA.
Limitations
AIR data contained several internal validity issues associated with many types of
errors and reporting of immunization information. I excluded incomplete or mismatched
records from the data analysis to minimize internal-validity limitations and unreliable
results. Duplicate doses of the same vaccine were not included in immunization-rate
calculations, based on the criteria delineated in Appendix A, Table A1. Incomplete
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transmission of immunization records during reporting to the registry are common
limitations in immunization-registry data (Stevenson et al., 2000). Electronic records and
hard-paper reporting systems have limitations in transmission, formatting, standardization
of documentation, and legibility of documents (CDC, 2000b; Stevenson et al., 2000).
The registry data was built from health-provider documented and reported
immunization histories of individually administered vaccines (CDC, 2001; Khare et al.,
2000). Consequently, the accuracy and completeness of the immunization histories and
eliminating significant errors in child’s name, date of birth, vaccine types, no data
reported, and overall duplicate records are important in calculating coverage estimates
(Khare et al., 2000). Early enrollment of children into the registry from birth, when Hep
B globulin was administered, enhances accuracy of the registry data. The CDC (2000c)
recommended early enrollment, within 2 months of birth for each newborn child.
PCA adolescent immunization-result generalizability is significant to the external
validity of this immunization study. Adolescent immunization results from this study are
generalized and limited to PCA, and did not include the entire Arkansas population or
other populations. Researchers and future users may draw inferences to influence policy,
awareness, knowledge, and social-marketing campaigns. However, my interpretations of
the results are applicable and specific to adolescents in PCA.
Social-Change Implication
The social-change implication relates to primary prevention of VPD among
adolescents (CDC, 1999c; Shefer et al., 1999). The social-change impact of
understanding adolescent immunization uptake is valuable in public health functions.
Improving immunization coverage among NHAs, FCAs, or other adolescents will
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enhance their quality of life and life expectancy (CDC, 1999c) and reduce frequency of
VPD outbreaks (Schaffer, Gillette, Hedberg, & Cieslak, 2006). The outcome of this study
may influence five societal levels of social change: individual, institutional,
organizational, community, and policy.
Parents and adolescents of PCA constitute the individual level and are the primary
target for social change. Because of results from this study, evidence of change in this
group includes increased immunization knowledge, awareness, and positive attitudes
toward immunization uptake. The second societal level likely to be impacted by findings
from this study is the institutional level, comprised of school nurses in public schools in
PCA whose focus is immunization compliance of FVSE. I include physicians and public
health agencies in the organizational level, as their health practices influence adolescent
behavior and access to immunization services. Community-level supports are cultural
norms, attitudes, and availability of professionals and organizations that provide
immunization services.
The final level that findings from this study impact is the policymaker level.
Policy-level change influences financing and eligibility criteria, as well as rules and
regulations associated with adolescent immunization coverage. Arkansas’ major policy
stakeholders include the Arkansas Departments of Education, Health, and Human
services. The specific role of these departments influences policy change.
Findings from this study potentially will benefit parents through increased
immunization awareness and will support compliance with school-entry laws. This
positive immunization chain effect could also benefit future populations through
increased herd or community immunity. Results from this study identified disparities
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among vaccines with low coverage among adolescents in the 1990 PCABC. The
identified immunization disparity data stimulated innovative communication methods in
the community to address parental vaccine safety and efficacy concerns in PCA.
Summary
Four research questions were cogent to examine whether disparities in FVSE
vaccination coverage existed among a birth cohort in the archival AIRD. The first
research question was pertinent to determine if a difference ensued between the 2006–
2008 PCABC calculated percent VCU for the FVSE and the reported 2006–2008 U.S.
adolescent NIS-Teen estimated percent VCU for the FVSE. In the second research
question, I examined if differences emerged in percentage of FVSE vaccine coverage
uptake between NHAs and FCAs in the 2003–2008 PCABC. Third, I examined if the
association between HOR, defined as NHA and FCA, and UTD FVSE coverage mediated
through the sociodemographic characteristics of age, race, ethnicity, and gender in
PCABC. With the fourth research question, I examined game-theory mathematical
models to determine if individuals’ decisions to receive vaccine for the FVSE affected
the group interest.
The social-change implications maintain or improve awareness and understanding
of FVSE vaccination coverage among NHAs and FCAs in PCA. Vaccines align with
benefits of improved childhood, adolescent wellness, and public health (CDC, 1999c;
Shefer et al., 1999). For this quantitative study, I used a cross-sectional study design,
analyzed archival AIRD, and examined disparities in vaccine coverage for FVSE among
NHAs and FCAs in PCA.
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The next section is the literature review in Chapter 2. The literature review
contributes detailed focus on published research on vaccination coverage, providing
information on how vaccinations influenced disease elimination, resurgence, outbreaks,
prevention, and control. The literature review further probes the theoretical basis for
relationships between immunization behavior and negative consequences of lowimmunization rates. The key sections in this literature review included the search
methods as well as the identification of gaps in the literature. Specific issues discussed in
the literature review that relate to gaps in the literature include the economic burden
associated with disease outbreaks, loss of workdays, school closings, and disability and
mortality related to VPD.
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Chapter 2: Literature Review
Introduction
Immunization rates among adolescents in Arkansas were disproportionately lower
than the U.S. national average for routinely recommended vaccines and FVSE required
for adolescents (ADH, 2014a; CDC, 2010d). The adolescent-vaccination-coverage uptake
was a significant component in this study. The purpose of this cross-sectional study was
to establish quantitative vaccine UTD status for the FVSE among the 1990 PCABC of
NHAs and FCAs. The literature review focused on peer-reviewed articles, textbooks, and
publications on the TOG, immunization rates, adolescent-vaccinations uptakes, laws,
disparities, disease outbreaks, and resurgence.
Literature-Search Strategy
I accessed and retrieved published research articles from physical library and
online databases. Peer-reviewed journals, reports, and bulletins from online databases
accounted for more than 90% of the information used in this study. Examples of these
databases included PubMed, Clinic Trials.gov, Cochran Library, Healthy People, The
Community Guide, World Health Organization (WHO), and Global Health. The search
strategy consisted of key words, databases, search engines, and retrieved articles from
more than 5,000 published articles dated during the 5 years between 2008 and 2013.
These key words included names of nine communicable and childhood diseases;
Diphtheria, hepatitis B, measles, mumps, pertussis, poliomyelitis, rubella, tetanus, and
varicella, vaccines, adolescents, immunization, vaccine rates, schedules, vaccine
preventable diseases, disease outbreaks, resurgence and prevention, foster care
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adolescents and health, natural home adolescents and health, school entry laws, vaccine
rules, regulations, adverse events, Pulaski County, Arkansas, and immunization registry.
The second search strategy of databases and search engines included the ALB,
ADH, CDC, WHO, and Pub-Med indexed publications. Searches included public and
private universities, the legislature, professional associations, and industry websites using
immunization categories such as articles, reports, policies, press releases, and bulletins.
Other databases were accessible through their websites with registered authorization, user
identification, and a password. The ALB (2012) website yielded legislative reports and
34 immunization laws enacted between 1987 and 2009. The third search strategy required
physical access to documents at the ALB library and Arkansas State Board of Health
archives. Immunization laws enacted before 1987 were not initially available on the ALB
website. I physically accessed and retrieved pre-1987 immunization laws from bounded
legislative historic archives at the Arkansas State Capitol in Little Rock, Arkansas. These
pre-1987 immunization laws were significant foundations for AILs that affected 1990
birth-cohort-immunization rates. Arkansas immunization laws relevant to this study were
enacted between 1987 and 2009 and are listed in Appendix A., Table A2. I also
physically accessed and retrieved other Arkansas historic immunizations reports and
State Board of Health documents archived at ADH headquarters in Little Rock, Arkansas.
Archived records from Arkansas Board of Health meetings provided important
information on childhood- and adolescent immunization rates.
Background
School-entry vaccine mandates were one of the six key areas of concern identified
in 2008 National Vaccine Advisory Committee (NVAC) recommendations. NVAC
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(2008) recommendations addressed challenges in adolescent immunization.
Immunization rates among adolescents in the 1990 PCABC were lower compared to
adolescents nationally (ADH, 2012c; CDC, 2010c). The major focus areas within the
scope of this study included coverage uptake rate and UTD status among adolescents in
the 1990 PCABC and FVSE. Immunization barriers, behavior risk factors, parental
knowledge, and access to vaccines were challenges that contributed to low adolescentvaccine-coverage uptake (CDC, 2005b; Washington State Department of Health, 2012).
Similar immunization challenges persisted among adolescents in the 1990 PCABC, in
spite of 2008 NVAC (2009) recommendations and the 1977 National Childhood
Immunization Initiative. These challenges were in five key areas: venues for vaccineadministration consent for immunization, communication, financing, surveillance, and
the potential for school mandates (CDC, 2011f; NVAC, 2008, 2014; Stokley et al., 2009).
The U.S. national goal for minimum vaccination achievement has been 90% for all
children since 1977 (CDC, 1982, 2009d). School-entry vaccine mandates contributed and
aligned with increased high childhood-vaccination-coverage rates and low rates of VPDs
(Hinman, Orenstein, Williamson, & Darrington, 2002; Orenstein & Hinman, 1999).
Vaccine contributions and achievements of public health, concepts of routine vaccination
for children (Hamborsky, Kroger, & Wolfe, 2015), and continued outbreaks of VPD in
recent years accounted for three significant and relevant challenge areas related to
adolescent immunization coverage uptake.
Vaccination and Public Achievements
Vaccinations were one of the 10 greatest public health achievements during the
20th century and the first decade of the 21st century (CDC, 1999h, 2011k). Vaccines
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were fundamental cornerstones in preventing mortality from disease outbreaks (Schaffer
et al., 2006), and increasing life expectancy (CDC, 1999c). During the 1950s, infantmortality rates improved in the United States, decreasing from 29.2 deaths per 1,000 live
births to 7.1 deaths per 1,000 live births (CDC, 1999c). For example, in 1950, 33,300
polio cases and 1,904 deaths ensued, compared to six cases and no deaths in 1990 (CDC,
2011e). Vaccine-uptake coverage increased during the 20th century, eradicating smallpox
in 1971 in the United States, and globally in 1980 (IAC, 2012). The trend in increased
immunization rates among children and adolescents during the 20th century contributed
to elimination of four major childhood diseases: measles (CDC, 2009e, 2009f; WHO,
2013), neonatal tetanus, OPV/IPV (CDC, 200g), and rubella congenital syndrome (CDC,
1999e; USDHHS, 2010e).
Routine Vaccination for Children
Childhood vaccines were cost effective in disease prevention, reducing the burden
of morbidity (ADH, 2014b), infant mortalities, and disabilities associated with diseases
such as poliomyelitis (CDC, 2009c; Salk, 1955a). Public support for vaccination
increased during the 1950s when VPD outbreaks (Santoli et al., 2004; Washington State
Department of Health, 2012) and epidemics caused high rates of infant mortality (CDC,
1999e). Since 1967, AILs required vaccination against these highly communicable
diseases including diphtheria, measles, pertussis, poliomyelitis, varicella, and more than
nine childhood diseases from birth to age 22 years (ALB, 1967; CDC, 2010e, 2011g;
Marin, Guris, Chaves, Schmid, S., & Seward, 2007; Vitek et al., 1999). School-entry
regulations and immunization laws in Arkansas intended to increase immunization rates
based on UTD requirements, shown in AIRR Table II (ADH, 2008).
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Vaccine compliance for school-entry requirements prevented diseases and
protected all children in daycare facilities, kindergarten to 12th grade, and college
students (ADH, 1997, 2008). Similarly, immunization was a national health objective
established by Healthy People 2000, 2010, and 2020 to increase childhood and adolescent
immunization rates to reach the 90% threshold indicator (USDHHS, 2012). Furthermore,
the ACIP annually updated immunization recommendations (Broder et al., 2006; CDC,
1991a, 2005a, 2006c, 2007c, 2008b) and schedules, ensured adequate UTD, increased
immunization rates, standardized national immunization policies, and encouraged
practices to prevent disease resurgence and outbreaks (CDC, 1991b, 1998c, 1999f,
2011h, 2013).
Access to Immunization
Given the potential disparity in vaccine coverage between NHAs and FCAs, it
was important to examine access to immunization as a potential contributor to this
disparity. The individual decision to vaccinate relates to self-interest (Galvani, Reluga, &
Chapman, 2007; Ibuka, Li, Vietri, Chapman, & Galvani, 2014), actions of others (Hilbe,
Nowak, & Sigmund, 2013; Meszaros et al., 1996), risk of infections, the perceived costs
and benefits (Basu, Chapman, & Galvani, 2008), ethnicity and language preference
(Haviland, Elliott,, & Hambarsoomian, 2011), and primary immunization access. Parents
of adolescents who decided to vaccinate experienced lack of access to vaccines as
another contributing immunization-barrier factor.
The Vaccine for Children’s (VFC) program was a federal program intended to
improve access to immunization for all eligible children (CDC, 1998d, 2011o, 2012c,
2012m; Lee et al., 2007). The VFC improved child and adolescent UTD status based on
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ACIP recommendations, access to vaccines, and medical home (Smith, Santoli, et al.,
2005) for vaccine. ACIP recommended children’s UTD coverage (2012a) include more
than four doses of Td/Tdap (Broder et al., 2006), more than three doses of OPV/IPV,
more than one dose of MMR, more than three doses of haemophilus influenza type b
(Hib), and more than three doses of Hep B (CDC, 2005a; Salk, 1955b; Salmon et al.,
2009). Adolescents required two doses of VAR vaccine for school enrollment to improve
waned immunity and reduce disease outbreaks (CDC, 2005b; Lopez et al., 2006).
Barriers to Immunization
Immunization barriers offered opportunities and challenges to vaccinated
adolescents. Barriers included risk factors that contributed to potential challenges of lowimmunization rates (Kaplan, 2010), and low coverage for the FVSE among children and
adolescents. I based adolescent immunization barriers described in this study on the TOG
construct (von Neumann & Morgenstern, 1944), and how decisions to vaccinate
influenced coverage uptake of individuals and groups (Bauch & Earn, 2004). TOG
constructs compared immunization costs and benefits related to self-interest, minimized
costs, and group-interest maximized-payoffs deaths. These constructs were central to the
comprehension of other important barriers to immunization. The seven important barriers
to immunization from the literature review comprised adolescent risky behaviors;
parental factors; physicians; healthcare providers; clinicians; cultural and societal
practices; and finance, policy, regulations, and laws.
The great proportion of immunization barriers aligned with parental concerns.
Parental immunization concerns (Daley et al., 2010; Dorell et al., 2011) and
immunization barriers contributed to low immunization rates. Some studies listed these
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four categories among other parental vaccine concerns: safety, effectiveness, adverse
events, and efficacy (CDC, 2012f; Baxter et al., 2013; Freed, Clark, Butchart, Singer, &
Davis, 2011; Hall & Jolley, 2011; Offit et al., 2002; Slade et al., 2009). Two studies listed
knowledge and awareness as parental concerns (Caskey, Lindau, & Alexander, 2009;
Shapiro et al., 2011) and two studies defined attitudes and beliefs as parental concerns
(Gust, Darling, Kennedy, & Schwartz, 2008; Kennedy, Basket, & Sheedy, 2011a). Some
studies about parental concerns and vaccinations provided information based on medical,
philosophical, and religious beliefs (Klein et al., 2012; Safi et al., 2012; Thompson et al.,
2007). Vaccine exemptions for FVSE contributed to suboptimal and low immunization
coverage (Diekema et al., 2005; Imdad et al., 2013). For example, high religiousexemption counties had 33.1 per 100,000 pertussis incidence compared to 20.1 per
100,000 pertussis incidences, p < .001, in low religious-exemption counties (Imdad et al.,
2013). Vaccines are safe, effective, and efficacious (CDC, 2012i, Civen et al., 2008;
Lopez et al., 2006; Seward, Marin, & Vázquez, 2008; Shapiro et al., 2011). However,
parental perceptions and attitudes were risk factors associated with immunization barriers
such as vaccine hesitancy (Salmon, Dudley, Glanz, & Omer, 2015), vaccine refusal to
immunize children against VPD such as pertussis (Civen et al., 2008; Dorell, Yankey, &
Strasser, 2011; Dredze, Broniatowski, Smith, & Hilyard, 2015; Lopez et al., 2006;
Seward et al., 2008; Shapiro et al., 2011). Children of parents who refused to immunize
their children had a 23-fold risk of contracting pertussis compared to children of parents
who had them vaccinated (Glanz et al., 2010).
Five clinician-immunization-barrier risk factors were clinician decision support
(Fiks et al., 2013; Hughes, Jones, Feemster, & Fiks, 2011; Szilagyi et al., 2006), clinical
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practice (Fiks et al., 2013; Rand et al., 2011a; Rosenthal et al., 2008; Vadaparampil et al.,
2011), missed opportunities (Ladak, Gjelsvik, Feller, Rosenthal, & Montague, 2012; Lee
et al., 2008), attitudes (M. M. Davis et al., 2006; Humiston et al., 2009), and electronic
health records (EHR; Fiks et al., 2012; Shojania et al., 2009; Suh et al., 2012). Cliniciandecision support systems contributed to increased vaccination coverage through audit of
health records in physicians’ practices, education materials (vaccine information
statements), and physician education. The clinician-decision support system enhanced
clinicians’ justifications to recommend adolescent vaccines during wellness visits (Fiks et
al., 2013). EHRs effectively improved immunization rates in clinical practice, alerting
physicians, families, and adolescents about their next visit and vaccine UTD status. For
example, EHR immunization recall/reminder systems encouraged parents and
adolescents to receive recommended vaccines during their next wellness visit (Smith,
Lindley, Shefer, & Rodewald, 2009; Suh et al., 2012). Physician EHR systems alerted
providers when the next adolescent vaccine dose was due (CDC, 2012j; Fiks et al., 2013).
EHR systems also provided current clinical history evidence and minimized any lost
opportunity to vaccinate adolescents in their medical homes or nonpediatric clinics,
school athletic health physicals, and gynecological visits (Shojania et al., 2009; Smith,
Jain, Stevenson, Männikkö, & Molina, 2009).
Vaccinated adolescents reduced morbidity and mortality from VPD to protective
levels. For example, morbidity from VAR reported cases in PCA declined to 11 cases in
2010, compared to 46 VAR cases in 2006 (Lopez et al., 2006) before the 2007 ACIP
second-dose policy. The initial varicella vaccine one dose was licensed and introduced in
1995 (CDC, 1999a). In PCA in 2007, of 808 VAR cases among all ages, the county saw
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172 cases (21.3%) among children and adolescents 10–18 years (ADH, 2012a). In 2001,
PCA had 194 pertussis cases compared to 21 pertussis cases in 2011 in PCA (ADH,
2012a).
Barriers to immunization were significant risk factors that threatened public
health and safety. These significant risk factors aligned with low immunization rates
among adolescents (Dorell, Yankey, Kennedy, & Stokley, 2013). Since 2006, public
school-entry vaccines required for adolescents in seventh grade included a Hep B series
of three doses; an MMR two-dose series; a one-dose booster Tdap, and a two-dose series
of VAR. Disease resurgences and outbreaks aligned with low immunization rates,
unvaccinated adolescents, and imports of VPD (Glanz et al., 2010). Vaccination policies
exempted adolescents from private or parochial schools (ADH, 2011b).
Vaccine Preventable Disease Outbreaks in Recent Years
In Arkansas, VPD resurgence and outbreaks had increased from 2005 to 2012
(CDC, 2012h). For example, U.S. reported resurgence and outbreaks included measles
(ADH, 2012b; Lopez et al., 2006; Vitek et al., 1999; J. G. Wheeler, 2012), mumps (ADH,
2006; CDC, 2006c, 2010f), pertussis (ADH, 2012a; Wheeler et al., 2004), and VAR
(Gould et al., 2009). These resurgences and outbreaks were attributable to unvaccinated
adolescents, vaccine hesitancy (Salmon et al., 2015), low immunizations, and disease
imports from endemic countries (CDC, 2011c).
During the last 2 decades of the 20th century, VPD reported cases declined to
historically low numbers for diphtheria, measles, mumps (CDC,1998c;WHO, 2013),
pertussis( CDC, 2010g, 2011b), poliomyelitis (paralytic), rubella, VAR, and tetanus
(CDC, 2006d, 2011j; Seward et al., 2008; WHO, 2011a, 2011b). However, significant
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barriers to immunization contributed to low adolescent immunization rates (Klein et al.,
2012; Stokley et al., 2011). These new immunization barriers included religious
exemptions (Imdad et al., 2013), immunization laws and policies (Safi et al., 2012;
Thompson et al., 2007), parental attitudes and knowledge (Gust et al., 2008), and vaccine
adverse events (Institute of Medicine, 2011a, 2011b).
Significance of Immunization Barriers and Solutions
VPD outbreaks resulted from immunization barriers. Disease outbreaks associated
with unvaccinated persons increased in 2012 for all reported cases of Hep B (10 cases),
measles (four cases Arkansas wide), pertussis (63 cases), and VAR (14 cases) in PCA
(ADH, 2014a). Measles was an example of a disease eliminated in the United States in
2000 (CDC, 2006b, 2011g). Other VPDs, including mumps, rubella, and VAR, were
controlled to less than 200 cases per year (CDC, 2012b). Examples of the significance of
immunization barriers were VPD outbreaks and resurgences that occurred annually
during the past 5 years (CDC, 2012d). The largest VPD outbreaks and immunization
barrier to date (2016) was the pertussis epidemic outbreak in Washington State in 2012
(CDC, 2012g). This pertussis outbreak aligned with unvaccinated children and high
immunization-exemption rates, providing another example of an immunization barrier.
The potential immunization solutions defined in this study explained published
research that illustrated increases in immunization rates and each level of individual or
group optimum described in VGT (Bauch et al., 2003). Low-immunization rates
increased the risk of disease outbreaks. The impacts of barriers to immunization to
society consisted of negative outcomes, social and financial burdens to society, missed
school and work days, and costs to public health resources (Wheeler et al., 2004). These
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research-based attributable risk factors of immunization barriers included awareness and
knowledge (Gust et al., 2008), parental attitudes, cultural and social beliefs, religious,
philosophical, and medical beliefs (Thompson et al., 2007), parental refusal (Glanz et al.,
2009), vaccine safety (Institute of Medicine, 2012, 2013; NVAC, 2005), socioeconomic
factors (Wooten, Luman, & Barker, 2007), insurance, and access.
These immunization barriers were expressed as choices or behaviors to either
preemptively vaccinate, delay, or refuse vaccination. The importance of vaccinated
adolescents relates to costs such as disability, death, disease, infection, and recovery
(Bauch et al., 2003). Bauch and Earn (2004) measured individual equilibrium and groupoptimum coverage-uptake levels based on archival immunization data collected in the
AIRD. Differences in levels of vaccination associated with immunization barriers were
influenced by differences in interest between individuals and groups (Bauch & Earn,
2004).
Public-health-agency and institution-implemented innovative strategies to
increase immunization rates have also reduced VPD population risk and controlled
disease exposure. Federal public health insurance programs, VFC, State Medicaid
eligibility plans, school-entry laws, and healthcare-provider influence were effective
vaccine-uptake strategies. In addition, adolescent and childhood immunization rates
increased from 85% to 92% for certain vaccines (CDC, 2009b, 2012m). Although U.S.
adolescent immunization rates improved, challenges persisted for achieved and desired
90% immunization-rate indicators in Healthy People 2020 objectives (CDC, 2010b).
Parental awareness and knowledge are essential for parental consent to immunize
children and adolescents. Federal immunization laws encourage parents to receive
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informed knowledge about the risks and benefits of vaccination. In addition, the National
Childhood Vaccine Injury Act, section 2126 of the Public Health Service Act (USDHHS,
1996) required healthcare-provider immunization information to educate parents and
children during preventive and wellness visits. Federal law also mandates that parents
receive vaccine-information statements (VIS) and other vaccine information before
healthcare providers administer any vaccines to children or adolescents. All VIS and
educational materials provide specific and relevant vaccine information that enhances
parental awareness and knowledge. Parental knowledge and awareness influences
positive vaccine perceptions and attitudes associated with parental vaccine acceptance for
children and adolescents (Dorell, Yankey, Byrd, & Murphy, 2012; Glanz et al., 2010;
Klein et al., 2012). Healthcare-provider information is important and influenced 89.7% of
positive parental vaccination decisions (Kennedy et al., 2011). Physicians routinely
recommend and administer MMR, OPV/IPV, and Td/Tdap childhood and adolescent
vaccines.
Underimmunizations
Underimmunization was a significant finding in this dissertation, confirming
previous research. Significant associations arose for underimmunizations (Smith, Chu, &
Barker, 2004), with race, income, parental marital status, education, and number of
children in the household (Kesselsa et al., 2012; Salmon et al., 2009). Similarly, children
of parents who participated in the Special Supplemental Nutrition Program for Women,
Infants and Children (WIC) were more likely to not have completed a vaccine-dose series
compared to parents who did not participate in the program (CDC, 2014c; Salmon et al.,
2009; Shefer, Webb, & Wilmoth, 2000).
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Adolescent-Vaccine Access
Immunization registries functioned as official repositories of quantifiable
evidence of adolescent-vaccine access. Immunization coverage for adolescents aged 10 to
18 years in the United States lagged behind childhood rates for 19- to 35-month-old
children and adults 65 years and older (CDC, 2010b). Adolescent catch-up vaccine doses
improved in the NIS-Teen 2008 (CDC, 2009b). Vaccination data collection was through
national immunization surveys (Smith, Hoaglin, Battaglia, Khare, & Barker, 2005),
immunization-patient records from providers (Broder, Cohn, Schwartz, & Working
Group on Adolescent Prevention Priorities, 2008), state and local immunization
registries, immunization information systems, the Arkansas Children’s Network, and
NIS-Teen (CDC, 2010b; Children’s Reporting and Information System [CHRIS], 2013).
Immunization registries are confidential, population-based, computerized information
systems that attempt to collect vaccination data about all children in a geographic area
(CDC, 2010c, p. 5). Local immunization registries focus on their geographic catchment
area, thereby providing tools for monitored immunization assessment and surveillance.
Healthy People 2020 objectives for adolescent immunization are difficult to achieve. The
challenges and associated risk factors include vaccine safety (Baggs et al., 2011), access
to immunization, and provider-practice guidelines. In studies, health providers’ influence
accounted for 21.5% of risk factors; parental attitudes included mistrust of safety of
vaccines at 5.7%. Parental reluctance or refusal also contributed as challenges (Cooper et
al., 2008; Glanz et al., 2009; Smith, Kennedy, Wooten, Gust, & Pickering, 2006).
Arkansas immunization rates reported in the immunization-information-systems
data for children between 19 and 35 months declined from 78% UTD (CDC, 2008a) to
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71.4% UTD coverage (CDC, 2010b, p. 10). The UTD criteria were four or more doses of
Td/Tdap; three or more doses of OPV/IPV; one or more doses of meningococcal
conjugate vaccine; three or more doses of Hib; and three or more doses Hep B vaccine
(for 4:3:1:3:3). The vaccination 4:3:1:3:3:1:4 dose series has additional four or more
doses of pneumococcal conjugate vaccine (CDC, 2010b, p. 17).
Adolescent Vaccine Coverage: Reducing Disease Recurrence and Outbreak
Key public health contributions to social change with the implementation of
viable vaccine strategies included reduction in morbidity, disability, and death from
vaccine-preventable infectious diseases. The effect of middle school-entry requirements
positively impacted adolescent vaccine coverage. Coverage rates for Hep B vaccines
increased among adolescents (91%) in states with school-entry requirements (CDC,
2011m; Wilson, Fishbein, Ellis, & Edlavitch, 2005) compared to (58%), p > .001 in states
without school-entry vaccine requirements (CDC, 2011n, 2012b; Jacobs & Meyerhoff,
2004).
Disparities in Immunization Coverage between NHAs and FCAs
I identified three reasons adolescents are placed in foster-care services: abuse,
abandonment, and neglect from their birth parents (American Academy of Pediatrics
[AAP], 2005). When adolescents were removed from their natural birth home to foster
care, such actions caused difficult and stressful situations for the adolescent and the
medical home. Adolescents displaced from their birth family and foster parent(s) must be
assured they will receive the best possible emotional and physical care (AAP, 2005;
CDC, 2014c; Leathers, 2005). Because many FCAs were affected by emotional or
developmental problems, foster parents often face the unfortunate choice of either
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tackling any psychological issues or obtaining routine preventive health services, such as
immunization, often to the demise of the latter (AAP, 2005; Leathers, 2005).
Another barrier to preventive health services FCAs often face is that birth parents
retain authority to provide consent for all health and medical procedures (American
Academy of Child and Adolescent Psychiatry [AACAP], 2005; Freundlich, 2003;
Humiston et al., 2013). These health and medical procedures include immunizations,
reproductive health, sexually transmitted diseases, HIV testing, and substance abuse
(AACAP, 2005). The birth parent’s consent often wanes, given the contentious situation
that result in the removal of the adolescent from the home. Unlike FCAs, those in the
natural-home setting are unlikely to face these barriers. Barring particular circumstances
such as lack of health insurance preventing access to preventive health services, most
adolescents in the natural-home setting adhered to prescribed preventive health services
(AACAP, 2005; Freundlich, 2003).
Arkansas Immunization Laws
Arkansas Immunization Laws for School Enrollment Grades K–12
Arkansas legislators enacted more than 12 immunization-important laws and
amendments since 1987 (ALB, 1987). Five of these laws were significant immunization
laws that grounded the relevance of this study. These five significant AILs were enacted
in 1987, 1989, 1993, 1995, and 1997, and appear in Table A3 of Appendix A. These five
immunization laws relate to five critical immunization areas in the scope of this study:
child care and school-entry vaccine requirements; immunization access, financing, and
schedules; a statewide immunization registry in Arkansas; adequate minimum percent
levels of immunization coverage, specific required number of vaccine doses for each
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series, and vaccine types; disease prevention (ALB, 1995b); and outbreak control. The
2003 immunization laws had one major societal development: authorizing exemptions for
medical, personal, religious, and philosophical beliefs (ALB, 2003). Arkansas legislative
Act 141 of 1987 authorized the Arkansas State Board of Health to mandate proof of
measles, rubella, and other disease immunization prior to enrollment in daycare facilities
and schools (ALB, 1973) and Arkansas colleges and universities.
The Arkansas 1987 immunization law stated two purposes, required proof of
immunity, and alleviated the potential for an outbreak of communicable diseases (ALB,
1987). Arkansas legislative Act 387 of 1989 committed to achieving and maintaining
adequate immunization levels for all children in Arkansas. The minimum required
immunization levels established by law were 95% of children in public and private
schools and above 90% of children in childcare facilities (ALB, 1989).
Arkansas legislative ACT 591 of 1993 addressed availability, adequacy,
promotion, and use of immunization programs for infants and preschool children in
Arkansas. These legal provisions also enhanced achievement of minimum immunization
levels of 95% of children in public and private schools and above 90% of children in
childcare facilities (ALB, 1989). Two Arkansas laws, Act 432 and 685 of 1995, promoted
the efficiency and effectiveness of immunization services and coverage for all children in
Arkansas.
ACT 685 of 1995 mandated coverage of children’s preventive health care (ALB,
1995a) from birth through the age of 18, with periodic preventive-care visits (ALB,
1995b), and appropriate immunizations. ACT 685 funded immunization services under
the Medicaid program in the State of Arkansas and eased the financial burden for low-
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income, uninsured children through benefits for recommended immunization services.
The law also provided exemptions for eligible children from any copayment,
coinsurance, deductible, or dollar-limit provisions in the health-insurance policy.
ACT 432 of 1995 established the Arkansas statewide childhood-immunization
registry. The AIR serves three functions: The AIR provides information on childhoodimmunization status from birth to 22 years to parents, guardians, and providers. Second,
AIL ACT 432 requires physicians and health providers to register and report all vaccines
administered to children and adolescents from birth to 22 years (ALB, 1995a). Third, AIL
ACT 432 imposed a penalty of $25 dollars on all providers who do not report
administered vaccines to the registry (ALB, 1995a).
In 1997, two AILs, ACT 870 of 1997 and ACT 871 of 1997, mandated
immunization prior to school enrollment and required specific vaccines for all children
(ALB, 1997a, 1997b). These two laws impacted the 1990 birth-cohort school enrollment.
These students were the first adolescent-age cohort to comply with FVSE requirements.
The law required immunizations for students in kindergarten through 12th grade who
attended Arkansas schools (ALB, 1997a). AILs also authorized the ADH and Arkansas
Department of Education to impose penalties for violation.
Arkansas Act 871 of 1997 also placed compliance enforcement responsibilities on
school boards, superintendents, and principals of all schools. In PCA, school nurses have
direct responsibility to verify immunization records and require each student to receive
all age-appropriate vaccines (ALB, 1987). AIL ACT 870 of 1997 authorized the
Arkansas State Board of Health to require school-children receive immunization prior to
enrollment in public or private school from kindergarten through 12th grade, or childcare

38
facilities, and for other purposes. Similarly, ACT 871 required age-appropriate
immunization of children with OPV/IPV, Td/Tdap, red (rubeola) measles, rubella, and
other diseases designated by the State Board of Health.
Arkansas Immunization Exemptions
ACT 999 of the 2003 Arkansas legislative regular session authorized
immunization exemptions based on philosophical, religious, and personal beliefs. The
ADH is the only legal authority to approve and grant exemptions each year (ALB, 2003).
Several researchers suggested associations among immunization exemptions,
immunization coverage, and immunization rates. In Arkansas, requests for immunization
exemptions increased following 2003 (Safi et al., 2012; Thompson et al., 2007).
However, no published studies exist on specific associations between immunization rates
and exemptions. In addition, no published studies exist on 1990 PCABC adolescent
immunization rates, based on analysis of AIR data in the literature.
Changes in Arkansas Rules and Regulations 1990–2012
AIRR changes were consistent with ACIP adolescent-vaccine routine
recommendations. Arkansas school-entry vaccine requirements were limited to five
vaccines, tetanus and diphtheria toxoids, and Tdap (CDC, 2013). The human
papillomavirus and meningococcal conjugate vaccine were also recommended for
adolescents (CDC, 2013). The ADH increased VAR-dose requirements to two dose series
in AIRR in 2006 due to the resurgence of VAR in Arkansas (Lopez et al., 2006).
Childhood and adolescent vaccines recommended against 11 childhood diseases
in the United States since 1900 are Hep B, Td/Tdap; measles, mumps ( CDC, 2012d),
congenital rubella syndrome CRS, Hib, OPV/IPV (Salk, 1955b), smallpox, and VAR
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(CDC, 1999d). These 11 vaccines, except for smallpox, were required for school entry in
Arkansas and established in Table II immunization regulations for children attending
kindergarten through 12th grades (ADH, 2008). Adolescent immunization changes
applicable to this study are changes in the number of vaccine doses and schedules
implemented between 2003 and 2008. Extensive cohort vaccine changes appear in
Appendix A., Table A2.
Arkansas adolescent immunization rates were persistently low, compared to
national immunization indicators established in Healthy People 2020 (2012). Arkansas
immunization rates ranked lower compared to other states in the region with similar
demographics and rural populations. The Arkansas 1995 immunization law required
vaccine compliance and immunization reporting for enrollment in daycare facilities,
Grades K–12, colleges, universities, military, and for state employees (ADH, 2008; ALB,
1995a). The 1995 immunization law directly improved adolescent immunization rates
and indirectly reduced immunization disparities among adolescents.
Evaluating Changes in Arkansas Rules and Regulations 2000–2008
Evaluation changes in Arkansas rules enhanced school-entry immunization
requirements. Arkansas rules and regulations pertaining to changes in vaccine types,
number of doses, and vaccine administration from 2000 to 2008 were important in
compliance with school-entry immunization requirements. Immunization relationships or
correlations existed between changes in adolescent immunization rates and changes in
Arkansas and national requirements (Kroger, Sumaya, Pickering, & Atkinson, 2011).
Arkansas State mandated immunization rules and regulations, influenced changes in
quantitative variables such as number of doses required for completion of vaccine series,
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age-appropriate doses, and vaccine UTD coverage. This evaluation of changes in
adolescent immunization regulations facilitated assessment and determination of any
relationships or correlations to changes in immunization rates and changes in statemandated immunizations.
Change emphases were on vaccine doses because no changes had occurred in
AIRR since 1995 (see Appendix A, Table A2; ADH, 2008). The 2000 Table II of AIRR
requirements were limited to adolescents spanning seventh through 12th grades. A
second criterion was age-appropriate completion of required immunization for children
aged 13 to 18. Adolescent students in the seventh grade UTD required three doses of
Tdap, three doses of Hep B vaccine, two doses of a measles-containing vaccine (usually
MMR), three doses of OPV/IPV vaccine, and one dose of VAR vaccine (ADH, 2000).
Adolescent transfer students from seventh grade through 12th grade received similar
UTD requirements (ADH, 2000). The chronological list of the immunization rules and
regulations between 2001 and 2008 follows from Table II of the 2001 AIRR.
In 2001 and 2002, no new changes or additions accrued for adolescents who
began seventh through 12th grades. In 2003, AIL authorized exemptions for medical,
religious, and philosophical beliefs (ADH, 2003). AIL made no changes in 2004 and
2005 for adolescents. In 2006, Table II included recommendations for the addition of a
second dose of VAR for adolescents (CDC, 2006a) in seventh grade through 12th grades
(ADH, 2006). No changes accrued in 2007 or 2008.
Solution to Low Adolescent Immunization
Adolescent immunization solutions to low-immunization rates were implemented
at policy and individual levels. The Healthy People 2000 national health promotion
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identified immunization as a national health priority (USDHHS, 1999). Federal solutions
to low-immunization rates (Kalies, Redel, Varga, Tauscher, & von Kries, 2008) since
1994 included funding eligibility insurance programs, Medicaid, and the VFC program
(CDC, 2012l; Zhou, Santoli, et al., 2005). Federal law required VIS sheets for each
vaccine. A VIS was an immunization strategy and a national policy (USDHHS, 1987)
that targeted education of adolescents, parents, and physicians on vaccine safety and
adverse events. Healthcare providers educated parents, adolescents, and children before
administering vaccines. These health-promotion strategies and mechanisms targeted
multiple levels that influenced individual health behaviors at the interpersonal,
community, organization, and policy levels.
The individual immunization health-behavior-change approaches contributed to
increases in adolescent immunization rates (Stokley et al., 2011). The parental-influence
approach targeted interpersonal increases in knowledge, awareness, and attitudes, and
provided potential solutions that addressed parental reasons for not immunizing
adolescents (Darden et al., 2011). Individual health-behavior change for parents involved
multiple mechanisms of influence that incorporated social networks, organization, and
policy influences. Parents who refused to vaccinate their adolescents had to sign and
document the informed refusal of consent to vaccinate (Burns & Zimmerman, 2005).
WIC and VFC programs improved parental awareness (Kennedy, Stokley, Curtis, &
Gust, 2011) and knowledge of the benefits of vaccines, contributing to increases in
childhood and adolescent access to vaccines and immunization rates.
Community solutions included clinical decision support and maximized
opportunities to immunize adolescents during each wellness visit (Schaffer et al., 2008;
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Szilagyi et al., 2008). Solutions included immunization standing orders and EHR
immunization audits to minimize missed opportunities and increase immunization rates
(Burns & Zimmerman, 2005). The implemented reminder/recall systems were time and
cost intensive (Burns & Zimmerman, 2005); however, direct immunization
communication between providers and vaccine recipients or parents of recipients were
effective and increased immunization rates (T. C. Davis et al., 2001). Healthcare
providers who used EHR recall/reminder systems improved adolescent immunization
rates (Clark, Butchart, Kennedy, & Dombkowski, 2011; Fiks et al., 2013; Hambidge,
Phibbs, Chandramouli, Fairclough, & Steiner, 2009; Szilagyi et al., 2002). Pharmacists’
additional roles as vaccinators also increased immunizations in inner-city, rural, and
nontraditional sites beyond local county health units (Hogue, Grabenstein, Foster, &
Rothholz, 2006; Ndiaye et al., 2003; Neuhauser, Wiley, Simpson, & Garey, 2004).
Policy solutions included school-entry laws (ALB, 1967; Omer, Salmon,
Orenstein, deHart, & Halsey, 2009; Orenstein & Hinman, 1999), access to immunization
in Arkansas (ALB, 1967) through federal and state eligibility programs such as VFC,
Medicaid, and supplemental children’s insurance (ARKIDS) programs in Arkansas
(ADHS, 2011c). Legislative actions of immunization laws and school-entry requirements
influenced societal and environmental levels. School-based immunization clinic practices
aligned with increased adolescent immunization coverage (Allison et al., 2007; Daley et
al., 2009; Federico, Abrams, Everhart, Melinkovich, & Hambidge, 2010; McNall, Lichty,
& Mavis, 2010).
The central concept of adolescent immunization health was individual behavior
change related to specific health, contributing large social-change impacts and beneficial
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economic gains (Lee, Feaver, Miller, Hedberg, & Ehresmann, 2004). Commensurate
health gains decreased childhood disease and deaths and increased life expectancy.
Adolescent immunization contributed to several other great achievements of vaccinations
in the 20th century and the first 2 decades of the 21st century (CDC, 1999c).
The specific health problems of unvaccinated adolescents related to individual
behavior change were VPD resurgence, outbreaks, disease transmissions, and
importations of measles, mumps, pertussis, and VAR (CDC, 2006b, 2006e, 2012d). Other
effective solutions that increased immunization rates included reduced adolescent-crowd
opportunities, minimized proximal interaction between disease carriers and exposed
unvaccinated or underimmunized individuals, increased social distancing, and school
closings during outbreaks (Glass & Barnes, 2007; C. Jackson, Vynnycky, Hawker,
Olowokure, & Mangtani, 2013; Miller et al., 2010). During the prevaccine era of the 19th
and 20th centuries, childhood diseases and mortality were prevalent (CDC, 1999a). Since
vaccines were licensed and introduced as part of a health-promotion strategy, childhood
diseases have significantly decreased and mortality has declined (CDC, 2000a). For
example, approximately 4 million people were infected annually with measles during the
1963 measles prevaccine era (Zhou et al., 2004).
Vaccines contributed to personal high economic costs (Lee et al., 2004; Zhou,
Harpaz, Jumaan, Winston, & Shefer, 2005) and societal costs (Shapiro et al., 2011), and
provided communitywide and societal protection from disease morbidity and mortality
(Zhou et al., 2004). Parental delayed vaccination of their children as a consequence of
vaccine hesitation, resistance, and refusal at the individual level increased the risk of
resurgence of diseases (Opel et al., 2011). Disease risks were greater during the
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predominant host-agent-environment models of disease experienced during the
prevaccine era of societal and environmental outbreaks, epidemics, and pandemics (Opel
et al., 2011).
The relevance of adolescent immunization is more important today than in the
20th century as a result of narrow social distancing (Reluga, 2010). In addition,
adolescent immunizations are relevant because of the frequency of disease transmission
facilitated by global travel, the availability of cost-effective vaccines (Whitney, Zhou,
Singleton, & Schuchat, 2014), and increased parental objection and refusal of vaccines
(Diekema, 2012; WHO, 2011a). Experiences ranging from immunization resistance to
global poliomyelitis eradication initiatives aligned with parental health-behavior
influences in Afghanistan, India, Nigeria, and Pakistan (CDC, 2009g; WHO, 2011b).
Increased use of vaccines provided effective defenses in environments where global
disease transmissions were facilitated by factors related to individual, community, and
societal behaviors.
Theoretical Foundation
The Theory of Games
The theoretical foundation used in this study was the TOG (von Neumann &
Morgenstern, 1944). I applied TOG constructs as a mathematical model to measure
individual vaccine behavior (Bauch & Earn, 2004; Bauch et al., 2003), called individual
equilibrium, because the FVSE affects the group’s interest, known as the group optimum.
Individual equilibrium examines the probability and cost of delayed vaccination among a
population, whereas the group optimum examines the probability of preemptive
vaccination coverage and minimum payoff death or disability from VPD, for which there
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is routine vaccination among a population. If the proportion of preemptively vaccinated
individuals in the group is significantly large and the disease is sparsely distributed across
the population, then community or herd immunity exists in the group. Thus, community
or herd immunity mitigates the payoff for preemptive vaccination in the group, to avoid
or minimize death or disability. Individuals with self-interest behavior therefore choose
not to become vaccinated.
Framework for Modeling
TOG was an important framework used to model an individuals’ probability of
vaccination, calculated for the 1990 PCABC. I also calculated the group payoff deaths for
preemptive vaccination coverage. Vaccination payoff deaths references the cost
associated with VPDs if individuals with self-interest in the group were not vaccinated.
The TOG construct predicted individual and group vaccine behavior. This predictive
function was essential and significant in preemptive vaccination calculations (Bauch et
al., 2003) for public health interventions of disease resurgence, outbreaks, epidemics, and
pandemics. Participants’ strategies, individual self-interest adolescent actions, and group
altruistic action are key constructs of the TOG (Bauch et al., 2003).
The TOG was also useful in evaluating vaccine policy and assessing advantages
of vaccination self-interest and group utilitarian optimization (Galvani et al., 2007). The
probability, proportion, frequency, and immunization outcome of UTD variables aligned
with the key predictive payoff death functions in this quantitative study. These
immunization outcome UTD variables were vaccine-coverage rates for FVSEs for school
entry (ADH, 2008).
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Social-Change Implications
The social-change impact of adolescent immunization-uptake prediction is
valuable to public health functions. The TOG application in immunization quantitative
analysis incorporated in several research studies included vaccine uptake among
adolescents (Reluga, Bauch, & Galvani, 2006), immunization rates (Niccolai & Hansen,
2015; Skoff & Martin, 2016), UTD predictors, and uptake coverage (Ibuka, Chapman,
Meyers, Li, & Galvani, 2010). The TOG was an effective model used in this study to
investigate and describe risk factors associated with health outcomes (Bauch et al., 2003).
The low-immunization rates among populations explained the individual and groupequilibrium framework (Bauch et al., 2003). For example, VGT explained how selfinterest, altruistic decisions, and maximization and minimization of payoff concepts or
frameworks (Bauch & Earn, 2004) influenced immunization policy (Bauch et al., 2003). I
applied TOG constructs and determined how individuals’ decisions or actions related to
immunization uptakes and coverage rates probabilities (Bauch & Earn, 2004). Similarly,
Arkansas immunization policy influenced school-entry vaccine requirements (ADH,
2008) and contributed to increased immunization rates for specific vaccines (Morita,
Ramirez, & Trick, 2008).
The TOG was important in understanding, investigating, and developing solutions
for health problems with multilevel risk factors such as immunization (Bauch &
Bhattacharyya, 2012; Bauch et al., 2003). The TOG framework was also applicable to
significant determinants and predictors of vaccine uptake (Bauch, 2005) during acute
events such as smallpox outbreaks that occurred in several developing nations (Bauch et
al., 2003).
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Summary and Conclusion
Summary
This study determined how HOR aligned with vaccination coverage UTD. This
associative concept was significant in vaccine-coverage improvements and interventions.
Increased adolescent immunization rates contribute to community health and prevention
of VPD outbreaks. Individual decisions to vaccinate often relate to self-interest (Ibuka et
al., 2014). VPD outbreaks among school children and index cases are more likely to
occur among unvaccinated children compared to vaccinated children with waned
immunity (Skoff, Cohn, Clark, Messonnier, & Martin, 2012; Sugerman et al., 2010).
VPD outbreaks are also common among highly vaccinated populations that were
underimmunized and only received one dose in a vaccine series (Lopez et al., 2006;
Sugerman et al., 2010).
Outbreaks of VPDs reported in Arkansas included pertussis in 2001 (Wheeler et
al., 2004) and VAR in 2005 (Lopez et al., 2006). Disease outbreaks such as pertussis
associated with pneumonia, encephalitis complications, hospitalization, and deaths
reported during the California pertussis outbreak (California Department of Public
Health, 2010). School outbreaks of VPDs frequently disrupt educational activities,
increase absenteeism due to illness (King et al., 2006), and lead to hospitalization and
school closure (M. M. Davis et al., 2008). VPDs such as VAR are highly contagious and
easily transmitted (CDC, 1999c) by airborne and contact between persons (Ross, 1962;
Schmid & Jumaan, 2010). Control of VPD outbreaks is financially costly and a public
health burden (Wheeler et al., 2004).
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Societal and individual health costs were consequences of unassured full
immunization coverage among at-risk populations. At the societal level, these costs
include disease transition among socially congregating adolescents at public venues and
events. The outcomes of congregating groups at sports events, church activities, and
shopping complexes often results in increased illness and hospitalization in the
community (Reynolds et al., 2008). At the individual level, costs associated with lost
productivity and wages often occurs when parents or guardians stay home to care for
affected children (M. M. Davis et al., 2008).
Conclusion
For this study, I analyzed data from the AIRD to establish vaccine UTD status for
the 1990 PCABC. Differences emerged in vaccine-coverage uptake between NHAs and
FCAs among the PCABC. PCABC FVSE immunization rates were included in the four
main outcomes. A literature review gap emerged in that peer-reviewed studies on
disparities of vaccination coverage for the FVSE among NHAs and FCAs in the 1990
PCABC were not found or did not exist. The AIRD analysis implemented in this study
quantitatively addressed this gap in the literature. Several peer-reviewed studies
previously addressed components of immunization in Arkansas, including infant and
childhood coverage rates, VPD outbreaks, vaccine exemptions, school-enrollment
requirements, immunization policies, and state-mandated immunization laws. However,
these studies did not apply quantitative analysis of immunization-registry data, nor did
they focus on NHAs and FCAs in the 1990 PCABC to establish immunization-coverage
rates for the FVSE. The NIS-Teen coverage rates reported for adolescents in Arkansas
(CDC, 2008a; Darden et al., 2013; Jain, Singleton, Montgomery, & Skalland, 2009;
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Stokley et al., 2011) were based on a random-digit dialing survey (RDDS) of sampled
households. RDDS consents were corroborated with consent from participants to use
provider-based immunization data. In contrast, this study was an archival cohort analysis,
and consent from participants was not required to access deidentified registry data. I
satisfied all institutional review board (IRB) requirements and gained approved for this
study.
The next chapter of this dissertation, Chapter 3, includes the research
methodology. Key sections of Chapter 3 consist of the study design, research questions,
and hypotheses, sample frames and sample sizes, data analysis, and ethical
considerations.
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Chapter 3: Research Method
Study Purpose
I achieved four main purposes in this quantitative study. The first was to calculate
and compare adolescent immunization rates between the 1990 adolescent PCABC
adolescent and the U.S. national adolescent immunization data from 2003 and 2008. The
second purpose of the study was to identify whether an association emerged between
HOR, defined as NHA or FCA, and the UTD status of FVSE. The third purpose was to
determine whether disparities in immunization rates existed based on sociodemographic
risk factors that included age, gender, race, and ethnicity in PCAs. The fourth purpose,
based on the TOG, was to develop mathematical models to illustrate how an individual’s
decision to receive vaccination for the FVSE affected the group interest.
Research Design and Rationale
Research Design
I used the cross-sectional study design to conduct this quantitative inquiry.
Because information on vaccine coverage and HOR were captured at a single point in
time, the cross-sectional design was the ideal study design; however, no feasible methods
could account for temporality. Although other quantitative study designs were useful, the
inability to account for temporal order made their utility in this instance inappropriate.
Design Rationale
The cross-sectional study design was an appropriate design to explain the problem
statement and answer the four research questions in this study. I analyzed the individual
immunization registry data to establish immunization rates, vaccines with low uptake,
and UTD status for NHAs and FCAs, all collected at a single point in time. The cohort
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independent variable was the HOR, defined as NHA and FCAs. The dependent variables
were five vaccines required by AIL for school entry: diphtheria, Hep B, MMR,
OPV/IPV, and VAR. The individual immunization records were coded with unique
identification criteria and formulae for specific recommended vaccines for school entry
(ADH, 2008).
Operationalization of the Theoretical Construct
Operationalizing Game Theory
The TOG (von Neumann & Morgenstern, 1944) theoretical construct was
operationalized using several steps. First, the variables that corresponded to TOG
constructs included individual equilibrium and group optimum, identified for each FVSE.
Next, I developed mathematical models to examine individual equilibrium and group
optimum for each of the FVSE in the 1990 PCABC. Because county data reported to the
CDC does not distinguish NHA and FCA, I calculated overall probabilities. Additionally,
if county data for PCA were incomplete in the national database, I used a representative
sample of the 1990 U.S. birth cohort to calculate attack rates.
I measured individual health behavior using the frequency function of all vaccine
doses recorded for that type of vaccine. Appropriate individual immunization was the
maximum number of doses required, according to recommendations of the CDC for that
specific vaccine to complete the dose series (CDC, 1999c). For example, Tdap vaccine
had a maximum of four doses to complete the vaccine series compared to MMR or VAR,
which required a maximum of two doses to complete the vaccine series. The frequency of
completed vaccine series used to determine probabilities needed in the calculation of the
individual equilibrium and group optimum was equal to the total number of individuals
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with completed vaccine series in the study population. The frequency function was a
statistical tool that predicted vaccination proportions and probabilities (Bauch, 2005) for
a given TOG individual equilibrium and group optimum construct. Bauch and Earn
(2004) used the TOG to explain how individual behavior contributed to adolescent
immunization coverage rates.
The Theory of Games Constructs
The two constructs used as part of the TOG in this study were individual
equilibrium and group optimum. The payoff calculations used in both mathematical
models were based on data obtained from the AIR and from the CDC’s immunization
database, which compiled national immunization rates.
The following parameters defined the equations to express the individual
equilibrium and the group-optimum equation:
•

C = optimum cost;

•

Evac = the efficacy of vaccination for an individual who receives the vaccine;

•

dv = the probability of death of the individual from vaccination;

•

peff = the proportion effectively vaccinated;

•

p = the proportion of individuals preemptively vaccinated;

•

r = the risk of attack from a VPD after an outbreak;

•

ϕs(p) = the probability that a delayer becomes infected with disease after an
outbreak;

•

ds = the probability of death due to a VPD;
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•

ϕv(p) = the probability that a delayer is vaccinated successfully after an
outbreak;

•

N = the population size.

The population size was equal to N adolescents in the 1990 PCABC and was
based on U.S. population census data. The importance of adolescent vaccination is the
cost of vaccination in terms of death. The cost equals the total number of deaths where
Evac = −dv and is the probability outcome (Q; Bauch et al., 2003). The group optimum cost
(C(p)) is the vaccine coverage level needed to avert deaths due to VPD.
Assumptions
I noted several assumptions in the calculation of individual equilibrium and group
optimum. First, the risk of attack from a VPD after an outbreak, r, was based on a priori
knowledge found in the literature. Additionally, the ϕs(p), probability that a delayer
became infected after an outbreak, as well as the ds, probability of death due to a VPD,
was based on a priori knowledge found in the literature. The ϕv(p), probability that a
delayer was vaccinated successfully after an outbreak was based on the number of
available vaccine series available in PCA. I assumed enough vaccine existed for any of
the FVSE, available for all unvaccinated adolescents. I based all other probabilities on
information obtained from the AIR.
Constructs Used in the Theory of Game
Individual equilibrium. I used the individual-equilibrium equation to examine
the relationship between those who preemptively received vaccination and those who
delayed vaccination for each of the FVSE. The payoff for an individual who received
vaccination can be expressed as Evac = −dv where dv is the probability of death from
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vaccination. Because the probability of death due to vaccination was usually small, dv
was usually ignored in the equation; therefore, Evac was usually assumed to be 100%, or 1
when expressed as a probability. I therefore focused on the effect of an individual
delayed vaccination and the risk of the disease if an outbreak occurred, Edel(p). The
equation examined vaccine delay and the payoff associated with delay was
Edel(p) = −r[ϕs(p)ds + ϕv(p)dv],
where Edel(p) calculates the payoff to an individual who chose to delay vaccination; r is
the risk of attack from a VPD after an outbreak, calculated as number of people likely to
become infected if there were no vaccine protection divided by total population at risk of
becoming infected; ϕs(p) is the probability that a delayer becomes infected with disease
after an outbreak, calculated as the total number of eligible unvaccinated people divided
by the total population at risk of becoming infected; ds is the probability of death due to a
VPD, calculated as the total number of deaths among those who were unvaccinated from
VPD divided by the total population at risk of becoming infected; ϕv(p) is the probability
that a delayer is vaccinated successfully after an outbreak, calculated as the total number
of disabilities among delayers receiving the vaccination divided by total number of
delayers who received vaccination; and dv is the probability of death of an individual
from vaccination, calculated as the total number of deaths due to the vaccination divided
by the total number of those who received the vaccine.
Because the goal of individual equilibrium, Pind, is to examine the relationship
between Evac and Edel, one would expect to see a maximized payoff from receiving
vaccines, where Evac = 1 or 100% vaccine efficacy, no deaths from vaccination, and a
minimized payoff of delaying vaccination where Edel = 0 or no payoff for delaying
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vaccination. Therefore the association expected was Evac > Edel. If Evac ≤ Edel; then the
individual equilibrium, Pind, may approach zero where, although the vaccine is effective,
the payoff for delaying vaccination may not pose any additional risk of harm (Bauch et
al., 2003). Under such circumstances, individuals may choose not to be vaccinated,
thereby eliminating individual equilibrium, Pind. An important assumption to make when
calculating the individual equilibrium is that individuals will act to increase survival from
a VPD when vaccines are readily available. See Table 1 on how I identified each
construct.
Table 1
Theory of Game Parameters, Definition, and Sources
Parameter

Definition

Source

r

Risk of attack from a vaccine preventable
disease for an individual

CDC’s U.S. morbidity national data published in
the Morbidity and Mortality Weekly Report

ds

Probability of death from a vaccinepreventable disease for an individual

CDC’s U.S. mortality national data published in
the Morbidity and Mortality Weekly Report

ϕs(p)

Probability an individual delayer becomes
infected after an outbreak

CDC’s U.S. morbidity national data published in
the Morbidity and Mortality Weekly Report

ϕv(p)

Probability an individual delayer is
successfully vaccinated after an outbreak

Arkansas vaccine stockpile information. CDC
national vaccine stockpile information.

Population size

2000 U.S. census data, for PCA

N

Note. Adapted from “Group Interest Versus Self-Interest in Smallpox Vaccination Policy,” by C. T. Bauch,
A. P. Galvani, and D. J. D. Earn, 2003, Proceedings of the National Academy of Sciences, 100 for Pulaski
County, Arkansas, Birth Cohort Analysis, 2015.

The group optimum. For the group interest, it was important to minimize the
total number of deaths due to vaccination and infection if an outbreak of a VPD occurred.
Thus, to examine group optimum, I applied the equation
C(p) = pdv + r(1 − p)[(ds − dv)ϕs(p) + dv],
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where C(p) was measured as a probability between zero, and 1 was the coverage level
that would have to be imposed to minimize the total expected number of deaths due to a
VPD. All other variables are the same as those described for individual equilibrium and
reported in Table 1.
Research Methodology
Immunization Registry Archival Data
The initial process began with a cover letter and an attached summary of the
project proposal sent to the deputy director of health programs and state epidemiologist at
ADH. I sent a request letter to the ADH director for permission to examine official
archived State Board of Health minutes from 1980 to 2012. These minutes provided
gainful understanding of background knowledge on the history, policy, and practices of
immunizations in Arkansas.
From April 2011 to August 2012 the ADH Immunization and Communicable
Disease Branch offered me an unpaid graduate internship to work on special projects. I
initiated the process to request immunization data access during this period. Another
access-to-data requirement was a memorandum of understanding between ADH and
ADHS to acquire a foster-care identification roster of Datalink immunization records. I
sent numerous e-mails and letters of request to ADHS leadership for permission to
acquire the foster-care identification roster. The ADH Scientific Advisory Committee
(SAC) has legal authority to release the data. I obtained the study data from AIRD
through SAC.
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Roadmap to Data Merge
To obtain the initial list of the 1990 PCABC, I used the Arkansas Department of
Public Health Vital Statistics database to extract the name, date of birth, gender, race, and
ethnicity of all children born in 1990 in PCA. The individual birth-record information is
publicly available when requested. To extract information on children who enrolled in the
public school system, the list of children born in 1990 was sent to the Arkansas Board of
Education. Once I obtained the list of identified children who enrolled in public school
from the Board of Education, this list was sent to the AIR to obtain the immunization
history of children born in 1990 in PCA who attended public school.
FCA and NHA data were combined in the immunization-registry data, as required
by Arkansas law (ALB, 1995a). FCA and NHA data were coded by registry staff—0 =
FCA and 1 = NHA—then reviewed by a senior epidemiologist before being released to
me. However, the data were deidentified to protect minors, in accordance with Arkansas
law (ALB, 1995a).
The final list obtained from the immunization registry included the patient unique
identifier, date of birth, age, gender, race, and ethnicity of only cohort children. Figure 1
illustrates the topography of Arkansas immunization linkage databases.
Deterministic Data Linkage
The Arkansas vital-statistics database and the AIRD were large databases that
contained similar important PCABC unique identifiers and demographic variables (Lin,
2003). I used these identifiers and variables to develop an optimal file-linkage algorithm
that yielded quality matched immunization records (Lin, 2011). I performed all linkages
under close advisement and guidance of the senior statistician at the ADH. I used the
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algorithm shown in Figures 1 and 2 in the linkage process. The constructed optimal filelinkage algorithm required three types of data files: birth-certificate data, immunization
data, and a gold-standard file (Lin, 2011). The birth-certificate-file variables included
social security number and demographic data (Lin, 2003). The immunization data
included social security number, date of birth, vaccine type, number of doses, date of
vaccine administration, and specific demographic data.

Figure 1. Arkansas immunization linkage database.
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Figure 2. Optical file linkage algorithm.
Note. Adapted from “Designing the optimal file linkage algorithm,” by T. M. Lin, 2003, retrieved
from Retrieved from http://webcast.hrsa.gov/conferences/mchb/cdc/mchepi2003/index
.htm, and “Designing the optimal file linkage algorithm OFLA,” by T. M. Lin, 2004, retrieved

from http://www.lexjansen.com/scsug/2004/Lin%20-%20Designing%20the%20Optimal
%20File%20Linkage%20Algorithm.pdf.
The deterministic linkage algorithm achieved accuracy and true positive matches
of linked records from the independent databases (Lin, 2011). I achieved true positive
matches of linked records when I combined unique identifiers such as social security
numbers with gender, name, and birth date variable fields (Grannis, Overhage, &
McDonald, 2002; Lin, 2011). The deterministic linkage algorithm was accurate for
matched records, achieved high sensitivity of 90–92%, and maintained 100% specificity
of linked records (Grannis et al., 2002). Therefore, the deterministic-linkage-algorithm
method was appropriate to link birth records with immunization records in this study.
The deterministic method of data linkage was important and matched records
from the vital records and immunization database (Lin, 2003). The data-linkage process
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has potential problems associated with errors such false negatives, false positives, and
duplicate records when matching data sets or records (Bohensky et al., 2010; Lin, 2003).
Therefore, I matched a proportion of records and a proportion remained unmatched
(Bohensky et al., 2010). New parameters included the addition of race, gender, and
ethnicity, assimilated in the linkage to match all unmatched records (Grannis et al., 2002;
Lin, 2003).
IRB Approvals
I completed all ADH IRB requirements, which included Health Insurance
Portability and Accountability Act (HIPAA) compliance, confidentiality, and privacy
trainings. This was the required regulatory process to obtain archival data from the ADH.
I obtained IRB approvals from ADH and Walden University (03-17-15-0137370) and
eventually obtained the data from ADH, after the dissertation committee approved the
draft proposal and after Walden University IRB approved the IRB application to conduct
this study. The Walden approval number for this study is 03-17-15-0137370.
Instrumentation
I did not require a study instrument to establish a calculated adolescent
immunization rate. I used archival data from the AIRD to obtain information on
immunization rates for the 1990 birth cohort, PCA (ADH, 2008). I obtained archival data
for the 1990 PCABC upon approval of the ADH SAC. This archival data contained
immunization histories and records of all children born in PCA between January 1, 1990
and December 31, 1990. Each individual immunization record contained a history of
vaccine type, date of administration, demographic, and a deidentified number instead of a
name. The registry data combined FCA and NHA data, as required by law. The registry
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staff coded FCA and NHA data; then senior epidemiologists reviewed the coding before
releasing the data to me. This process ensured protection of minors in accordance with
Arkansas law. All 1990 cohort names were in the registry. The deidentified data were
coded as 0 for FCA and 1 for NHA.
Target Population
The target population was adolescents in the 1990 PCABC, and had three
inclusion criteria: (a) adolescents aged 13–18, born between January 1 and December 31,
1990 in PCA; (b) attended public schools in PCA from 1996 to 2008; and (c) had
immunization records in the AIRD. The 1990 cohort PCA was stratified in two groups:
NHA and FCA. FCA represented the high-risk group because of their social status as
wards of the state. The cohort demographic distribution was by gender; race including
Caucasian, African American, and other; and age, assumed to be constant because of
their identical birth year 1990.
Target-Population Approximate Size
The ADH reported 9,102 births in PCA in 1990 (ADH, 2015). The targeted
analyzed population of adolescents born in 1990 in PCA was limited to the universe of
individuals who were 13 years old in 2003, attended public school, and had vaccine
records in the AIRD.
Foster-Care Sample Size
The average annual enrollment of FCAs in the ADHS system from 2000 to 2008
was 83.11 per year. The largest foster-care enrollment was 164 adolescents in 2006. The
estimated annual sample-size range was 83 to 164 adolescents (ADHS, 2010). The
sample size was less than the cohort population due to a proportion who attended private
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school, immigration and emigration, relocation, mortality, and loss to follow up. Several
other factors influenced the FCA sample size such as social family structure, domestic
violence, family social disruption, and judicial actions due to child abuse and
maltreatment (ADHS, 2010).
The AIR data were coded for FCA and NHA as zero and 1, respectively. The
foster-care sample size was based on the total number of adolescents coded as foster care
in the 1990 PCABC. The AIR received all reported immunization histories, provided
confirmation, and verified compliance with immunizations for school enrollment (ALB,
1995a). The AIRD incorporated functions to match the name and unique identification
roster of adolescents with their immunization histories, for analysis that determined 1990
PCABC immunization rates.
Sampling and Sampling Procedure
Sampling Strategy
The study sample was drawn from census data of 5,257 births, registered in ADH
vital statistics, for PCA (ADH, 2015) and from AIRD. All records with date of birth,
location, date of vaccination, dose, lot number, and type of vaccine administered were in
the sample and analyzed. Physicians, healthcare providers, and all facilities that
administered vaccines were required to report the name, date of birth, location, date of
vaccination, dose, vaccine lot number, and type of vaccine administered to all children
and adolescents within 30 days to the AIRD (ALB, 1995a).
Sampling frame
The sampling frame was based on population and I used the HL7 form for the
entire cohort population data collection. Healthcare providers are required to use the HL7
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form to report individually administered immunizations to the registry (ALB, 1993). The
sampling frame in this study was not a predetermined sample of selected households.
Inclusion criteria. This study had four inclusion eligibility criteria: vaccine types,
date of birth and geographic location, specific year interval, and education. The four
eligibility criteria were (a) children with health-provider-reported immunization records
for five routinely recommended vaccines required for school entry; (b) children with birth
dates between January 1, 1990 and December 31, 1990 who were born in PCA, (c)
eligible cohort children who attended public schools in PCA between 1996 and 2008, and
(d) vaccine records in the AIR.
Exclusion criteria. Children who did not attain the four inclusion eligibility
criteria defined in the cohort period were excluded from the study analysis. The first
criterion was date of birth. The second criterion was geographic criterion and was limited
to the contiguous residential zip codes in PCA. The third exclusion criterion in this study
was school attendance. I excluded adolescents born in 1990 who were not enrolled in
public schools in PCA. The fourth exclusion criterion was children who did not have
vaccine records in the AIR. For example homeschooled or adolescents who attended
private schools were excluded from this study because homeschooled children and
students who did not attend public school are not required to comply with FVSE
requirement.
Procedures for Recruitment, Participation, and Data Collection
This quantitative study design did not require recruitment, participants, or data
collection. I analyzed archival immunization data from AIRD. I focused and obtained
access to deidentified Arkansas adolescent immunization data from ADH and did not

64
require participant recruitment procedures. The data were limited to a 1990 birth cohort
of all births between January 1, 1990 and December 31, 1990, recorded in PCA.
I sent two request letters to obtain access to data. I sent the AIRD request letter to
the Chief of Immunization Branch, ADH to request permission to obtain and use
deidentified AIRD data. I obtained coded immunization data on FCAs and NHAs. The
AIR removed all names and social security numbers, and maintained confidentiality and
privacy protection. The ADH is responsible for all immunization records in Arkansas
(ALB, 1995a). The process to obtain access to deidentified 1990 birth cohort AIRD was a
significant challenge, due to regulatory requirements.
Variable Measurements and Definitions
Measures of Immunization Status
Measures of immunization status analyzed in this study was FVSE UTD of
specific rates for each of the FVSE defined in AIL (ADH, 2008).
Five vaccines for school entry and adolescent up-to-date status. For
examination of the UTD of the FVSE, I examined each required vaccine. Table 2 outlines
each vaccine, the number of doses needed, the interval between each administered dose,
and the age at which the full vaccine is required. In this study, I examined the 1990 birth
cohort; most adolescents in this cohort were 13 years of age at the time, and I expected
that all childhood immunizations were completed. However, in some instances, this was
not the case. Thus, an adolescent was considered not UTD if any of the following
occurred:
1. Any one dose was missing among any of the FVSE;
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2. The interval between the booster dose (the first dose) and any subsequent dose
was more than 5 days of when the follow-up dose was expected;
3. An exception was noted to immunization due to religious or political reasons.
Thus, the analysis of UTD coverage was based on an all-and-on-time or nothing
concept. For example, UTD was coded as 1 if the adolescent had all required vaccines in
a series and these vaccines were given within the stated time. An adolescent was coded as
0 when doses of a given vaccine were missing or when the interval between the booster
dose and the follow-up exceeded the maximum allowable time between vaccine series.
All children who had a vaccine exemption were coded as 0 for their UTD.
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Table 2
Vaccination Schedule for the FVSE

Vaccine

Minimum
number doses
in complete
series

Minimum
age at 1st
dose
schedule

Minimum age
at 2nd dose
schedule

Minimum
age at 3rd
dose
schedule
7–18 months
or 8 weeks
after 2nd
dose

Minimum
Minimum age
completion
at 4th dose
milestone age
schedule
and school grade

Diphtheria,
Pertussis,
Tetanus

4

3–4 months 5–6 months or
within 8
weeks of 1st
dose

Poliomyelitis

3

3–4 months 5–18 months 19–48
or 8 weeks
months or 8
after 1st dose weeks after
2nd dose

N/A

11–13 years or
7th grade

Measles,
Rubella,
Mumps

2

13–48
months

N/A

11–13 years or
7th grade

Hepatitis B

3

3–4 months 5–12 months 13–18
or 8 weeks
months or 8
after 1st dose weeks after
2nd dose

19–48 months 11–13 years or
or 8 weeks
7th grade
after 2nd dose

Varicella

2

13–18
months or
history of
diagnosed
varicella

N/A

49–72 months N/A

49–72 months N/A
or history of
diagnosed
varicella

19–48 months 11–13 years or
or within 8
7th grade
weeks after
3rd dose

11–13 years or
7th grade

Note. Adapted from “Arkansas State Board of Health: Rules and Regulations Pertaining to Immunization
Requirements,” by Arkansas Department of Health, 2008, Retrieved from http://www.healthy.arkansas
.gov/Aboutadh/Rulesregs/Immunizationreporting.pdf.

Education grade and vaccine completion. Table II in AIL identified specific
numbers of doses and vaccine types required and completed on or before attaining certain
grade levels (ADH, 2008). The adolescent was unvaccinated if the dose series was not
completed and documented or if an exemption was noted in the immunization-registry
records.
Certain clinical criteria were based on the immunization schedule, such as age and
interval since the last dose was received and before the next dose was administered. This
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interval in time was the time between date of birth and the date when the specific vaccine
was administered, reported in AIR. If the interval of days between vaccine doses was
within ± 5 days of the maximum length of time required for the next recommended dose,
those children was considered vaccinated (ADH, 2008; CDC, 2014a, 2014b). However,
intervals greater than 5 days of the maximum length of time for any vaccine series
requiring more than one dose meant I classified the adolescent as unvaccinated, if they
did have a documented new series of completed vaccinations among those previously
missed.
In addition to the age vaccine milestone, I also had a grade-appropriate
vaccination requirement. The state mandated certain vaccine milestones for kindergarten,
third grade, and seventh grade, to achieve school-entry requirements. Table 2 simplifies
the recommended schedule and reflects the expected coverage for all children enrolled in
public school (ADH, 2008). However, the observed immunization coverage varied and
because of missed vaccine doses, inappropriate intervals sometimes accrued for
immunization doses or immunization exemptions (LoMurray & Sander, 2011a).
Age-appropriate status. Age-appropriate status means the specific duration or
optimal age to receive all vaccine doses in a series (Kim & Lee, 2011). For example, ageappropriate status for the first dose of Tdap vaccine was 12–15 months (CDC, 2011i).
Age-appropriate status was expressed as an age-specific trend through measured
parameters such as rates of vaccine coverage for age-specific groups: younger than 1
year, 1 to 10 years, and 11 to 18 years (Skoff et al., 2012). In these measurements, the
numerator was the number of persons in the age-specific group who received the vaccine
such as Tdap and the denominator was the total number of persons in the cohort who
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were eligible to receive the vaccine (Lindley, Smith, & Rodewald, 2011). The cohort
vital statistics data provided eligibility status. Eligibility-inclusion criteria were based on
the cohort birth date, January 1, 1990 to December 31, 1990, county birth place of
Pulaski, and valid vaccine doses administered between January 1, 1990 and December
31, 2008.
Measure of Home Status
The ADHS foster-care criteria were legal court and state-award assignment of
children for social custody-protection services. Children assigned to ADHS socialprotective services were registered in the CHRIS system as foster-care children eligible
for adoption (ADHS, 2010). The CHRIS system was the source for FCA demographic
information used by the registry to match vaccine records. The ADHS provided an
identified FCA name roster to ADH. The ADH matched the FCA names with their
corresponding vaccine records. All FCA and NHA vaccine records in AIRD were coded,
deidentified with unique numbers, and then released to me. The ADH also processed
NHA and FCA vaccine records to protect adolescents and maintain confidentiality and
privacy. NHAs were individuals who were not wards of the state, never enrolled in
ADHS, and were not identified in the CHRIS system.
Variable Definitions
Vaccination coverage uptake (VCU): The number of adolescents with FVSEcompleted dose series divided by the number of adolescents in the 1990 birth cohort,
PCA, and then multiplied by 100.
Immunization rate: The number of adolescents in the age group (1990 PCABC)
who received FVSE in PCA divided by the number of adolescents in the target
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population who were legally required to receive FVSE (ADH, 2008; ALB, 1993)
multiplied by 100,000.
Age-specific immunization rate: The proportion of vaccines in a dose series
received by children, as prescribed in ACIP immunization schedules (CDC, 2007d). For
example, this category includes the number of adolescents of a specific age such as 13–
15 years old in the 1990 PCABC who received a number of vaccine doses of FVSE
divided by the total number of adolescent vaccine doses of FVSE in that target 13–15year age group who are legally required to receive FVSE (ADH, 2008; ALB, 1993)
multiplied by 100,000.
Five vaccines for school entry (FVSE): Four doses of Td/Tdap, three doses of Hep
B, two doses of MMR, three doses of OPV/IPV, and two doses VAR (ADH, 2008).
Pulaski County, Arkansas birth cohort (PCABC): Adolescents born in PCA in the
birth cohort between January 1, 1990 and December 31, 1990.
Natural-home adolescent (NHA): An adolescent who lives with their natural or
adoptive parents, has never been in child-protective services, and attended public schools
from 1996 to 2008 in PCA (ADHS, 2010).
Foster-care adolescent (FCA): An adolescent up to age 18 years who does not
live in their natural or adoptive parents’ residence and are under court-ordered judicial
protective care supported through ADHS control (ADHS, 2010).
Potential Covariate Variables
Age, race, ethnicity, and gender were important covariates in which immunization
coverage for the FVSE differed between groups, thereby confounding true associations.
The specific race and ethnic codes I used appear in Table 3.
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Table 3
Covariate Codes, Pulaski County, Arkansas, 1990 Birth Cohort
Covariates

Codes

Caucasian

W

African American

AA

Other

O

Hispanic

H

Not Hispanic

NH

Female

F

Male

M

Data-Analysis Plan
Variable Calculations
Immunization-completion calculation. I calculated the total number of doses
per vaccine recommended for FVSE based on adolescent-age distribution in Appendix A,
Table A1, adopted from tables in AIRR (ADH, 2008). Each vaccine dose series had a
maximum number of doses required to complete the vaccine series. I based the vaccinecompletion calculation on addition of all valid doses at appropriately administered
intervals established in the ACIP vaccine schedules (CDC, 2008b).
Independent and dependent variables. The independent variable was HOR,
defined as NHA or FCA in the 1990 PCABC. The dependent variables were UTD and
age-appropriate UTD FVSE. Potential covariates included gender, race, and ethnicity.
Descriptive Statistics
Descriptive statistics were a descriptive quantitative analysis plan for normaldistribution archival-immunization data. The quantitative parametric test included
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multivariate analysis and statistical central tendencies: frequencies. The specific
cumulative vaccines required for school entry were Td/Tdap, Hep B, MMR, OPV/IPV,
and VAR. I analyzed the 1990 PCABC archival-immunization data from AIRD with SAS
9.3 software (Cary, North Carolina, USA).
I counted duplicate vaccine doses for the same vaccine series administered at
spaced interval as valid doses in the numerator. I corrected multiple different
immunization dates for the same vaccine series based on the ACIP vaccine schedule
(CDC, 2008b). I considered a vaccine series to have been completed if the total number
of valid doses was equal to the number of doses for that vaccine type. I repeated this
process for all FVSE and calculated the percent of immunization rates.
AIR built immunization-registry records from health-provider documented and
reported immunization histories of individually administered vaccines (Khare et al.,
2000). However, it was important to maintain the accuracy and completeness of the
immunization histories and eliminate significant errors in children’s names, dates of
birth, vaccine types, no data reported, and overall duplicate records to calculate coverage
accurately (Khare et al., 2000). Each unique identifier number accompanied vaccine type
with doses administered. If the same vaccine dose was administered beyond the required
maximum dose number, then I considered the rest to be duplicates and did not include
them in the analysis. Thus, I defined excess doses as over-immunization.
The names of individual adolescents were not important in this analysis. ADH
coded individual immunization records with a unique number and identified all FVSE
vaccine doses received and documented in that record. I did not count or include the
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vaccine doses that fell outside the defined ACIP vaccine schedule (CDC, 2008b) in the
analysis as valid doses for that vaccine series.
Research Questions and Hypotheses
Four Research Questions and Data-Analysis Plan
This data analysis plan addressed four research questions.
RQ1: Are the calculated 2006–2008 adolescent percent vaccination uptake (VCU)
for FVSE among the 1990 Birth cohort in PCA (PCABC) significantly different
from the FVSE reported 2006–2008 U.S. national adolescent estimated
immunization rates?
Ho1: There is no difference between the 2006–2008 PCABC calculated
percent VCU for the FVSE and the reported 2006–2008 U.S. adolescent
national immunization teen (NIS-Teen) estimated percent VCU for the FVSE.
Ha1: There is a difference between the 2006–2008 PCABC calculated percent
VCU for the FVSE and the reported 2006–2008 U.S. adolescent NIS-Teen
estimated percent VCU for the FVSE.
Research Question 1 analysis plan. To compare rates in the PCABC and the
United States, I conducted direct standardization, standardizing the rates by age. The
standardization accounted for any mixing of a third factor, age, and vaccine coverage
uptake. The goal of the standardized rates was to account for any mixing of a third factor
and multiple other factors with the primary association of interest. I then performed the ttest statistical analysis to compare differences between PCABC and the United States for
test significance.
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Direct-standardization statistical tool. I standardized the PCA birth cohort
PCABC vaccine UTD to the 2010 U.S. Census to compare adjusted rates between
PCABC and U.S. NIS-Teen. I determined the total population census for 2010 for the
United States, Arkansas, and PCA from the U.S. Census Bureau for 2010. An example of
direct standardization steps and Table 4 illustrate how I adjusted immunization rates. I
extracted the age distributions total census for 16, 17, and 18 years from the U.S. Census
Bureau to determine the weighted factor (w) for each age group. The number of PCA
adolescents was the numerator. The number of U.S. adolescents in the U.S. Census 2010
was the denominator. The numerator divided by the denominator equaled the weighted
factor. The weighted factor is the fraction of PCA adolescents for each age group, 13–18
years, depending on the years 2003–2008, based on U.S. Census adolescents for that
year. I determined the weighted factor for each age group (13–16 years for 2006) for
PCABC and U.S. NIS-Teen. I converted the vaccine percentage from SAS frequency
analysis to fractions (m) for each vaccine for each year 2003–2008. I multiplied the m
value by the w for each age stratum for that year. Then m*w yielded the adjusted UTD for
that age. I repeated this multiplication for ages 13–16 years (if 2006), then summed to
obtain the vaccine-adjusted rate for that year.
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Table 4
Calculations Direct Standardization Vaccination Rates: Age Standardized to 2010 U.S.
Population
Arkansas
2006
PCABC

Standard
population
2010 census

U.S. 2006
NIS

Standard
population
2010 census

Age

m

w

m*w

Age

m

w

m*w

13

x

b

xb

13

x

b

Xb

14

x

b

xb

14

x

b

Xb

15

x

b

xb

15

x

b

Xb

16

x

b

xb

16

x

b

Xb

sum(m*w)

CT.00%

sum(m*w)

CT.00%

Note. PCABC = Pulaski County Arkansas birth cohort; NIS = national immunization surveys.

Direct standardization steps.
1. U.S. 2010 total census came from the U.S. Census Bureau
2. Arkansas population 2010
3. Total number of adolescents each year 16, 17, and 18 years
4. PCA number of age specific 16, 17, and 18 years
5. Vaccine percentages for each year 2006, 2007, and 2008
6. Immunization rates from the SAS frequency for each vaccine for each year
2003–2008: 2003 represents age 13. Next, I determined PCABC and U.S.
NIS-Teen percentages for UTD all vaccines Td/Tdap, Hep B, MMR,
OPV/IPV, and VAR. The vaccine UTD is the m value in the equation to
determine the adjusted vaccine UTD for 2010
7. The weighted factor w was the percent of PCA based on U.S. Census
adolescents for that year.
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8. m*w yielded the adjusted UTD for that age. I repeated these multiplications
for 13–16 years for 2006 because in 2006 the cohort was 16 years old. I
summed m*w to obtain the 2006 UTD for each vaccine.
9. D and P were the confidence-interval-value minimum and maximum ranges.
RQ2: Are there differences in percentage of FVSE vaccine coverage uptake
between NHA and FCA among adolescents in the 2003–2008 PCABC?
Ho2: There is no significant difference in FVSE coverage uptake between the
HOR defined as NHA and FCA in the 2003–2008 PCABC.
Ha2: There is a significant difference in FVSE coverage uptake between the
HOR defined as NHA and FCA in the 2003–2008 PCABC.
Research Question 2 analysis plan. I dichotomized FVSE as yes, UTD for all
five vaccines, or no, not UTD, even if one vaccine was missing. I conducted chi square
analysis to examine whether an association emerged between UTD FVSE and HOR:
NHA or FCA. A significant association existed; I then conducted multiple logistic
regressions to determine the odds of being UTD for FVSE for an NHA versus an FCA. I
conducted multiple logistic regressions to control for the confounding effects of age, race,
ethnicity, and gender.
Chi square test statistic and confounding analysis.
•

I calculated the chi-square test (χ2) and reported p-values in Chapter 4.

•

I used the chi-square test (χ2) to test the association between NHA/FCA HOR
and the vaccine UTD dependent variable.
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•

I found that confounding variables distorted the strength of the relationship
between the independent variable HOR (NHA or FCA) specific stratum and
the UTD outcome variable.

•

I calculated and compared five-vaccine UTD rates among NHA/FCA-specific
stratum related to a covariate variable (race, gender, and ethnicity).

•

I compared NHA and FCA stratum-specific association significance with
vaccine UTD-specific stratum when controlling or adjusting for race, gender,
and ethnicity.

•

For example, NHA or FCA had a stratum for race (African American,
Caucasian, and other); gender (male or female); and ethnicity (Hispanic and
non-Hispanic).

•

The criteria for significant association was p-value (p < .05) when I included a
confounder stratum (race, gender, and ethnicity) in the logistic regression
model, based on test statistics of p-value (p < .05) and the odds ratio (OR)
likely associated value (if the OR has a positive or negative value). Caucasian
adolescent was the reference (1) in the race covariate.

•

I performed the chi-square test (χ2) analysis, OR calculations in SAS
applications. I controlled and eliminated the confounding variable to establish
a clearer relationship between the NHA/FCA and UTD.

•

I performed manual calculations of the chi-square test vaccine UTD.

•

χ2 = (o − e)2/e; observed (o), expected (e).
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RQ3: Is the association between HOR, defined as NHA and FCA, and UTD of
FVSE coverage mediated through sociodemographic characteristics, which
include age, race, ethnicity, and gender in PCABC?
Ho3: The associations between HOR, as defined as NHA or FCA, and UTD
FVSE in PCABC is not mediated through sociodemographic characteristics,
including age, race, ethnicity and gender.
Ha3: The associations between HOR, defined as NHA or FCA, and UTD
FVSE in PCABC is mediated through sociodemographic characteristics,
including age, race, ethnicity and gender.
RQ3 analysis plan. I examined the statistically significant effect mediation by
sociodemographic characteristics on the main-effect association, association between
HOR, and UTD FVSE (see Figure 3). I conducted multiple logistic regression analyses
by including interaction terms in the model. I performed bivariate logistic regression to
examine the association between FVSE and HOR while controlling for covariates race,
gender, and ethnicity. I report the results in Chapter 4.
Multiple logistic regression model to account for mediated variables.
•

I tested if the mediating variable has a significant direct or indirect effect on
the relationship between NHA/FCA (X variable) and vaccine UTD (Y
variable).

•

I tested the effect significance-based calculated OR and p < .05 in the
regression model to determine if the mediator variable p-value estimates
increased or decreased.
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Figure 3. Mediating effect diagram.
Three outcomes.
•

I gained a better understanding of the overall relationship between NHA/FCA
(X variable), vaccine UTD (Y variable), and covariates.

•

I performed a bivariate logistic regression to examine mediation from
covariables.

•

The mediator explains the X–Y relationship when a significant association
emerged with or without the mediator. If the X and Y variables and covariates
aligned or related because of a mediator (M) variable such as gender, race, and
ethnicity, then M facilitated the association between X and Y. Changes in OR
and p < .05 without M yielded no association between X and Y. Thus, X −> M
−> Y.
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•

I measured the association and mediation bases estimates of OR and p < .05;
p-value significance was based on p < .05.

I measured three outcomes using estimates of p-value based on p < .05.
•

Mediation present: The calculated p-value diminished to near zero (.0001), a
direct effect is not significant, and the mediator is present. The effect of X on
the mediator is significant and the effect of the mediator on Y is significant.

•

Partial mediation: The direct effect of X to Y is borderline significant when the
mediator is absent.

•

No mediation: The direct effect from X to the mediator is insignificant and the
Mediator to Y is insignificant.

Accounting for mediated variables will increase understanding of three potential
outcomes when the mediating variable is included in the multiple logistics model.
Determining mediation. A variable must satisfy three criteria before it is deemed
a mediator. It must align with the main outcome variable; it must align with the exposure
variable; and it must be in the causal pathway between the exposure variable and the
outcome variable. I conducted bivariate analyses to determine whether each covariate
satisfied these criteria. Each variable that was not associated with the outcome variable
and the exposure variable was not a mediator. Further testing prevented Type II error,
incorrectly concluding that mediation does not exist. These bivariate regression processes
detected simple mediation (Preacher & Hayes, 2008) and identified any differences in
direct and indirect mediation (Preacher & Hayes, 2004). The additional examination
decomposed any causal association to expose the contribution of each variable
(MacKinnon, Lockwood, Hoffman, West, & Sheets, 2002). This process ensured
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exhaustive and complete testing (MacKinnon et al., 2002) of all variables in the bivariate
logistic regression analysis, examining the association between FVSE and HOR and
mediating variables (Baron & Kenny, 1986; MacKinnon, Krull, & Lockwood, 2000). The
extent and strength of the association revealed and explained, for each variable, the effect
of that variable on the outcome (Preacher & Hayes, 2004).
RQ4: Will differences in individual vaccine payoff, measured by avoidance of
disease development as a result of vaccine receipt, affect group interest, measured
by deaths as a result of nonvaccination for the FVSE among the PCA?
Ho4: Differences in individual vaccine payoff, measured by avoidance of
disease development as a result of vaccine receipt, will not affect group
interest, measured by deaths as a result of nonvaccination, for the FVSE
among the 1990 PCABC.
Ha4: Differences in individual vaccine payoff, measured by avoidance of
disease development as a result of vaccine receipt, will affect group interest,
measured by deaths as a result of nonvaccination, for the FVSE among the
1990 PCABC.
Research Question 4 analysis plan. I operationalized the vaccination TOG
equation parameters and developed a model for payoffs. I then applied the individual
equilibrium equation and group optimum equation to calculate payoffs. The r (attack
rate) parameter was significant in the two equations:
•

The attack rate [r] for a VPD was the number of persons in the age group with
the VPD divided by the number of persons in the age group, then multiplied
by 100.
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•

The individual strategy was the delayer strategy: The goal was to delay
vaccine maximized protection-benefit payoff, reduce risk from VPD attack,
and diminish death from vaccine.

•

I used the attack rate r in the individual equilibrium equation to calculate the
probability of death due to VPD or vaccine.

•

The group optimum is a preemptive strategy: The payoff outcome minimizes
the expected cost of vaccination, which is death from VPD.

•

I used the attack rate r in the group optimum equation to calculate the
expected cost of vaccination: the level of vaccine coverage to minimize death
due to VPD or vaccine.

The individual-equilibrium equation. I used the individual-equilibrium
equation to examine the relationship between those who preemptively received
vaccination and those who delayed vaccination for each of the FVSE. The payoff for an
individual receiving vaccination can be expressed as Evac = −dv where dv is the
probability of death from vaccination. Because the probability of death due to vaccination
was usually small, I usually ignored dv in the equation; therefore, I usually assumed Evac
was 100%,

or 1 when expressed as a probability. Therefore the focus was on the effect of

an individual who delayed vaccination and the risk of acquired disease when an outbreak
occurred. Edel (p) was the equation to examine vaccine delay and the payoff associated
with delay:
Edel (p) = −r[ϕs(p)ds + ϕv(p)dv],
where, Edel(p) calculated payoff when an individual chose to delay vaccination; r is the
risk of attack from a VPD after an outbreak occurred, calculated as the number likely to
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become infected when no vaccine protection was divided by total population at the risk of
becoming infected. ϕs (p) is the probability that a delayer becomes infected with the
disease after an outbreak; calculated as the total number of eligible unvaccinated divided
by the total population at risk of becoming infected. ds is the probability of death due to a
VPD; calculated as the total number of deaths among those who are unvaccinated from
VPD divided by the total population at risk of becoming infected. ϕv (p) is the probability
that a delayer was vaccinated successfully after an outbreak; calculated as the total
number of disabilities among delayers receiving the vaccination divided by the total
number of delayers who received vaccination. dv is the probability of death of the
individual from vaccination; calculated as the total number of deaths due to the
vaccination divided by total number of those receiving the vaccine.
Because the goal of the individual equilibrium, Pind was the examined relationship
between Evac and Edel, the mathematical model for a maximized payoff of receiving a
vaccine was significant. In the model where Evac = 1 or 100% vaccine efficacy, no deaths
from vaccination occurred, and a minimized payoff of delayed vaccination where Edel = 0
had no payoff for delayed vaccine. Therefore, the expected association was Evac > Edel.
When Evac ≤ Edel then the individual equilibrium, Pind, may approach zero, where,
although an effective vaccine existed, the payoff for delayed vaccine did not pose any
additional harm (Bauch et al., 2003). Under such circumstances, individuals chose not to
be vaccinated, thereby zeroing out the individual equilibrium, Pind. An important
assumption when calculating individual equilibrium was that individual behaviors would
increase survival from VPDs when vaccines were readily available.
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The group optimum. The group interest and importance was to minimize the
total number of deaths due to vaccination and infection when an outbreak of a VPD
occurred. Thus, I examined the group optimum and applied the equation
C(p) = pdv + r(1 − p)[(ds − dv)ϕs(p) + dv],
where C(p) was measured as a probability between zero and one. This was the coverage
level required and imposed to minimize the total expected number of deaths due to a
VPD. All other parameters in the group-optimum equation and variables were the same
as those described in the individual equilibrium.
Threats to Validity
External Validity
The results of this study were drawn from a sample of children born in a 1990
PCABC. External validity was the ability to generalize results of this study from a sample
to the general population (Trochim, 2006). The results are generalizable to the population
of all children born in 1990 in PCA who attended public schools between the ages of 6
and 18 years from 1996 to 2008.
Extrapolating results of the study to other adolescent populations threatens the
validity of the study. External factors during the data periods influenced certain causal
relations between variables. Such influencing factors had the same effect when the results
were generalized to another population. For example, in 2003 Arkansas state law allowed
immunization exemptions based on medical, philosophical, religious, and personal beliefs
(ADH, 2003). The effect of the law influenced immunization rates for vaccines such as
exemptions from Hep B, VAR, and Tdap at the time and age when the vaccine was to be
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administered. During 2003, adolescents in the 1990 birth cohort were 13 years old,
eligible, and required to receive these seventh-grade vaccines.
The methods and analysis of registry data were replicable when I defined
immunization parameters, variables, and outcomes. Dissemination of research results is
important for future research (Steckler & McLeroy, 2007). These results provide
evidence-based immunization rates and may support strategies to prevent disease,
hospitalization, and mortality among adolescents in PCA.
Internal Validity
This study had four significant internal validly threats: immunization enrollment
and reporting (Stevenson et al., 2000), no vaccine history or missing records,
immunization data-quality assurance (American Immunization Registry Association,
2008), and duplicate records (American Immunization Registry Association, 2006).
Errors in vaccine administration included documentation of date of birth and vaccination
dates (Khare et al., 2000). These threats contributed to incorrect reported results.
Therefore, individual-history record completeness and correctness of variables in
immunization data were essential in maintaining the accuracy of the reported outcomes.
Incomplete vaccine-records data were due to passive reporting to AIR and
provider delays beyond the allowed 30-day reporting period. Another problem with
record accuracy was duplicate records (American Immunization Registry Association,
2006). Immunization-record duplication occurred when transposing name order, date of
birth, wrongly coded vaccines, incorrect vaccine type, errors in documented dose series
number, errors in lot numbers, and incorrect reported date of immunization. Vaccinehistory data were lost, not reported, or incomplete due to electronic transmittal, or used
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incompatible electronic formats or software. The HL7 2.x data-exchange format was the
compatible standard that used an open architecture and facilitated effective immunization
data transfer between healthcare providers and AIR (ADH, 2011a).
The research focus was to examine each record for duplicate vaccine doses and
invalid doses. The unique identifier-number feature aggregated all vaccine records
associated with the unique number. Therefore, documentation of the same vaccine type
administered with the same date of administration indicated duplication. I included only
one dose of that specific vaccine, administered on the same day, in UTD calculations and
completion of that vaccine dose series. I matched an individual’s date of birth with
interval dates of vaccine administration to enhance outcome accuracy and minimize
internal-validity threats. I verified complete vaccine-dose series and birth-date matches
with established ACIP schedules for vaccine series completion for childhood- and
adolescent immunization schedules. Standardized EHR with compatible HL7 2.x
exchange software increased accuracy in Datalink between provider offices and the AIR.
Use of handwritten reports exacerbated errors. Bar-code systems used in scanning patient
records and vaccine vitals at point of vaccine administration further eliminated any
clerical documentation errors (Khare et al., 2000). This efficient system linked to the
registry, thereby eliminating delays in passive reporting. Also, computerized systems
improved individual vaccine-records documentation and retrieval. Duplicate records were
minimized and points of delivery enhanced through documentation of correct names,
dates of birth, vaccine types, and dates of administration, thereby minimizing records.
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Ethical Procedures
Confidentiality, privacy, and personal protected information were ensured through
deidentification of all immunization data for FCA and NHA. I recruited no participants
for this study; therefore I had no ethical concerns related to recruitment materials,
processes, and plans to address them. I completed the ADH ethical-research
requirements, Walden University IRB application, and the National Institutes of Health
certification course. ADH ethical-research requirements consisted of understanding the
Health Insurance Portability Accountability Act, confidentiality, and privacy training. I
obtained the data-use agreements from ADH and ADHS to enable access to research
data.
Institutional Review Board Application
I submitted an IRB application to the ADH with clear declaration that this study
did not involve or require any human subjects or participants. The IRB application was
required because information for this study involved confidentiality of individual healthprotected information. The name and identifiable individual information for each
immunization record was blinded to me as assurance of the confidentiality of minors
involved in this adolescent-cohort immunization study. I signed a memorandum of
understanding that the registry data were deidentified in that all names, social security
numbers, and any identifiable information were removed prior to receiving the data sets
from the ADH.
The ADH SAC and Walden University received IRB-request applications. I
obtained IRB approvals from each board before receiving any AIRD data. I submitted a
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certificate of completion of the National Institute of Health course on Protecting Human
Research Participants as part of the IRB-application process.
Ethical Concerns in Archival Data
Risk/benefit assessment. No risk or probability and magnitude of harm or
discomfort was imposed on any participant in this study. This research was limited to
immunization archival data. All personal information was deidentified and the ADH did
not release participants’ names to me. Although primary data collection was not part of
this study, data collected by the AIR met scientific standards for research data, as
prescribed by federal law under section 45 CFR 46.102(h)(i)).
Benefit assessment. This immunization research has potential health-related
impacts and benefit for future policy, campaigns, or interventions. Any identified
vaccines with low coverage offered benefits to future adolescents through the
implementation of intervention or policies that target increased immunization coverage.
High-immunization rates lower the risk of disease among individuals (Glanz et al., 2010).
Any vaccine that achieved an immunization rate of 90% or greater, as established by the
Healthy People 2020 indicator, contributed community protection through herd immunity
(National Network for Immunization Information, 2006; Schlenker, Bain, Baughman, &
Hadler, 1992). Immunization rates of 90% and greater for populations were protective
over time and reduced the risk of VPD outbreaks such as varicella (Lee et al., 2008;
Vázquez et al., 2004). The risk of disease greatly diminished when populations achieved
critical immunization coverage thresholds. For example, coverage thresholds occurred at
levels as low as 85% for diphtheria, measles, rubella, and smallpox, and at 94% for
pertussis (National Network for Immunization Information, 2006).
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Summary
I used a cross-sectional study design to conduct this quantitative inquiry. The
cross-sectional design was appropriate because I analyzed and compared archival data on
PCABC NHA and FCA immunization rates for FVSE. The methodology was a
quantitative analysis of four research questions and commensurate hypotheses. The
outcomes measured in this inquiry included UTD for FVSE and percent vaccine coverage
uptake among PCABC. Study results were generalized to PCABC. The theoretical
foundation in this study was the TOG construct (von Neumann & Morgenstern, 1944).
This cross-sectional-design study employed a retrospective secondary analysis of
data collected through the AIR between 1990 and 2008 for the PCABC. The statistical
analyses were frequency, chi square, direct standardization, bivariate, and multiple
logistic regressions, determining that immunization-rate differences and disparities
existed among groups. The four findings from this quantitative analysis of the AIR data
contributed justification for immunization campaigns and public health interventions.
First, I calculated direct standardization adolescent-vaccination-coverage uptakes for
FVSE. I compared the adjusted vaccines uptake rates for the 1990 PCABC to U.S.
adolescent coverage uptakes from 2006 to 2008. Second, chi-square analysis identified
and compared differences in vaccine coverage between NHAs and FCAs among the 1990
PCABC. Third, I evaluated strength of association between HOR with vaccine UTD with
multiple and bivariate logistic regression analysis. For the 1990 PCABC, fourth, I used
VGT with applied individual equilibrium and group optimum constructs, and
mathematical-model equations that contributed to quantify payoff deaths associated with
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vaccination decisions. The TOG posited that the decisions of a group influence individual
behavior.
Analysis data were archival data from AIR for the 1990 PCABC. The analysis
plan was operationalized based on the four research questions and hypotheses. I defined
the independent variables, covariates, and dependent variables in the text along with
descriptive quantitative statistical tools used in this study. The important outcomes were
primary associations of HOR with immunization, vaccine UTD, and percent coverage
uptake.
The analysis in this study answered four main research questions and hypotheses
and compared FCA and NHA. This was important because the actions of a group
influence individual immunization behavior (Bauch et al., 2003). The adolescentvaccination coverage uptake was a significant component in this study because of the
FVSE. I used the individual equilibrium construct of TOG to examine the probability of
preemptive vaccination among individuals in the PCABC. If the proportion of population
preemptively vaccinated was greater than the proportion of population who refused the
vaccine, then the population achieved a herd immunity threshold.
The theoretical foundation for this study was the TOG. I used TOG constructs
(von Neumann & Morgenstern, 1944) to explain individual and group decisions related to
vaccination coverage uptake. Using the TOG framework, I calculated the threshold level
of VCU (Bauch & Earn, 2004) in a population herd immunity required to prevent disease
and minimize the total number of deaths (Baguelin et al., 2013) from vaccination delay or
refusal.
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The adolescent-vaccination coverage uptake was a significant component in this
study. I used the TOG construct (von Neumann & Morgenstern, 1944) to explain
vaccination decisions related to coverage uptake. The factors that affected individual
decisions to vaccinate related to self-interest (Ibuka et al., 2014), actions of others
(Meszaros et al., 1996), risk of infections, and perceived costs and benefits (Basu et al.,
2008; Whitney et al., 2014) associated with primary immunization-access factors.
The TOG (von Neumann & Morgenstern, 1944) offered an important modeling
framework for adolescent immunization actions, choices, or behaviors to maximize or
minimize payoffs. The “game” was a social situation that required behavior, choice,
actions, and payoff. The payoffs were quantifiable consequences associated with a
particular event, action, or behavior of each participant (M. C. Jackson et al., 2015). The
modeling included probabilities, proportions, and frequencies of immunization actions,
choices, or behaviors.
The importance of game theory and vaccination was the cost or payoffs associated
with adolescent immunization actions, choices, or behaviors. For example, group
equilibrium was the decision to immunize and the consequences of that immunization
(protection, disease, or death). The probability, frequencies, and proportion were
quantifiable actions performed by participants. I calculated the uncertainty actions of
participants to predict or forecast adolescent immunization behavior. The social-change
impact of predicting adolescent immunization uptake was valuable for public health
functions.
Three positive social-change implications accrued from this study. First, results
impact parents, community stakeholders, and legislative policymakers, providing
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awareness, knowledge, and understanding of the FVSE VCU-coverage quantifiable
evidence. The second positive social change was the ability to make informed decisions
to vaccinate (Shim, Kochin et al., 2010) associated with VCU coverage, vaccine UTD,
and disease outbreaks (Anderson & May, 1985). Another positive social change from this
study is the ability to calculate the minimum number of total deaths from not vaccinating
adolescents (Bauch & Earn, 2004) against infections from each of the five required
adolescent vaccines among the 1990 PCABC. The research focus of Chapter 4 was the
data analysis, interpretation, and presentation of results.
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Chapter 4: Results
Study Purpose
This cross-sectional study had four main purposes. The first purpose was to
calculate and compare adolescent immunization rates between the 1990 PCABC and the
U.S. national adolescent immunization survey from 2003 and 2008. The second purpose
was to assess whether an association would emerge between HOR, defined as NHA or
FCA, and UTD status of FVSE. The study’s third purpose was to determine if the
associations between HOR and UTD FVSE in PCABC were mediated by such
sociodemographic risk factors as age, gender, race, and ethnicity. The fourth purpose was
to test a mathematical model based on vaccination-coverage uptake and the TOG.
Data Collection
From January 1, 1990 to December 31, 1990, the PCA had 9,102 recorded live
births. However, only 3,371 met the data-collection criteria. The four eligibility data
collection criteria were (a) date of birth, (b) geographic criterion, (c) school attendance,
and (d) vaccine records in the AIR registry. From the 3,371 children, 74,292
immunization observations were recorded between 1990 and 2008 that covered the
FVSE. An observation was defined as each data point in the vaccine record. For example,
date of birth in a record is an observation. Similarly, gender, race, date of vaccine
administration, vaccine type, dose number in the vaccine series, and location are all
observations in a record for a vaccine-dose administration for each visit. I evaluated the
immunization records for all PCABC 1990 members based on established vaccine-dose
criteria (ADH, 2008) to determine vaccination UTD status for FVSE.
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From the extracted data, I was able to identify the demographic characteristics of
the 3,371 adolescents born in PCA in 1990, based on demographic ethnicity, gender, and
race. I defined ethnicity as Hispanic or not Hispanic, gender as male and female, race as
African American, Caucasian, and Other (which included Asian, Native American, and
Native Alaskan Islander). The HOR of the adolescent was the independent variable
defined as NHA and FCA. The UTD status was the dependent variable and was
calculated based on the ADH and CDC vaccination schedule for the FVSE, which
included Td/Tdap, Hep B, MMR, OPV/IPV, and VAR. I used Microsoft Excel and SAS
9.3 software (SAS Institute, 2012) for data analysis.
Results
Demographic Characteristics
Of the 3,371 adolescents, 53.2% were African American, 30.7% were Caucasian,
and 16.1% identified as Other. Adolescent females accounted for 54.9% of the birth
cohort. The majority of the birth cohort was non-Hispanic (97.3%). Overall, only 527 of
the adolescents (15.6%) were UTD for all FVSE. The UTD analysis for FVSE was
reported for HOR, gender, ethnicity, and race. The total UTD status for FCA was 29.4%
compared to 15.1% UTD for NHA. The PCABC overall UTD immunization rate for
FVSE was 15.6%. PCABC females were 15.4% UTD, compared to 16.4% UTD for
PCABC males. The UTD status for Hispanics was 16.5%, compared to 15.5% UTD for
non-Hispanics.
Table 5 shows the overall cohort vaccine-coverage uptake for the FVSE. The
VAR vaccine-coverage uptake among PCABC was 1.6 times lower than the FVSE
coverage. Among the PCABC, none of the vaccines reached the 90% coverage

94
recommended by Healthy People 2020 for any race or ethnic group. However, an overall
association between race and ethnicity and UTD status for FVSE did emerge in that
African-American adolescents were more likely to be UTD than Caucasian and otherrace adolescents (see Table 6).
Table 5
Pulaski County 1990 Birth Cohort Vaccine-Coverage Uptake, 2008
Vaccine

No

Yes
%

N
Td/Tdap

N (%)

%

570

16.9

2797

83.1

Hep B

1,099

32.6

2268

67.4

MMR

751

22.3

2616

77.7

OPV/IPV

522

15.5

2845

84.5

VAR

2,705

80.3

662

9.7

FVSE coverage

2843

84.4

524

15.6

Note. Td/Tdap = tetanus-diphtheria/tetanus-diphtheria-acellular pertussis; Hep B = hepatitis B; MMR =
measles-mumps-rubella; OPV/IPV = poliomyelitis; VAR = varicella.

Table 6
Pulaski County, Arkansas 1990 Birth Cohort Population and Five Vaccines for School
Entry FVSE Coverage Uptake By Race
FVSE vaccine UTD status by race
Total
Race

N

No
%

N

Yes
%

N

%

Total

3,371

100.0

2,840

84.3

531

15.7

African American

1,792

53.2

1,456

81.3

336

18.7

Caucasian

1,036

30.7

907

87.5

129

12.5

543

16.1

477

87.8

66

12.2

Other

Note. Statistically significant, p < .05.

χ2

p-value

25.93 < .0001
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Research Question 1 and Hypothesis 1
RQ1: Are the calculated 2006–2008 adolescent percent vaccination uptake (VCU)
rates for FVSE among the 1990 Birth cohort in PCA (PCABC) significantly
different from the reported FVSE 2006–2008 U.S. national adolescent estimated
immunization rates?
Ho1: There is no difference between the 2006–2008 PCABC calculated
percent VCU for the FVSE and the reported 2006–2008 U.S. adolescent
national immunization teen (NIS-Teen) estimated percent VCU for the FVSE.
Ha1: There is a difference between the 2006–2008 PCABC calculated percent
VCU for the FVSE and the reported 2006–2008 U.S. adolescent NIS-Teen
estimated percent VCU for the FVSE.
Direct-Standardization Analysis
As shown in Table 7, I compared the PCABC adjusted UTD coverage rates to
U.S. adjusted UTD coverage rates for 2006–2008 U.S. NIS-Teen. These results for
adjusted vaccine percent UTD coverage rates were based on U.S. 2010 Census data. The
U.S. NIS-Teen had a greater vaccine percentage of coverage uptakes for Hep B (12.0%),
MMR (11.6%), and VAR (70.2%) compared to PCABC from 2006 to 2008. Except for
Td/Tdap, PCABC had 16.4% vaccines coverage uptake greater than that of the United
States for 2006–2008. I included no comparison for OPV/IPV because U.S. NIS-Teen
has not collected polio data since 2000, when polio was eradicated in the United States.
The greatest vaccine differences between the two groups emerged among the UTD
coverage rates for the VAR vaccine.
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Table 7
Adjusted Adolescent Vaccine Coverage Uptake Differences (as Percentages) Between
Pulaski County, Arkansas Birth Cohort and United States, 2006–2008
Pulaski County, AR. 1990 birth cohort

U.S. National Immunization Survey

Vaccine

2006

2007

2008

Average

2006

2007

2008

Td/Tdap

84.0

84.0

83.8

83.9

58.2

72.3

72.1

67.5

3.51 .025

Hep B

77.9

75.6

74.2

75.9

82.1

87.6

87.9

85.9

4.59 .01

MMR

77.7

77.7

77.7

77.7

87.1

88.9

89.3

88.4 15.86 .000009

OPV/IPV

86.2

86.0

82.8

85.0

N/A

N/A

NA

VAR

17.0

17.4

28.8

21.1

89.4

92.7

91.3 17.59 .000006

N/A
91.8

Average t-test

p-value

N/A

N/A

Note. Td/Tdap = tetanus-diphtheria/tetanus-diphtheria-acellular pertussis; Hep B = hepatitis B; MMR =
measles-mumps-rubella; OPV/IPV = poliomyelitis; VAR = varicella; Pulaski County, AR birth cohort
1990 Data Analysis, p < .05 statistically significant; *Standardized to 2010 U.S. population.

Also shown in Table 7, I conducted a student’s t test for each vaccine—Td/Tdap,
Hep B (12.0%), MMR (11.6%), and VAR—to determine whether statistically significant
differences arose in adjusted average VCU reported for PCABC and the United States. A
statistically significant difference emerged for each vaccine—Td/Tdap, Hep B (12.0%),
MMR (11.6%), and VAR at p < .05—between PCABC and the United States.
Figure 4 illustrates the vaccine trends from 2006 to 2008 for PCABC and the
United States. The PCABC coverage declined 0.2% for Td/Tdap between 2006 and 2008
compared to U.S. adolescents’ 14.1% Td/Tdap coverage increase from 2006 to 2007 and
0.2% decline from 2007 to 2008. Hep B coverage showed a 3.7% coverage decline in
PCABC between 2006 and 2008. In contrast, U.S. adolescents had 5.8% increased
coverage for Hep B between 2006 and 2008. MMR coverage showed a 2.2% coverage
increase among U.S. adolescents between 2006 and 2008 compared to no coverage
change in the PCABC. OPV/IPV coverage showed a 3.4% decline among the PCABC
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between 2006 and 2008. In contrast, no U.S. data was available because the CDC
discontinued its household polio survey after 2006 because polio was declared eradicated
in the United States in 2000(CDC, 2011). The PCABC VAR vaccine coverage uptake
increased by 11.4% between 2006 and 2008 compared to a 3.3% increase among U.S.
adolescents.

Figure 4. Adjusted adolescent vaccine-coverage rate trends, United States and Pulaski
County, AR, 2006–2008.
Research Question 2 and Hypothesis 2
RQ2: Are there differences in percentage of FVSE vaccine coverage uptake
between NHA and FCA among adolescents in the 2003–2008 PCABC?
Ho2: There is no significant difference in FVSE coverage uptake between the
HOR defined as NHA and FCA in the 2003–2008 PCABC.
Ha2: There is a significant difference in FVSE coverage uptake between the
HOR defined as NHA and FCA in the 2003–2008 PCABC.

98
The chi-square analysis (χ2) results for RQ2 are in Table 8. An association arose between
HOR and vaccine uptake for four of the FVSE. Only Td/Tdap was not associated with
HOR and vaccine coverage. For all other individual vaccines, vaccine coverage was
higher among FCA than NHA. These three vaccines—Hep B, MMR, and VAR—had
strong positive associations with HOR. In contrast, OPV/IPV had weaker positive
association with HOR compared to the Hep B, MMR, and VAR vaccines. Children in
foster care, contrary to prior hypotheses, are no less likely to complete immunization
requirements than children in natural-home settings.
Table 8
Home of Residence Vaccine Coverage Uptake Comparison, 1990 Pulaski County,
Arkansas Birth Cohort
Foster care

Natural home
%

N

%

N

No

χ2

p-value

82.9

17.1

1.55

.21

2,172 1,077

66.9

33.1

10.89

.001

9.3

2,509

740

77.2

22.8

11.89

.0006

91.5

8.5

2,737

512

84.2

15.8

4.61

.0318

75

36.4

63.6

619 2,330

19.1

80.9

21.79

< .0001

83

29.7

70.3

619 2,630

19.1

80.9

18.5

< .0001

Vaccine

Yes

No

Yes

Td/Tdap

103

15

87.3

Hep B

96

22

MMR

107

No

Yes

No

Yes

12.7

2,694

555

81.4

18.6

11

90.7

OPV/IPV 108

10

VAR

43

FVSE

35

Note. Td/Tdap = tetanus-diphtheria/tetanus-diphtheria-acellular pertussis; Hep B = hepatitis B; MMR =
measles-mumps-rubella; OPV/IPV = poliomyelitis; VAR = varicella; p < .05 statistically significant.

To determine whether vaccine coverage remained associated with HOR after
controlling for race, ethnicity, and gender, I conducted multivariable logistic regression
analyses. After controlling for sociodemographic risk factors, HOR no longer associated
with UTD status for FVSE. As shown in Table 9, the race variable is the confounder
because it influenced the outcome of UTD status for FVSE. Race influences the
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relationship between FVSE and HOR, specifically through the OR, by increasing the
likelihood of association between FVSE and HOR. In fact, compared to Caucasian
adolescents, African American adolescents were statistically 77% more likely to be UTD
for FVSE (OR = 1.77, 95% CI 1.49–2.09) whereas adolescents listed as Other were 46%
less likely to be UTD (OR = 0.54, 95% CI 0.43–0.67).
Table 9
Logistic Regression Examining the Association Between Five Vaccines for School Entry
and Home of Residence Controlling for Univariates
Variable and covariate

Odds ratio (OR)

95% confidence limits

p-value

Foster-care adolescent

1.02

0.67–1.56

.91

Natural-home adolescent

1

0.86–1.17

.99

Home-Residence

Gender
Male

1

Female

1

Race
African American

1.77

1.49–2.09

< .0001

Other

0.54

0.43–0.67

< .0001

Caucasian

1

0.78–1.87

.4005

Ethnicity
Hispanic

1.21

Non-Hispanic

1

Note. p < .05 statistically significant.

Therefore, I conducted multivariable logistic regression (see Table 9) to
determine whether mediation existed between HOR, sociodemographic characteristics,
and vaccine UTD coverage. In answering RQ2, I found that HOR was associated with
FVSE. However, after controlling for sociodemographic risk factors, HOR was no longer
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statistically significantly associated with UTD for FVSE. Therefore, this finding satisfied
one of the criteria for mediation, that the association between the main outcome variable
and the exposure variable may be mediated by a third variable.
For this research question, I further examined whether the overall association
found in Research Question 2 could have been due to mediation. Results suggested that
one variable, race, mediated the association between HOR and UTD for FVSE.
Specifically, African American adolescents, regardless of their HOR, were statistically
significantly more likely to be UTD for FVSE compared to Caucasian adolescents. In
contrast, adolescents categorized as Other, regardless of HOR, were significantly less
likely to be UTD for FVSE compared to Caucasian adolescents (see Table 9).
Research Question 3 and Hypothesis 3
RQ3: Is the association between HOR, defined as NHA and FCA, and UTD
FVSE coverage mediated through sociodemographic characteristics, which
include age, race, ethnicity, and gender in PCABC?
Ho3: The associations between HOR, defined as NHA or FCA, and UTD
FVSE in PCABC is not mediated through sociodemographic characteristics,
including age, race, ethnicity and gender.
Ha3: The associations between HOR, defined as NHA or FCA, and UTD
FVSE in PCABC is mediated through sociodemographic characteristics,
including age, race, ethnicity and gender.
I conducted bivariate analyses to determine whether each covariate listed in Table
10 satisfied these criteria. If I failed to find an association between either the outcome
variable and the mediator or the exposure variable and the mediator, then that variable
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was not considered a mediator. The result for the bivariate mediation effect between
HOR and race for African American was not statistically significant (OR = 1.23; 95% CI
0.85–1.88). African Americans were 23% more likely than Caucasians to be associated
with HOR. The bivariate mediation effect between HOR and race for Other race groups
was statistically significant (OR = 0.19; 95% CI 0.07–0.53). Other race groups were 81%
less likely than Caucasians to with HOR. These results showed a weak positive
association between HOR and race when including all race categories in the analysis,
regardless of their home status as NHA or FCA.
When I tested HOR mediated by gender, the results for males were not
statistically significant (OR = 1.29; 95% CI 0.90–1.85, p = .1716). Similarly, results for
HOR mediated by ethnicity for Hispanic was not statistically significant (OR = 1.29;
95% CI 0.90–1.85, p = .1716). Then I conducted univariate analysis for the association
between race and UTD for FVSE. Results were statistically significant for African
Americans (OR = 1.79; 95% CI 1.51–2.12; p = < .0001) and Other race (OR = 0.48; 95%
CI 0.39–0.59; p=< .0001). African Americans were 79% more likely than Caucasians to
be associated with UTD for FVSE. Other race groups were 52% less likely than
Caucasians to be associated with HOR.
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Table 10
Bivariate Logistic Regression Results for Examining Possible Variables in the
Association Between FVSE and HOR
Variable and covariate

Odds ratio

95% confidence limits

p-value

Home Residence (NHA and FCA) Mediated by Race
Association between HOR and Race
African American

1.23

0.85–1.88

.2422

Other

0.19

0.07–0.53

.0016

Caucasian

1.00

Association between Race and UTD for All FVSE
African American

1.79

1.51–2.12

< .0001

Other

0.48

0.39–0.59

< .0001

Caucasian

1.00

0.90–1.85

.1716

0.85–1.14

.8072

0.61–1.88

.806

0.64–1.96

.6984

Home Residence Mediated by Gender
Association between Gender and HOR
Male

1.29

Female

1.00

Association between Gender and UTD for FVSE
Male

0.98

Female

1.00

Home Residence Mediated by Ethnicity
Association between HOR and ethnicity
Hispanic

1.07

Not Hispanic

1.00

Association between Ethnicity and UTD for FVSE
Hispanic
Not Hispanic
Note. p < .05 statistically significant.

1.12
1.00

I stratified HOR in Table 10 for the three covariates—race, ethnicity, and
gender—to examine mediation. Race (OR = 1.79; 95% Cl, 1.51–2.12; p < .0001)
significantly aligned with FVSE, but gender and ethnicity did not. The race OR and
p-value did not decrease or change during multivariate and bivariate logistic regression
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analyses. However, change did emerge in the ORs and p-values for gender and ethnicity.
Race mediated the association between HOR and FVSE based on established statistical
mediation criteria (Baron & Kenny, 1986; Fairchild & MacKinnon, 2009; MacKinnon et
al., 2000; Preacher, Zyphur, & Zhang, 2010; Sobel, 1986).
The results shown in Table 11 of the logistic regression hypothesis test for HOR
and FVSE revealed significant association when controlling for specific univariates:
home-residence FCA versus NHA (OR = 1.61; 95% Cl 1.47–3.34–1.56; p = 0.0001),
African American race versus Caucasian race (OR = 2.22; 95% Cl 1.29–2.004;
p=<.0001) when controlling for Other race groups. An association emerged between
HOR and FVSE, stratified for FCA versus NHA in logistic regression analysis (see Table
11). Controlling for covariates showed that FCAs have 122% greater odds of FVSE than
NHAs after adjusting for race. This outcome also shows that race is significant in the
model.
Table 11
Logistic Regression Examining the Association Between Five Vaccines for School Entry
and Home of Residence FCA vs. NHA Controlling For Covariates
Variable and covariate

Odds ratio

95% confidence interval

p-value

Home-Residence FCA vs. NHA

2.22

1.47–3.34

.0001

Race African American vs. Caucasian

1.61

1.29–2.004

< .0001

Race Other vs. Caucasian

0.94

1.29

.405

Note. p < .05 statistically significant.
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Results Research Question 4 and Hypothesis 4
RQ4: Will differences in individual vaccine payoff, measured by avoidance of
disease development as a result of vaccine receipt, affect group interest, measured
by deaths as a result of nonvaccination for the FVSE among the PCA?
Ho4: Differences in individual vaccine payoff, measured by avoidance of
disease development as a result of vaccine receipt, will not affect group
interest, measured by deaths as a result of nonvaccination, for the FVSE
among the 1990 PCABC.
Ha4: Differences in individual vaccine payoff, measured by avoidance of
disease development as a result of vaccine receipt, will affect group interest,
measured by deaths as a result of nonvaccination, for the FVSE among the
1990 PCABC.
Table 12 reports the VGT results of the estimated payoff death for each of the
nine vaccine-preventable diseases (diphtheria, hepatitis, measles, mumps, pertussis,
poliomyelitis, rubella, tetanus, and varicella) and compares the results for individual
equilibrium to the group optimum summarized payoff death for these same diseases. The
estimated payoff deaths for the individual equilibrium for diphtheria was 2.61; pertussis
1.30; tetanus 3.39; Hep B 5.44; measles 0.001; mumps 0.000095; rubella 0.222;
OPV/IPV 0.001; and VAR 12.03. The estimated payoff deaths for the group optimum
were diphtheria 0.441; pertussis 0.22; tetanus 0.57; Hep B 1.78; measles 0.0002; mumps
0.000021; rubella 0.050; OPV/IPV 0.0002; and VAR 9.66.
The four highest estimated numbers of deaths were for varicella (12.0 deaths),
Hep B (5.4), tetanus (3.4), and diphtheria (2.6). These four highest estimated deaths with
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individual equilibrium, defined as a vaccine delayer or individual self-interest group. The
four lowest estimated numbers of deaths reported in Table 12 are mumps (0.000021
death), measles (0.0002), poliomyelitis (0.0002), and rubella (0.05). These four lowest
estimated numbers of deaths are associated with the group optimum, also defined as the
preemptive vaccinator or altruistic group.
Table 12
Pulaski County Arkansas 1990 Birth Cohort Estimated Payoff Comparison Deaths
Vaccination Game Theory
Individual equilibrium deaths

Group optimum deaths

Diphtheria

2.610000

0.441000

Pertussis

1.300000

0.220000

Tetanus

3.390000

0.570000

Hepatitis B

5.440000

1.780000

Measles

0.001000

0.000200

Mumps

0.000095

0.000021

Rubella

0.222000

0.050000

Poliomyelitis

0.001000

0.000200

12.030000

9.660000

Varicella

Note. Pulaski County Arkansas Birth Cohort 1990 Data Analysis.

VGT payoff deaths represent vaccine-behavior scenarios and estimated numbers
of deaths that would occur among this cohort of 3,371 adolescents if vaccines were
unavailable due to refusal, shortage, or disruption in supply during an outbreak.
Consequently, among the four highest estimated deaths, cohort adolescents in the
individual-delayer–self-interest equilibrium who refused VAR vaccine would experience
a high number of deaths compared to adolescents in the group-optimum preemptivevaccinator or altruistic group.
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Because fewer deaths are predicted for group-optimum behavior, this is the better
vaccine behavior. These results suggests that preemptive vaccination was the most
protective behavior strategy during an outbreak where group optimum had an estimated
9.6 varicella deaths compared to 12.0 among individual delayers or the self-interested.
The group optimum Hepatitis B outcome was an estimated 1.78 death compared to 5.44
Hepatitis B deaths among individual equilibrium or the self-interested delayer
equilibrium. Similarly, in the preemptive-vaccinator group optimum an estimated 0.57
tetanus deaths emerged, compared to 3.39 tetanus deaths among individual equilibrium or
self-interest delayers. The group optimum estimated 0.441 death from diphtheria
compared to 2.61 diphtheria deaths among individual equilibrium or self-interest
delayers, suggesting the vaccine-delayer behavior offers a riskier outcome during an
outbreak or disease resurgence.
The estimated deaths reported in Table 12 differed from and were higher than the
actual number of deaths reported in Table B1 (ADH, 2015). The reported number of
deaths in Table B1 is attributable to improvements in public health (CDC, 1999b) and
improvements in disease surveillance, hospitalizations, and laboratory and medical
services. Therefore, the choice of either the individual equilibrium vaccine behavior, selfinterest or vaccine refusal, or the group optimum and preemptive vaccinator before an
outbreak was important based on the estimated burden of the number of deaths associated
with that specific vaccine.
Individual equilibrium was the self-interest and vaccine-delayer strategy whereas
group optimum was the altruistic or group strategy. I calculated the vaccine estimatedpayoff deaths based on a model generated from the analysis and the VGT mathematical
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formula (Bauch et al., 2003). I reported the estimated payoff deaths for each of the nine
VPDs: diphtheria, pertussis, tetanus, hepatitis B, measles, mumps rubella, poliomyelitis,
and varicella. The best protection against these nine diseases were the five vaccines
diphtheria, Hep B, MMR, OPV/IPV, and VAR that are required for school entry in PCA.
The vaccine-efficacy values of the five vaccines diphtheria, MMR, OPV/IPV, and
VAR are important in the payoff-death calculation for each of the nine diseases protected
by these vaccines. Tables B5 and B6 contain variables to calculate payoff deaths or risks
associated with the individual equilibrium (Pind) and group equilibrium (Pgr) constructs
defined in the VGT. The VGT predicts the payoffs where the individual choice depended
on the group choice. The game-theory constructs were behavior choices of self-interest or
group interest that correlated with small or large vaccine-coverage rates. These
parameters in each equation included probabilities of disease mortality, disease
morbidity, disease attack rate, proportion of vaccinated or unvaccinated, efficacy of
vaccines, probability of death from the vaccine, and protective values related to
preemptive or delayed vaccination.
Table B5 focuses on the individual equilibrium whereas Table B6 focuses on
group optimum. The main difference between Table B5 and Table B6 is the vaccinedelayer choice and the probability that the delayer became infected after a disease attack
(ds). Consequently, vaccine delay, risk of disease, and probability of successful vaccine
during an outbreak influenced the individual-equilibrium payoff deaths. The vaccine
behavior strategy was to delay or refuse vaccination. Each individual equilibrium
equation parameter was used in the payoff-death calculation and these parameters are
clearly defined in Table B7.
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The main focus in Table B6 was the proportion of preemptive vaccinated
population and minimized total number of deaths. I used the defined parameters to
calculate group equilibrium in Table B6. Some disease parameters were constant for both
groups such as probability of death from vaccine (dv), probability of death from VPD
(ds), disease attack rate (r), and total number in the cohort. When the parameters in each
equation were executed to obtain the payoff values for that vaccination choice or
behavior, the comparison determined the preferred vaccination strategy before disease
outbreaks occurred.
Table 12 illustrated the calculated payoff death scenario for the individual
equilibrium and the group optimum for each disease. The payoff deaths were larger in the
individual-equilibrium scenario. When the payoff-death scenario for each disease was
compared to the group optimum, smaller numbers of payoff deaths aligned with the
group-optimum scenario.
The conclusion was that more deaths occurred in individual equilibrium, where
vaccine refusal was the dominant vaccination-behavior choice. The group optimum had
fewer payoff deaths, as reported in Table 12. Therefore, the desired and preferred
vaccination choice was the group optimum because of the minimal numbers of deaths
associated with preemptive vaccination choice. The group optimum offered the greater
preemptive public health protection during an outbreak for any of the nine VPDs.
Summary
The results and findings from analysis of the four research questions and
hypotheses help explain the relationships between HOR and vaccine coverage. The first
finding showed that U.S. adolescents have higher immunization coverage for Hep B,
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MMR, and VAR than PCABC from 2006 to 2008. The exception was PCABC
immunization rates for Td/Tdap, which was 16.4% greater than U.S. immunization rates.
The U.S. comparative data for OPV/IPV was unavailable to evaluate against PCABC
OPV/IPV data. The low finding for PCABC matches the research problem statement.
Low vaccinations are associated with disease outbreaks (CDC, 2013). The low vaccine
coverage and the consequences of low-vaccination rates are supported by several
previous researchers on immunization strategies to increase coverage rates (Humiston et
al., 2013; USDHHS, 2010b). Examples of strategies to increase vaccinations include the
Behavior Risk Factor Surveillance System, the WIC program, the VFC program, school
immunization laws, and Healthy People 2020 (CDC, 2013).
The second finding revealed that FCAs had a 10.6% higher UTD for FVSE than
NHAs. The immunization rate for FCAs was greater than NHAs for each specific
vaccine. In fact, FCA immunization rates for MMR (90.7%) and OPV/IPV (91.5%)
attained the greater-than-90% threshold recommended by Health People 2010. Compared
to FCA immunization rates, NHAs failed to achieve the recommended 90% threshold for
any of the FVSE. This finding differs from other published studies and the expectation
that FCAs are more predisposed to have fragmented medical homes than NHA. Other
authors averred that, compared to NHAs with stable medical homes, FCAs have low
immunization coverage due to social disruption and fragmented medical homes to access
recommended age-specific vaccines. High vaccine UTDs are associated with stable
medical homes (Humiston et al., 2013).
The third finding from the bivariate logistic regression revealed that race
mediated the association between HOR and UTD for FVSE. Specifically, African

110
Americans have 80% greater odds of FVSE and Other races have 10% lower odds of
FVSE compared to Caucasians, after adjusting for residence. The race ORs explained that
race was significant regardless of residence status. This finding is significant because,
historically, African Americans have had lower vaccination rates compared to
Caucasians. Also, race was significant and accounted for in the model. The justification
for not including gender and ethnicity (Hispanic and non-Hispanic) in the model was that
these groupings did not significantly associate with FVSE.
The fourth finding from the VGT analysis showed that group optimum had lower
estimated deaths compared to individual equilibrium for all nine vaccine-preventable
diseases. This finding of lower estimated deaths associated with group optimum supports
the VGT framework (Bauch et al., 2003). The VGT analysis also revealed that individual
equilibrium had higher estimated deaths for each of the nine diseases compared to group
optimum. High estimated deaths related to low immunization, which is not protective
during a vaccine-preventable disease outbreak (Bauch et al., 2003).
In Chapter 5, I discuss the research findings, study limitations, implications, and
positive social change.

111
Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this quantitative study was to examine adolescent immunization
rates and uptake coverage for the 1990 PCABC. In Arkansas, some anecdotal evidence
emerged that a disparity existed in vaccination coverage among adolescents in foster care
compared to those in their natural home (Daniels, Jiles, Klevens, & Herrera, 2001;
Lindley et al., 2011; Smith, Jain, et al., 2009; Smith, Santoli, et al., 2005). I implemented
a retrospective cohort design to examine this immunization-coverage problem among
PCABC. I analyzed immunization records for PCABC from the AIRD to answer four
research questions. Although Arkansas law requires UTD immunization for FVSE, only
15.6% of PCABC attained the legal immunization requirement for FVSE.
This study produced four findings from the data analysis. First, U.S. adolescent
adjusted vaccine-coverage uptake rates were 12.0% higher for Hep B, 11.6% for MMR,
and 70.2% for VAR than for PCABC. For Td/Tdap, adjusted PCABC immunization rates
were 16.4% higher than for U.S. adolescents. The second finding revealed FCAs had
10.6% higher UTD status for FVSE compared to NHAs. The immunization rate for FCAs
was greater than NHAs for each specific vaccine. FCA immunization rates for MMR
(90.7%) and OPV/IPV (91.5%) attained greater than the 90% threshold recommended by
Healthy People 2010 compared to none among NHA. The third finding was an
association between HOR and UTD status for FVSE. The results from a bivariate logistic
regression revealed that race mediated the association between HOR and UTD status for
FVSE. Specifically, African Americans have 80% greater odds of being UTD with FVSE
and Other races have 10% lower odds of being UTD with FVSE compared to Caucasians,
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after adjusting for home residence. Fourth, findings from the VGT analysis revealed
individual equilibrium had higher estimated deaths for each of the nine diseases
compared to the group optimum.
Chapter 5 is organized into seven parts: introduction, research results,
interpretations of findings, limitations of the study, recommendations, implications, and
conclusion.
Research Findings and Theoretical Context
The study results included significant underimmunization for individual vaccines
among the PCABC. Only 15.6% of PCABC were UTD for FVSE. Significant differences
emerged from 2006 to 2008 in UTD vaccine coverage between PCABC and U.S.
adolescents. During 2006 to 2008 U.S. adolescents showed higher average adjusted UTD
coverage rates for Hep B (85.9%); MMR (88.9%), OPV/IPV (no data available), and
VAR (91.3%), compared to average adjusted PCABC Hep B (75.9%), MMR (77.7%),
OPV/IPV (85.01%), and VAR (21.1%). In general, U.S. adolescents showed average
lower Td/Tdap adjusted UTD coverage rates (67.5%) compared to PCABC (83.9%); the
difference between the U.S. and PCABC t tests was 3.51, p = .025.
I found significant associations between HOR and UTD status for FVSE (χ2 =
18.5, p≤.0001) from the chi-square analysis. The specific vaccines associated with HOR
were Hep B (χ2 = 10.89, p 0.001), MMR (χ2 = 11.89, p = .0006), OPV/IPV (χ2 = 4.61,
p=.318), and VAR (χ2 = 21.79, p < .0001). The vaccine not associated with HOR was
Td/Tdap (χ2 = 1.55, p = .21). I further compared FCAs to NHAs; and the findings
revealed that among FCAs only MMR (90.7%) and OPV/IPV (91.5%) achieved the 90%
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UTD immunization threshold established in Healthy People 2010. In contrast, NHA had
no vaccines that attained Healthy People 2010 immunization recommendations.
The mediation analysis revealed race mediated the association between HOR and
UTD status for FVSE (OR = 1.79; 95% Cl 1.51–2.12; p = < .0001). This finding explains
that African Americans have 80% greater odds of being UTD with FVSE compared to
Caucasians, after adjusting for HOR. The race ORs explained that race was significant,
regardless of HOR. The mediation analysis revealed race was a mediating variable. Race
mediated the association between HOR and UTD status for FVSE.
The quantifiable payoffs or deaths associated with vaccine behavior and strategies
supported the constructs in VGT. The theoretical construct for this study was the VGT
(Bauch et al., 2003; von Neumann & Morgenstern, 1944). The quantified differences
between the vaccine self-interest strategy and group-interest strategy in VGT are
important findings. Disparity emerged for estimated deaths for each reported disease
between individual equilibrium and group optimum immunization. These findings
confirmed similar results reported by Bauch et al. (2003). Overall, study findings showed
greater estimated deaths among individual equilibrium compared to group optimum.
Specifically, the mortality differences ranged greater than one to three deaths for
diphtheria, hepatitis B, pertussis, tetanus, and varicella diseases. In addition, a similar
trend but with smaller differences emerged in estimated deaths between individual
equilibrium and group optimum for measles, mumps, poliomyelitis, and rubella diseases.
The estimated payoffs or deaths for individual-equilibrium specific-disease-rank
order, highest to lowest, was varicella, 12.03 estimated deaths; hepatitis B, 5.44 estimated
deaths; tetanus, 3.39 estimated deaths; diphtheria, 2.61 estimated deaths; pertussis, 1.30
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estimated deaths; rubella, 0.222 estimated deaths; measles, 0.001 estimated deaths;
poliomyelitis, 0.001 estimated deaths; and mumps, 0.0000895 estimated deaths.
The group optimum estimated death rate for specific-disease-rank orders was
similar to that for individual equilibrium. However, group optimum estimated deaths
were lower compared to those for individual equilibrium. The group-optimum diseaserank order from highest to lowest was varicella, 9.66 estimated deaths; Hepatitis B, 1.78
estimated deaths; tetanus, 0.57 estimated deaths; diphtheria, 0.441 estimated deaths;
pertussis, 0.22 estimated deaths; rubella, 0.05 estimated deaths; measles, 0.002 estimated
deaths; poliomyelitis, 0.0002 estimated deaths; and mumps, 0.000021 estimated deaths.
Four findings emerged. First, the 2003 to 2008 U.S. adjusted UTD vaccine rates
for FVSE were greater than those for PCABC except for Td/Tdap. Second, significant
differences existed between FCA and NHA individual vaccine UTD coverage-uptake
rates. The FVSE was (χ2 = 18.5, p < .0001). In comparison, I found the FCA FVSE
uptake rate (29.7%) was greater than that of the NHA FVSE (19.1%).
Third, an association emerged between HOR and UTD status for FVSE when
stratified for FCA versus NHA (OR = 2.22; 95% CI 1.47–3.34, p = .0001). Results
revealed FCA had 2.2 greater odds of UTD status for FVSE than NHA after adjusting for
race However, race aligned with UTD status for FVSE, and African Americans were 1.8
times more likely to be UTD for FVSE compared to Caucasians. Race was a mediating
variable in the association between being UTD with FVSE and HOR in the bivariate
logistic regression model analysis. The mediator variables were gender and ethnicity in
the multivariate analysis. Fourth, I reported individual equilibrium or self-interest
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strategy in the VGT had greater estimated payoffs or deaths compared to the groupoptimum or group-interest strategy.
Interpretation of the Findings
Low UTD coverage is an endemic public health problem (Dempsey & Zimet,
2015; Dorell et al., 2011) similar to the evident underimmunization problem prevalent in
PCABC. This study provided two main contributions to the literature. It provided
evidence that African Americans had higher UTD vaccine coverage for all five vaccines,
compared to Caucasians. Evidence reported in Table 6 did not support findings from
other studies that showed African Americans historically had low vaccine-coverage rates.
First, results from other registry data driven studies were lower for African
American UTD coverage rates compared to findings from this PCABC study. The
registry data are population-level-based data that are reproducible and stable (Bundy et
al., 2013; Gowda, Dong, Potter, Dombkowski, & Dempsey, 2013; LoMurray & Sander,
2011a; Rees-Clayton, Montgomery, Enger, & Boulton, 2013) compared to sample-based,
survey-dependent, dynamic, and fluid studies (Lindley et al., 2011a). Immunization
registries have more reliable data (Curran, Bednarczyk, & Omer, 2013) and may be the
gold standard for immunization population results compared to survey samples. These
registries have comprehensive data and accurate descriptions of characteristics of young
adolescents who have received recommended vaccines (Rees-Clayton et al., 2013).
Second, this study supported the value of registry data (Gowda et al., 2013;
LoMurray & Sander, 2011a) required to establish verifiable true vaccine coverage based
on historical documentation (Bundy et al., 2013) compared to surveyed vaccine-coverage
studies (Curran et al., 2013). Furthermore, the registry system includes the AIRD, but
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improved by eliminating duplicate and mismatched records to become useful, accurate,
and efficient reporting tools for adolescent immunization (Rees-Clayton et al., 2013;
Sittig, Teich, Osheroff, & Singh, 2009). I used registry data to examine trends in
adolescent immunization similar to other published studies (LoMurray & Sander, 2011b;
Rees-Clayton et al., 2013). Immunization-registry data are more reliable than surveys
because of data cleaning, new technology, and standardized provider-reporting systems to
the registry (Bundy et al., 2013).
A trend below the optimal 90% Healthy People threshold for UTD coverage rates
persisted among PCABC and U.S. adolescents between 2006 and 2008. The low UTD
rates for FVSE coverage associated with disease outbreaks among PCABC and U.S.
adolescents are consistent with published literature on vaccines (CDC, 2009b). The low
VAR coverage among PCABC may be attributed to varicella outbreaks in Arkansas in
2001, 2004, and 2006 (Gould et al., 2009; Lopez et al., 2006). Exposed siblings or those
with a history of varicella did not require VAR immunization, and thus did not require
reporting to the immunization registry, which is consistent with the low immunization
trend between 2006 and 2008.
A congruent trend emerged in high UTD coverage rates among FCAs compared
to NHAs. Similarly, FCAs had higher UTD rates for FVSE than NHAs. Furthermore,
FCAs attained the Healthy People 2010 objectives for two vaccines—MMR and
OPV/IPV—compared to none among NHAs. I found no significant or appreciable
increases in vaccine uptake after the age of 16 among PCABC. This may be due to
migration of individuals in the cohort. Vaccine coverage rates decreased over time from
2006 to 2008 among PCABC because the 1990 birth cohort was not fixed, but limited to
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birth date and other inclusion criteria. Children moved in and out of the study area and
vaccines administered outside Pulaski, Arkansas, may not have been reported to the
registry. If the coverage rates of those who moved were better than those who stayed
behind, one might expect to see a slight decrease in coverage between 2006 and 2008.
FCAs had greater UTD vaccine-coverage uptake rates for all FVSE compared to
NHAs. The FVSE coverage uptake for FCAs was 29.7%, whereas for NHAs it was
19.1%, and χ2 =18.5 (p = .0001). Children in foster care, contrary to prior hypotheses, are
no less likely to complete immunization requirements than children in natural home
settings. The significant differences in vaccine-coverage-uptake rates between FCAs and
NHAs may be attributed to court-ordered immunization enforcement policies for all
children entering the foster care system (ADHS, 2010). NHAs may exercise their
medical, philosophical, and religious exemption rights allowed under Arkansas
immunization laws (ADH, 2004b; ALB, 2003). This evidence of social services
regulations and laws supports the contributions of other factors not included in the data
and may account for the observed FCA–NHA differences in immunization rates.
The bivariate logistic model revealed an association between race and UTD for
FVSE. Study findings revealed differences in odds of UTD for FVSE among PCABC
race categories. Future race-specific interventions may improve overall PCABC
immunization rates through education, recall/reminder messages, and social media
information. For example, pediatricians, school nurses, health providers, and public
health stakeholders may target each race category with culturally specific messages. The
targeted messages may include evidence-based information with particular parental
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vaccine concerns that address vaccine safety, delay, autism, trust, exemptions, hesitancy,
and refusal.
African Americans contributed more than 50% of the PCABC population
compared to Caucasians (30.7%). This sociodemographic distribution may not account
for or completely explain the proportionally increased UTD coverage among PCABC.
The dichotomous outcome variable of “Yes or No” for UTD for FVSE in the registry
database may not include other measurable contributory factors that are not usually
collected. However, in the general population, the inverse distribution occurs such that
Caucasians account for the greater percentage of the population. Caucasians are twice as
likely to receive vaccines compared to other races in the general population (Darden et
al., 2011; Stokley et al., 2011). However, for race, a significant association emerged
between African American and vaccine coverage UTD status when controlling for HOR,
and Caucasian was the reference variable (OR = 1.77; 95% Cl 1.49–2.09). African
Americans were 1.8 times more likely to have UTD vaccine-coverage-uptake rates. This
association could not be explained from the data within the scope of this study. The
association between race and immunization rates was established in the literature with
inverse results to those of this study. Similarly, for race, a significant association emerged
between Other and vaccine coverage UTD status when controlling for HOR, and
Caucasian was the reference variable (OR = 0.54; 95% Cl 0.43–0.67). Other races had
10% lower odds of reaching UTD for FVSE.
This study supported VGT, which posits that the behavior of a group influences
individual behavior (von Neumann & Morgenstern, 1944). In VGT, I partitioned
participants into two groups: individual equilibrium/delayers/free-riders/refusers and
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group optimum/preemptors/early acceptors/vaccinators. The study also confirmed the
Bauch et al. (2003) construct of vaccine-uptake-behavior payoff differences between
preemptors and delayers. Diseases with high estimated deaths require preemptive
vaccinations, which are protective against potential disease risks, exposures, and
outbreaks, and can help reduce unintended deaths. A correlation emerged between highvaccine UTD and low number of estimated deaths associated with VGT. I concluded that
high-vaccine UTD protects against disease outbreaks.
The interpretation of the higher estimated payoffs or deaths confirmed that the
self-interest strategy was a high-risk behavior. Individual equilibrium indicated that this
delayer vaccination strategy has greater estimated costs and higher estimated risks. The
benefit of delaying vaccination was not protective. Vaccine delay increases VPD
morbidity (Bauch & Bhattacharyya, 2012; Schlenker et al., 1992), which may result in
death after a VPD outbreak (Bauch & Earn, 2004; Bauch et al., 2003; Baxter et al., 2013).
The group optimum was a better and less costly strategy because lower estimated payoffs
or deaths aligned with this preemptive vaccinator strategy. The benefits of the group
optimum were protective and fewer estimated deaths would accrue during a VPD
outbreak.
In summary, the findings yielded four important interpretations. First, U.S.
adolescents had higher adjusted vaccine-UTD for Hep B, MMR, and VAR compared to
PCABC. Overall, U.S. adolescents are more protected against Hepatitis B, measles,
mumps, rubella, and varicella outbreaks compared to PCABC. Second, immunization
rates among NHAs are low compared to FCAs. NHAs have less immunization protection
and higher disease risk and exposure. The consequences of high disease predisposition
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are disease risk and high estimated deaths during VPD outbreaks. VGT supports these
consequences. In addition, low immunizations with increased disease outbreaks, school
absenteeism, poor school performance, and adolescent hospitalization.
Third, the interpretation of improved immunization among African Americans in
this cohort is that future possibilities exist to sustain this vaccination gain among this
historically low-performing race. In future research, the process can be duplicated once
these contributory factors are explored and understood. The challenge is to understand
contributing factors associated with increased UTD for FVSE among African Americans
in PCABC. Although contributing factors associated with increased immunizations are
known in the published literature (Atwell et al., 2013; Darden et al., 2013; Diekema,
2012), they are outside the scope of this study. Immunization contributing-factor data
were not collected and were unavailable for analysis in this PCABC study.
Fourth, the interpretation of VGT group-optimum preemptive vaccination
behavior is protective compared to alternative behaviors. Preemptive vaccinations are
encouraged because reducing the risks of outbreaks has greater individual and
community-health benefits.VGT analysis showed numbers of payoff deaths associated
with individual equilibrium are higher than group optimum. This finding supports VGT,
showing that preemptive vaccination behavior among group optimum is protective and
associated with fewer deaths. In contrast, however, individual-equilibrium vaccination
behavior is riskier and aligns with higher numbers of deaths during a VPD outbreak or
resurgence.
This study contributed evidence of increased vaccination among historically lowperforming groups. Future researchers may examine benefits of immunization-registry
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data and assess their reliability, compared to survey-sample data. Future researchers may
enhance potential changes in cultural and social beliefs toward immunization among
African Americans. Future research is needed to determine if mothers whose children are
enrolled in vaccination social programs, such as VFC or WIC, are more receptive to
vaccinations. Empirical data from a larger population study are desirable to indicate that
vaccination is an essential requirement for enrollment in other welfare programs.
Socioeconomic data analysis with African Americans immunization data may justify
increase in immunization among such historically low-performing races as African
Americans. Community and faith-based immunization research should include African
Americans and address immunization safety, education, beliefs, biases, and cultural
attitudes (Gamble, 1997); social media and vaccine hesitancy (Dredze et al., 2015); and
health-provider ethical practices (Dempsey & Zimet, 2015). School nurses may use these
findings to encourage parents to immunize their children. Community campaigns citing
this improvement among this social group could cultivate community trust building.
Awareness of immunization improves among members of a social class with historical
mistrust for immunization.
Limitations of the Study: Generalizability
The study results and findings are generalizable to the 1990 birth cohort of all
children who met the study criteria, born between January 1, 1990 and December 31,
1990 in PCA, and had immunization records in the AIR. There were 9,102 live births in
1990, from which I obtained the representative sample for this study cohort. The study
was based on 3,371 children from the 1990 birth cohort and met the a priori established
selection criteria such as foster care, geography, and documented immunization records
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in the AIR. Records in the AIR database contained internal-validity issues similar to other
states’ immunization registries; documents contained incomplete records and many types
of errors in reporting immunization information (Khare et al., 2000). The PCABC 1990
study did not measure or include known factors associated with low-immunization rates
frequently analyzed in vaccine-coverage studies: socioeconomic factors(Wooten et al.,
2007), lack of access to care, parental attitudes, and educational levels. Arkansas registry
data were limited to vaccine type, vaccine-administration date, birth date in 1990,
ethnicity, gender, and race demographic factors.
The racial and ethnic profile of the 1990 PCABC population was not comparable
to the total United States, given the sample size (3,371), and the number of African
Americans (1,851; 53.2%); Caucasians (1,036; 30.7%); and Others (543; 16.1%).
Nevertheless, the findings should be generalizable to similar populations in the United
States, given that all states receive federal funding, such as from the VFC fund, and
follow the CDC ACIP guidelines (CDC, 2008b; Sneller et al., 2008). NHAs (96.3%)
comprise a greater proportion of the population of interest compared to FCAs (3.7%). In
contrast to FCAs (3.7%), NHAs’ (96.3%) profiles in PCA were widely different from
those of other counties across the United States. Furthermore, important variables
associated with vaccination-coverage rates—including socioeconomic status, parental
attitudes toward vaccination, and medical, philosophical, and religious exemptions—
were not captured or available in the AIR. In addition, social values, educational levels,
and parental attitudes toward children’s immunization may be different and influential in
parents’ immunization decisions. These factors were not captured in the data. Inclusion of
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such data in the analysis may help provide analytic evidence and explain differences in
immunization rates in this study.
The limitations of this study included missing records, underreporting, and lack of
reporting, such as in the case of the VAR, where more than 80% of the cohort had less
than one dose of the VAR. Underimmunization among the other four vaccines was fairly
consistent and in the range of 5–10% disparity from the desired 90% threshold
recommended in Healthy People 2010 (USDHHS, 2000). I excluded incomplete or
mismatched records from the analysis to minimize internal-validity limitations and
unreliable results. I did not include duplicate doses of the same vaccine for the same
unique identified immunization record when calculating UTD, which was limited to
immunization rates based on the criteria in Appendix A, Table A1. Foster care residence
was defined as any foster care residence regardless of duration in foster care and age
when the child entered into foster care. This crude definition may have overestimated the
benefit of foster care residence since the foster care system has strict immunization
policies and is a potential limitation of the study. Another limitation was not all foster
care children were included in this study because of place of birth. Excluding them may
have limited the power to falsify the null hypothesis. The validity and reliability of
interpretations of the results are applicable and specific to 1990 adolescents in PCABC.
Recommendations
The three main recommendations areas are research, public health stakeholders,
and study improvement.
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Recommendations for Research
Race- and culture-based immunization messaging through social media,
physicians, and health provider recall/reminder messages may enhance vaccination
acceptance for children and adolescents. African Americans have 1.8 greater odds of
FVSE compared to Caucasians. These successful contributing factors may be included in
educational interventions to increase adolescent immunization rates. I recommend future
researchers examine race- and culture-focused messaging, physicians, and health
provider influence, and social media contributing factors to this successful improvement
in a historically low-performing race in PCABC.
Recommendations for Public Health Stakeholders and Health Practitioners
U.S. adolescents have higher immunization coverage for Hep B, MMR, and VAR
compared to PCABC from 2006 to 2008. I recommend targeted vaccine intervention
campaigns to encourage parents to accept vaccines to attain the 90% threshold
established in Health People 2010. A targeted campaign in PCABC will address
underimmunization. Social media immunization messages, school-based clinics, and
physician recall/reminder are established best practices. Race- and culture-based
immunization messaging through social media, physicians, and health provider
recall/reminder messages may enhance vaccination acceptance for children and
adolescents. Direct physician and health-provider vaccination communication with
parents and adolescents may build trust and reduce vaccination misinformation that
predisposes parents to delay, hesitate, refuse, or seek exemptions (Safi et al., 2012).
Underimmunization for Hep B (15.5%) was higher than for Td/Tdap and MMR,
although the Hep B booster dose was strongly recommended for this age (Sneller et al.,
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2008; Wei et al., 2010) due to high-risk behavior among this age group. The Hep B
vaccine was also a seventh-grade school requirement (ADH, 2008). The low uptake of
VAR is of concern and a history of varicella disease should be reported in the registry to
reflect natural immunity compared to vaccine-induced immunity. The frequent
importation of measles, recent outbreaks, and cases of measles in Arkansas (ADH,
2012b) require further investigation.
This study contributed evidence of increased vaccination among historically lowperforming groups. The results could provide social-change benefits as public health
officials, healthcare providers, policymakers, and community members plan intervention
strategies that encourage parental vaccine decisions and improve UTD coverage among
PCABC. Healthcare providers may include these results in vaccine communications
during FCA and NHA wellness visits. Policymakers may include these findings to justify
interventions and policies that sustain increased immunization coverage among FCA and
NHA.
Recommendations for Study Improvement
I recommend clean and complete immunization information-systems data. The
immunization-registry data used in this study required data cleaning. Missing,
mismatched, or incomplete records were excluded from the analysis.
The Arkansas immunization data-quality and data-registration linkage with the
Arkansas vital-statistics database requires improvement with advanced technology that
can identify and control duplicate-records submission from immunization providers. The
technology implemented in immunization records reduced mismatched-record and
immunization-reporting errors from health providers (CDC, 2010h; Fath, Andujar,
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Williams, & Kurilo, 2015; Greene et al., 2009). The implementation of the electronic
standard HL7 form routinely used to report healthcare-provider immunization to the
state-registry enhanced data linkage, improved the quality of archival data, and facilitates
future research.
The AIR’s real-time quality data provides an advantage for future research.
Arkansas immunization state laws imposed legal penalties when immunization providers
or vaccinators do not report to the AIR within 30 days (ADH, 2008). Timely evidencebased vaccine-coverage data on other birth cohorts provides justification to implement
new policies that target vaccines and groups with low vaccine-coverage rates. National
immunization surveys become very expensive and irrelevant. Therefore, I strongly
recommend future studies on vaccine-coverage uptake base analysis on state-registry
data.
Implications for Positive Social Change
Findings from this study may enhance social-change contributions toward
immunization campaigns targeting natural-home parents and increase immunization rates
among PCABC. I partitioned social-change implications in this study into four main
areas: (a) protect vulnerable unvaccinated NHAs against recent VPD outbreaks;
(b) reduce vaccine delay, distrust, and hesitancy; (c) build vaccine trust between
providers and parents of unvaccinated or low UTD NHAs; and (d) health providers
enhance vaccine communication with hesitant parents of PCABC.
This dissertation offers information that may lead to protection of vulnerable
unvaccinated NHAs against recent VPD outbreaks, which would be an important social
change (NVAC, 2015). Social change through awareness of low UTD for FVSE among
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NHAs may prevent recent VPD outbreaks and resurgence among vulnerable
unvaccinated NHAs. Immunization awareness would be an important positive social
change for adolescents, minimizing school absenteeism and poor school performance
associated with VPD illness. School immunization requirements contribute positive
important roles to controlling VPDs (Omer et al., 2008). NHAs had lower UTD coverage
rates compared to FCAs. Immunization-intervention campaigns targeting low UTDperforming NHAs with low-immunization rates will contribute to behavioral change to
mitigate vaccine hesitancy, delay, or refusal. Hesitancy, delay, and refusal contribute to
low UTD for FVSE among unvaccinated NHAs compared to FCAs with higher coverage
rates.
The concerted focus to increase awareness and benefits of vaccines may
contribute to cultural and behavior change among NHAs to improve their UTD for
FVSE. Low-vaccination coverage is the most common risk factor associated with
measles resurgence (Hamborsky et al., 2015; Kennedy & Gust, 2008). Such cultural and
behavior changes toward vaccine acceptance are positive social changes at the individual
NHA level. Avoidance of low vaccine coverage among NHAs has immeasurable
downstream lifetime burden such as adolescent hospitalization. Acute encephalitis, otitis
media, and coma are reported measles complications (Hamborsky et al., 2015). Mumps
complications of orchitis in men and oophoritis in women contribute to infertility.
Permanent unilateral deafness complications from mumps (Hamborsky et al., 2015) may
impact an adolescent’s school performance and future economic productivity.
Vaccine delay, distrust, and hesitancy reduction among African Americans would
contribute to social change. Globally, African American parents who live in households
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with their children delay vaccine administration for their children (Smith, Humiston,
Parnell, Vannice, & Salmon, 2010). The African American increased UTD for FVSE
coverage compared to Caucasians in this study is a positive outcome, influencing
behavior or attitudes among other African American parents who delay, hesitate, and
distrust vaccination (Gamble, 1997). Although African Americans had higher UTD
compared to other races, the preferred target for PCABC was to attain greater than 90%
UTD for FVSE. Overall, PCABC adolescents did not attain greater than 90% UTD for
FVSE. Therefore, to attain immunization goals, direct physician–parent communication,
continuous education, and positive social-media immunization messages are valuable to
sustain and improve parental acceptance of vaccines for children and adolescents. Parents
of NHAs may benefit from such information and reduce their vaccination delays,
hesitations, and distrust (Phadke, Bednarczyk, Salmon, & Omer, 2016).
Social change as result of the outcomes from this study and others may increase
immunization rates especially among inner-city African American children (Wood et al.,
1998). Including findings of increased PCABC African American immunization in
physician–parent communications is valuable. Parents understand and accept empirical,
verifiable, and convincing evidence. These successful health-provider communications,
when repeated during wellness visits at inner-city health clinics or community health
centers, may convince other hesitant parents to accept vaccines. Such individual parental
vaccine acceptance, when duplicated and incorporated into standard practices in the
community, may increase the number of receptive parents and enhance overall
immunization rates.
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Building vaccine trust between providers and parents of unvaccinated or low
UTD NHAs may contribute to positive social change. Health providers can cite increased
coverage rates in UTD for FVSE as validation of vaccine confidence among African
Americans through effective trustworthy vaccine communication. Vaccine trust built
between providers and parents of unvaccinated or low UTD NHA may enhance positive
social change. Health providers can cite increased coverage rates in UTD for FVSE from
this study as validation and endorsement of vaccine confidence among African
Americans. Health providers are highly supportive of vaccines and may refer to findings
from this study to build trust so that parents engage their children in the recommended
immunizations (NVAC, 2015).
Healthcare providers enhance vaccine communication with hesitant parents to
improve UTD rates among PCABC during healthcare visits. Adolescent healthcare visits
provide excellent opportunities to address concerns about vaccines. Concerns may
include social norms, attitudes, beliefs, vaccine delays, hesitation, refusal, vaccine safety,
vaccine effectiveness, vaccination benefits, building trust, confidence, VPD, and
improving vaccine rates for adolescents. Social change may continue as school nurses
include information on low-UTD coverage rates among PCABC compared to U.S.
statistics when communicating and encouraging adolescents to accept vaccines. School
nurses may use these findings to encourage parents to immunize their children.
Healthcare-provider communication, endorsement of social norms, and vaccines are
central components in establishing trust, nurturing, and fostering vaccine confidence
among hesitant parents (NVAC, 2015).
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The social change potential benefit could enhance public health officials’ ability
to plan intervention strategies that encourage parental vaccine decisions and improve
UTD coverage among PCABC. Healthcare providers may include these results in vaccine
communications during FCA and NHA wellness visits. Policymakers may include these
findings to justify interventions and policies that sustain increased immunization
coverage among FCAs and NHAs.
This study contributed evidence of increased vaccination among historically lowperforming groups. Future researchers may examine benefits of immunization-registry
data more reliable than using survey-sample data. Future researchers may enhance
potential changes in cultural and social beliefs toward immunization among African
Americans. Community campaigns citing this improvement among this social group
cultivate community trust building. Awareness of immunization may improve among
members of a social class with historical mistrust for immunization.
Parents have direct duties and responsibilities to vaccinate their children to
provide health protection. Public health laws and policies require parents to comply with
school-entry vaccine regulations established by Arkansas law (ADH, 2008). The PCABC
adjusted UTD coverage for FVSE deficiency among Td/Tdap, Hep B, MMR, OPV/IPV,
and VAR ranged from coverage rates of 5 to 14.1% during 2006–2008. PCABC failed to
achieve the minimum recommended objectives established in Healthy People 2010.
These vaccines disparities and deficiencies should be targeted by public health campaigns
to prevent and reduce the burden of disease outbreaks among school children (Dempsey
et al., 2015; Gaensbauer, Armon, & Todd, 2014).
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Preemptive vaccination behavior was protective to the community and provides
positive social change. High vaccine-coverage rates prevent resurgence of previously
eradicated diseases, burden of disease imports, and outbreaks of VPDs (Cherry, 2010;
Toner, 2014; Winter et al., 2012). The public health policies contributing to positive
vaccine coverage among African Americans should continue to be encouraged. Such
interventions will enhance improvements in future vaccine coverage and continue to
break the historic cycle of low coverage among minority groups.
Low adolescent vaccine coverage was a public health threat and burden because
adolescents are reservoirs of VPDs (Dempsey et al., 2015) and these diseases are highly
communicable among school children. Therefore, public health initiatives targeted
toward these vaccines with low-coverage rates have a preventive and protective impact
against VPDs in the community. The quantifiable evidence reported in Table 7 for
specific racial groups was primary justification to influence individual-behavior changes
and improve the county-level immunization discussion.
Findings shown in Table 7 and trends shown in Figure 4 also indicated areas of
significant differences in vaccine-coverage uptake rates among the cohort to initiate
public health vaccine campaigns and achieve positive social change. Preemptive
vaccination behavior created positive social change through payoffs, supporting
justification. Thus, increased vigilance and compliance to reach required vaccination
coverage would reduce morbidity, hospitalization, health costs, and other public health
burdens. Preemptive vaccination behavior was preferred because low payoffs aligned
with fewer deaths that would occur during a VPD outbreak. The correlation of vaccines
with low-coverage rates and with vaccines that had high-payoff deaths was evident. The
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vaccine-coverage-uptake results shown in Table 5 for low-coverage vaccines such as
VAR and Hep B also correlated with high-payoff deaths shown in Table 12.
The low payoffs associated with preemptive behavior support justification for
increased vigilance and compliance with vaccination-coverage requirements. The high
estimated payoffs or deaths for individual self-interest aligned with low vaccine-coverage
rates. Vaccine refusal (Dredze et al., 2015) or underimmunization increased the risks
associated with disease outbreaks (Gould et al., 2009; Lopez et al., 2006). The reported
results and findings also indicated significant correlations between underimmunization,
race (Smith et al., 2004), and specific vaccines. These results may influence vaccineintervention campaigns and public health policy in PCA. Adolescent immunization
solutions to low immunization rates are implemented through policy at the individual
level. Healthy People national health promotions from 2000 identified immunization as a
national health priority (USDHHS, 1999).
Policy solutions include school-entry laws (ALB, 1967; Omer et al., 2009;
Orenstein & Hinman, 1999) and access to immunization in Arkansas (ALB, 1967)
through federal and state eligibility programs including VFC, Medicaid, and the
supplemental children’s insurance (ARKIDS) program in Arkansas (ADHS, 2011a).
Legislative actions influence societal and environmental levels through immunization
laws and school-entry requirements. School-based immunization clinics are associated
with increased adolescent immunization coverage rates (Allison et al., 2007; Daley et al.,
2009; Federico et al., 2010; McNall et al., 2010). Therefore, increased vaccinationcoverage rates through these innovative modalities for vaccination are achievable and are
improvements over current traditional vaccination-coverage methods.
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The use of archival-data analysis with VGT should become the gold standard for
determining coverage uptake compared to survey methods with potential systematic and
recall biases. The availability of archival data is an advantage and true evidence of
immunization providers’ practices, compared to national immunization-survey methods.
The second advantage is a comparison of different birth cohorts in the same community.
The third advantage is predicting immunization coverage uptake from analysis of
archival data with VGT. For example, VGT emphasizes and explains self-interest and
group behavior, immunization policy decisions, and maximization of payoff concepts
(Bauch & Earn, 2004; Bauch et al., 2003). I used VGT to establish different payoffs or
deaths for individual self-interest behavior and group altruistic behavior. Desirable
vaccination behavior decisions were supported with quantifiable payoff evidence. Future
archival data analysis with VGT of different birth cohorts in the same community would
provide comparative justifiable evidence for public health campaigns, vaccination
intervention, and policy decisions. The empirical implications presented here will
facilitate vaccination-strategy comparisons for future research.
Conclusion
The two novel findings in this study confirmed disparities in state-mandated
immunizations and reported significant improvement in immunization rates among
historically low-performing races. The first novel finding in this study confirmed
disparities in state-mandated immunizations among PCABC. Adolescents in foster care
were 2.2 times more likely to complete FVSE compared to adolescents in natural homes.
This novel finding contradicted previous literature that associated NHAs with higher
immunization rates. The second novel contribution of this PCABC study is that African
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Americans were 80% more likely than Caucasians to be UTD for FVSE. In other
population studies, immunization rates among Caucasian adolescents were usually higher
than those of African Americans.
This study made two main contributions to the literature. First, the study provided
evidence that African Americans had higher UTD vaccine coverage for all five vaccines
compared to Caucasians at the county or community level. This higher vaccine coverage
of African Americans compared to that of Caucasians is a novel finding, contrasting with
state and national reports and previous research in which Caucasians were the majority
race and usually had higher vaccine-coverage rates. Second, this study supported the
value of registry data required to establish verifiable true vaccine coverage based on
historical documentation compared to vaccine-coverage survey studies. Several previous
studies used telephone surveys to establish vaccine-coverage rates (CDC, 2010a). These
previous survey-designed studies often reported low vaccine-coverage rates for African
Americans.
The PCABC study confirmed some information described in previous literature.
The immunization rates in Arkansas, represented by the PCABC, are lower compared to
those of the United States. This study supported previous research findings that Arkansas
vaccine-coverage rates for Hep B, MMR, OPV/IPV, and VAR were lower than U.S.
national vaccine-coverage rates among adolescents (CDC, 2009b). PCABC vaccinecoverage rates for Td/Tdap were higher than U.S. national vaccine-coverage rates.
Estimates of immunization uptake from the national immunization survey should not be
necessary with the advent of web-enabled immunization registries that facilitate actual
computation of true vaccine coverage. Children in foster care, contrary to prior
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hypotheses, are no less likely to complete immunization requirements than children in
natural-home settings.
African Americans were twice as likely to complete their vaccine series compared
to Caucasians. No intuitive explanation arose for African Americans’ vaccine-coverage
rates from this study. Contributory factors that may explain the African American
coverage rate are outside the scope of this study. It is possible that, as a race, African
Americans were more compliant with school vaccine requirements or were enrolled in
federal vaccine programs compared to members of other races. Therefore, African
Americans are more receptive to childhood vaccination, as evident in the vaccinecoverage uptake of school-entry requirements. Furthermore, shifts in vaccine attitudes
among African Americans and persistent high infant mortality reported in other research
were outside the scope of this study.
The analysis of immunization archival data provided empirical evidence in
establishing vaccine-coverage uptake in this 1990 PCABC. No difference in
immunization uptake emerged for HOR. Foster children had higher immunization rates
before adjustment in a multivariate logistic-regression model. The difference, however,
disappeared after controlling for gender, race, and ethnicity. This study also confirmed an
immunization disparity between the 1990 PCABC and the NIS-Teen from 2006 to 2008.
The U.S. NIS-Teen adjusted vaccine-coverage-uptake rates for FVSE were higher
than the 1990 PCABC adolescent adjusted vaccine-coverage-uptake rates from 2003 to
2008. This study confirmed the persistent problem of low adolescent immunization
reported in previous research (Diekema et al., 2005; Imdad et al., 2013; USDHHS, 1999;
Zhou, Santoli, et al., 2005). Very few studies used archival registry data to establish
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immunization rates among adolescents (LoMurray & Sander, 2011b). This study
addressed this gap in the literature and used archival data to establish vaccine-coverage
rates for PCA.
Several peer-reviewed studies addressed components of immunization in
Arkansas. These components included VPDs, exemptions, policy, state-mandated
immunization laws, regulations, and infant and childhood coverage. However, these
studies did not apply quantitative analysis of immunization-registry data, nor did they
focus on NHA and FCA 1990 PCABC to establish immunization-coverage rates for the
FVSE. The immunization rates reported for adolescents in Arkansas (CDC, 2008a;
Darden et al., 2013; Jain et al., 2009; Stokley et al., 2011) were based on an RDDS of
sample households. In contrast, this cross-sectional study focused on archival registry
deidentified data to establish immunization coverage uptake rates for FVSE among the
1990 PCABC.
This study contributed evidence of increased vaccination among historically lowperforming groups. Such improvements enhance potential future changes in cultural and
social beliefs toward immunization among PCABC and specifically African Americans
and FCAs. Direct social change encourages school nurses to motivate parents to
immunize their children. Community immunization campaigns citing these
improvements among these social groups of people cultivates community trust building
and promotes overall health in the general society.
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Appendix A: Tables
Table A1
School Entry Requirements: Arkansas Adolescent Immunization Rules and Regulations
AIRR Table II, 2008

Vaccine
Diphtheria/Tetanus/ Acellular
Pertussis (DTaP),
Diphtheria/Tetanus/Pertussis

Number of
doses
4

(DTP), Diphtheria/Tetanus (DT
pediatric), or
Tetanus/Diphtheria (Td Adult),
vaccine
Hepatitis B vaccine

Age/school grade

Exemptions

All Grades Kindergarten to Notarized Annual Application for
12th Grade
Medical, Religious, and
Philosophical Exemptions.
Adolescent
13–18 years

3

Kindergarten, seventh
grade, and Transfer
students

Notarized Annual Application for
Medical, Religious, and
Philosophical Exemptions.

Adolescent
13–18 years
Measles vaccine, Mumps
vaccine, Rubella vaccine
(German measles)

2

All Grades
Adolescent

Notarized Annual Application for
Medical, Religious, and
Philosophical Exemptions.

13–18 years
Polio vaccine

Varicella (chickenpox)

3

2

All Grades Kindergarten to Notarized Annual Application for
12th Grade
Medical, Religious, and
Last dose on/ after 4th
birthday

Philosophical Exemptions.

Kindergarten, seventh
grade, and Transfer
students

Notarized Annual Application for
Medical, Religious, and

Adolescent

Philosophical Exemptions.

13–18 years
Note. Adapted from Table II of “Arkansas State Board of Health: Rules and regulations pertaining to
immunization reporting,” by Arkansas Department of Health, 2008, Retrieved from http://www.Healthy
.Arkansas.Gov/Aboutadh/Rulesregs/Immunizationreporting.pdf.
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Table A2
Changes Arkansas Adolescent Immunization Requirements, 1991–2009
Required number of doses
Vaccine
Diphtheria/Tetanus/ Acellular
Pertussis (DTaP),
Diphtheria/Tetanus/Pertussis

1991

2003

2004

2008

2009

4 Doses

3 Doses 3–4 doses

3–4 doses

3 Doses

(DTP), Diphtheria/Tetanus
4 Doses
(DT pediatric), or
Tetanus/Diphtheria (Td Adult)

3 Doses 3–4 doses

3–4 doses

3 doses

Tdap—Adult with Pertussis
(2008)

3 Doses 3–4 doses

3–4 doses

3 doses
7th grade

4 Doses

1 dose on or after 4th
birthday). 1 dose of
Tdap
Polio
OPV—Oral

3 doses

3 doses

3 doses

3 doses

3 doses

1 dose

2 doses

2 doses

2 doses

2 doses

Dose 2 at least 28
days after dose 1

Dose 2 at least 28
days after dose 1

IPV—Inactivated
Rubeola (measles) +MMR
(M, M/R, M/M/R) 2002/2004
Measles 2008 (M, M/R,
M/M/R, MMRV)
MMR (Measles, Mumps, and
Rubella) 2009

Dose 2 at least 28
days after dose 1

Rubella (German measles) (R,
M/R, M/M/R) (R, M/R,
M/M/R, MMRV) 2008

1 dose

1 dose

1 dose

1 dose

N/A

Mumps vaccine. (M, M/M/R)

1 dose

1 dose

1 dose

1 dose

N/A

N/A

3 doses

3 dose

3 doses

3 doses

2 dose alternative
schedule for 11–15yr. olds

2 dose alternative
schedule for 11–15yr. olds

1 or 2 doses

1 or 2 doses

28 days apart

28 days apart

Hepatitis B

Varicella (chickenpox)
(Varicella, MMRV) 2008

1 dose

1 dose

1 or 2
doses

2 doses for 7th grade; 2 doses for 7th grade;
13 yrs. and older or 13 yrs. and older or
Disease History
Disease History
Note. Adapted from “Arkansas State Board of Health: Rules and regulations pertaining to immunization
reporting,” by Arkansas Department of Health, 2008, Retrieved from http://www.Healthy
.Arkansas.Gov/Aboutadh/Rulesregs/Immunizationreporting.pdf.
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Table A3
Significant Arkansas Immunization Laws 1987–2008

Year

Arkansas
legislative
acts

Purpose

1987

Act 141

Mandated proof of measles, rubella, and other diseases immunization prior to
enrolling in Arkansas colleges and universities

1989

Act 387

To achieve and maintain adequate immunization levels for all children in Arkansas.
Children in childcare facilities 90% and Children in public and private schools 95%.

1993

ACT 591 Availability, adequacy, promotion and utilization of immunization programs for
infants and preschool children in Arkansas.

1995

ACT 432 Established a statewide childhood immunization registry in Arkansas.
Immunization registry provides information on childhood immunization status from
birth to age 22 years to parents, guardians and providers.
All providers shall register and report all vaccine administered to children and
adolescents from birth to age 22 years.
Imposed a penalty of $25 dollars enforced to all providers who do not report
administered vaccines to the registry.

1995

ACT 685 Mandated coverage of children’s preventive health care from birth through age 18
years.
Funded immunization services under the Medicaid program.
Eased financial burden and exempts low income, uninsured children from any
copayment, coinsurance, deductible or dollar limit provisions.

1997

ACT 870 Mandated immunization prior to school enrolment and specific required vaccines for
all children.

1997

ACT 871 Required immunization for students in kindergarten through 12th grade attending
Arkansas schools.
Authorized immunization compliance enforcement responsibilities on school boards,
superintendents, and principals, and any school.

2003

ACT 999 Authorized immunization exemptions for: Personal beliefs, religious, and
philosophical, and medical exemptions

Note. Adapted from “Historic acts,” by Arkansas Legislative Branch, 2012, Retrieved from http://www
.arkleg.state.ar.us.
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Table A4
Pulaski County Public School Enrollment and Adolescent 1990 Birth Cohort Census
2001–2008
Education Adolescent cohort Adolescent cohort Pulaski County wide
Percent
Year grade level
age (years)
enrollment
public school enrollment adolescent cohort
2001

5th

11

4,168

52,177

8.0

2002

6th

12

4,134

51,448

8.0

2003

7th

13

4,216

51,967

8.1

2004

8th

14

4,140

52,181

7.9

2005

9th

15

4,797

53,112

9.0

2006

10th

16

4,360

53,487

8.2

2007

11th

17

3,703

53,864

6.9

2008

12th

18

3,123

54,184

5.8

Note. Adapted from “Statewide Information System Reports: Student Status Counts,” by Arkansas
Department of Education, 2011, Retrieved from https://adedata.arkansas.gov/statewide/Students
/StatusCounts.aspx?year=16&search=&pagesize=10.

Table A5
Total Number of Foster Care Adolescents School Attendance 2000–2009

Year

Age in years

Adolescents school
attendance data 2000–2009

2000

10

27

2001

11

42

2002

12

43

2003

13

63

2004

14

90

2005

15

116

2006

16

146

2007

17

135

2008

18

86

2009

19

20

Note. Adapted from Children’s Reporting and Information System, Arkansas Department of Human
Services, 2011b, Retrieved from http://www.arkansas.gov/dhs/chilnfam/Survey%20-%20CHRIS.PDF.
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Table A6
Trends in Pertussis Cases, United States, and Arkansas, 2000–2010
Year

U.S. pertussis cases

Arkansas pertussis cases

2010

27,550

245

2009

16,858

396

2008

13,278

197

2007

10,454

173

2006

15,632

112

2005

25,616

208

2004

25,827

95

2003

11,647

92

2002

9,771

486

2001

7,580

1324

2000

7,867

44

Note. Adapted from “Summary of Notifiable Diseases—United States, 2004,” by Centers for Disease
Control and Prevention, 2006d, Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5353a1
.htm.

Table A7
Pulaski County, Arkansas Public School Enrollment and Adolescent 1990 Birth Cohort
Census 2000–2008

Year

Education grade Adolescent cohort Adolescent cohort Pulaski County wide
Percent (%)
level
age years
enrollment
public school enrollment adolescent cohort

2001

5th

11

4,168

52,177

8.0

2002

6th

12

4,134

51,448

8.0

2003

7th

13

4,216

51,967

8.1

2004

8th

14

4,140

52,181

7.9

2005

9th

15

4,797

53,112

9.0

2006

10th

16

4,360

53,487

8.2

2007

11th

17

3,703

53,864

6.9

2008

12th

18

3,123

54,184

5.8

Note. Adapted from “Statewide Information System Reports: Student Status Counts,” Arkansas Department
of Education, 2012, Retrieved from https://adedata.arkansas.gov/statewide/Students/StatusCounts
.aspx?year.
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Table A8
Vaccine-Preventable-Disease Reported Cases, All Ages, Pulaski County, Arkansas,
1995–2012
1995–1999

2000–2004

Vaccine

Hepatitis B

81

499

78

550

53

365

25

179

Measles

0

2

1

24

0

0

0

0

Mumps

1

24

0

1

6

23

0

0

Pertussis

57

253

413

1613

270

1,179

117

543

Rubella

0

12

1

4

0

0

0

1

Tetanus

0

1

1

3

0

1

1

2

Varicella

0

0

0

0

202

3,466

47

803

Arkansas

Pulaski
County,
Arkansas

2010–2012

Pulaski
County,
Arkansas

Arkansas

Pulaski
County,
Arkansas

2005–2009

Arkansas

Pulaski
County,
Arkansas

Arkansas

Note. Adapted from Arkansas Department of Health, 2014b.

Table A9
Vaccine-Preventable Diseases, By Year of Vaccine Development or Licensure United
States, 1798–1998
Disease

Year licensed

Smallpox

1798

Diphtheria

1923

Pertussis

1926

Tetanus

1927

Poliomyelitis

1955

Measles

1963

Mumps

1967

Rubella

1969

Hepatitis B

1981

Haemophilus influenzae type b

1985

Varicella

1995

Note. Adapted from “Final 2010 Reports of Nationally Notifiable Infectious Diseases,” Centers for Disease
Control and Prevention, 2011a, Morbidity and Mortality Weekly Report, 60, 1088–1101.
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Table A10
Vaccine Codes Arkansas Department of Health, 2005
Vaccine ID code

Type vaccine family

Vaccine name

1; 2; 3; 4; 21; 22; 24;
31;35; 42;43;44

A

DTP; PED DT; DTAP; Td; DTP-ACTHIB; DTP-HBOC; DTPHIB; DTAP/HIB; DTAP/P/HPB; DECAVAC; Tdap; Tetanus

5;6; and 7

B

OPV; EIPV; IPV

8;9;10;11; and 12

C

MMR; M/R; Measles; Rubella; Mumps

13;14;15;16; 23; 32

D

HBOC; PEDVAX-HIB; PROHIBIT; HIB; ACT/OMNI; HEP
B/HIB

17;18;19 and 34

E

HEP B-3dose; PHEPB-3dos; HBIG; HEP B 2 dose

27; 89

I

Varicella; Chicken PO

Note. Adapted from “ Unpublished vaccine codes. Internal Immunization Agency communication
document,” Arkansas Department of Health, 2005.

Table A11
Definitions of Variables

Variable type
Independent

Dependent

Covariates

Variable name

Type of variable /
measurement scale

Adolescent in 1990 cohort

Categorical

FCA

Categorical

NHA

Categorical

Five Vaccines School Entry (FVSE)

Categorical

Immunization rates

Ratio variables

Up-to-date status UTD

Categorical

Diphtheria Tetanus toxoid acellular Pertussis (DTaP
DTP, Tap)

Nominal; Categorical

Hepatitis B (Hep B)

Nominal; Categorical

Measles, Mumps and Rubella (MMR)

Nominal; Categorical

Poliomyelitis

Nominal; Categorical

Varicella

Nominal; Categorical

Gender

Nominal; Categorical

Race

Nominal; Categorical

Ethnicity

Nominal; Categorical

Age

Continuous

Note. Adapted from Pulaski County, Arkansas Birth Cohort, Analysis 2015.
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Appendix B: Calculation Tables
Table B1
Pulaski County, Arkansas Mortality Data, 1990–2008
Diphtheria

Pertussis

Tetanus Hepatitis B Measles

Mumps

Rubella

Poliomyelitis

Varicella

1990

0

0

0

0

0

0

0

0

0

1991

0

0

0

0

0

0

0

0

0

1992

0

0

0

0

0

0

0

0

0

1993

0

0

0

0

0

0

0

0

0

1994

0

0

0

0

0

0

0

0

0

1995

0

0

0

0

0

0

0

0

0

1996

0

0

0

0

0

0

0

0

0

1997

0

0

0

0

0

0

0

0

0

1998

0

0

0

0

0

0

0

0

0

1999

0

0

0

0

0

0

0

0

0

2000

0

0

0

0

0

0

0

0

0

2001

0

0

0

0

0

0

0

0

0

2002

0

0

0

0

0

0

0

0

0

2003

0

0

0

0

0

0

0

0

0

2004

0

0

0

0

0

0

0

0

0

2005

0

0

0

0

0

0

0

0

0

2006

0

0

0

0

0

0

0

0

0

2007

0

0

0

0

0

0

0

0

0

2008

0

0

0

0

0

0

0

0

0

Note. Adapted from Arkansas Department of Health NEDDS Statistics Data, 2015 for PCABC.
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Table B2
Calculations Direct Standardization Vaccination Rates, Age Standardized to 2010 U.S.
Population

Arkansas

Standard
population

United
States

Standard
population

2006
PCABC

2010 census

2006 NIS

2010 census

Age

m

w

Age

m

w

m*w

13

0.846

0.244

0.207

13

0.483

0.244

0.118

14

0.842

0.247

0.208

14

0.571

0.247

0.141

15

0.838

0.252

0.211

15

0.642

0.252

0.162

16

0.836

0.256

0.214

16

0.627

0.256

0.161

sum(m*w)
Arkansas

Standard
population

2007
PCABC

2010 census

Age

m

w

13

0.595

0.244

14

0.842

15
16

Hep B

Age

84.00%

sum(m*w)

58.20%

United
States

Standard
population

2007 NIS

2010 census

Age

m

w

m*w

0.145

13

0.886

0.244

0.217

0.247

0.208

14

0.846

0.247

0.209

0.838

0.252

0.211

15

0.8

0.252

0.202

0.836

0.256

0.214

16

0.756

0.256

0.194

sum(m*w)
MMR

m*w

Arkansas

Standard
population

2006
PCABC

2010 census

m

w

Hep B

m*w

77.90%

sum(m*w)
United
States

Standard
population

2006 NIS

2010 census

Age

m

w

m*w

MMR

m*w

82.10%

13

0.774

0.244

0.189

14

0.87

0.244

0.213

14

0.778

0.247

0.192

15

0.901

0.247

0.223

15

0.778

0.252

0.196

16

0.883

0.252

0.222

16

0.778

0.256

0.199

0.83

0.256

0.213

sum(m*w)

77.70%

sum(m*w)

87.10%
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Table B2
continues
Polio

Age

Arkansas

Standard
population

2006
PCABC

2010 census

m

w

Polio

m*w

Age

United
States

Standard
population

2006 NIS

2010 census

m

w

m*w

13

0.872

0.244

0.213

13

0.244

0.000

14

0.865

0.247

0.214

14

0.247

0.000

15

0.86

0.252

0.217

15

0.252

0.000

16

0.853

0.256

0.219

16

0.256

0.000

sum(m*w)
Varicella

Age

Arkansas

Standard
population

2006
PCABC

2010 census

m

w

sum(m*w)

86.20%
United
States

Standard
population

2006 NIS

2010 census

Age

m

w

m*w

Varicella

m*w

0.00%

13

0.157

0.244

0.038

13

0.895

0.244

0.219

14

0.162

0.247

0.04

14

0.893

0.247

0.221

15

0.172

0.252

0.043

15

0.905

0.252

0.228

16

0.188

0.256

0.048

16

0.883

0.256

0.226

sum(m*w)

17.00%

sum(m*w)

89.40%

Note. Adapted from PCABC 1990 Data Analysis, 2015; MMR = measles-mumps-rubella; PCABC =
Pulaski County, Arkansas, birth cohort; NIS = national immunization.
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Table B3
Calculations Direct Standardization Vaccination Rates, Age Standardized to 2010 U.S.
Population

Age

Arkansas

Standard
population

United
States

Standard
population

2007
PCABC

2010 census

2007
NIS

2010 census

m

w

m

w

m*w

m*w

Age

13

0.846

0.194

0.164

13

0.64

0.194

0.124

14

0.842

0.196

0.165

14

0.704

0.196

0.138

15

0.838

0.2

0.167

15

0.73

0.2

0.146

16

0.836

0.203

0.17

16

0.765

0.203

0.155

17

0.836

0.207

0.173

17

0.773

0.207

0.16

sum(m*w)
Hep B

Age

Arkansas

Standard
population

2007
PCABC

2010 census

m

w

84.00%

sum(m*w)
United
States

Standard
population

2007
NIS

2010 census

Age

m

w

m*w

Hep B

m*w

72.30%

13

0.595

0.194

0.115

13

0.906

0.194

0.176

14

0.842

0.196

0.165

14

0.919

0.196

0.18

15

0.838

0.2

0.167

15

0.863

0.2

0.172

16

0.836

0.203

0.17

16

0.854

0.203

0.174

17

0.67

0.207

0.139

17

0.841

0.207

0.174

sum(m*w)

75.60%

sum(m*w)

87.60%
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Table B3
continues
MMR

Age

Arkansas

Standard
population

2007
PCABC

2010 census

m

w

United
States

Standard
population

2007
NIS

2010 census

Age

m

w

m*w

MMR

m*w

13

0.774

0.194

0.15

13

0.888

0.194

0.172

14

0.778

0.196

0.153

14

0.91

0.196

0.179

15

0.778

0.2

0.155

15

0.872

0.2

0.174

16

0.778

0.203

0.158

16

0.904

0.203

0.184

17

0.778

0.207

0.161

17

0.872

0.207

0.18

sum(m*w)
Polio

Age

Arkansas

Standard
population

2007
PCABC

2010 census

m

w

77.70%

sum(m*w)
Polio

m*w

Age

United
States

Standard
population

2007
NIS

2010 census

m

w

88.90%

m*w

13

0.872

0.194

0.169

13

0.194

0

14

0.865

0.196

0.17

14

0.196

0

15

0.86

0.2

0.172

15

0.2

0

16

0.853

0.203

0.173

16

0.203

0

17

0.853

0.207

0.177

17

0.207

0

sum(m*w)
Varicella

Age

Arkansas

Standard
population

2007
PCABC

2010 census

m

w

86.00%

sum(m*w)
United
States

Standard
population

2007
NIS

2010 census

Age

m

w

Varicella

m*w

0.00%

m*w

13

0.157

0.194

0.03

13

0.926

0.194

0.18

14

0.162

0.196

0.032

14

0.929

0.196

0.182

15

0.172

0.2

0.034

15

0.91

0.2

0.182

16

0.188

0.203

0.038

16

0.885

0.203

0.18

17

0.188

0.207

0.039

17

0.94

0.207

0.195

sum(m*w)

17.40%

sum(m*w)

91.80%

Note. Adapted from PCABC 1990 Data Analysis, 2015; MMR = measles-mumps-rubella; PCABC =
Pulaski County, Arkansas, birth cohort; NIS = national immunization.
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Table B4
Calculations Direct Standardization Vaccination Rates, Age Standardized to 2010 U.S.
Population

Arkansas

Standard
Population

United
States

Standard
Population

2008
PCABC

2010 Census

2008 NIS

2010 Census

Age

m

w

Age

m

w

m*w

13

0.846

0.16

0.135

13

0.641

0.16

0.103

14

0.842

0.162

0.136

14

0.697

0.162

0.113

15

0.838

0.165

0.138

15

0.777

0.165

0.128

16

0.836

0.168

0.14

16

0.748

0.168

0.125

17

0.836

0.171

0.143

17

0.737

0.171

0.126

18

0.831

0.175

0.145

18

0.722

0.175

0.126

sum(m*w)
Arkansas

Standard
Population

2008
PCABC

2010 Census

Age

m

w

13

0.595

0.16

14

0.842

15

m*w

83.80%

sum(m*w)

72.10%

United
States

Standard
Population

2008 NIS

2010 Census

Age

m

w

0.095

13

0.928

0.16

0.148471

0.162

0.136

14

0.931

0.162

0.150686

0.838

0.165

0.138

15

0.896

0.165

0.147696

16

0.836

0.168

0.14

16

0.815

0.168

0.136666

17

0.67

0.171

0.114

17

0.829

0.171

0.141563

18

0.674

0.175

0.118

18

0.879

0.175

0.153706

Hep B

sum(m*w)

Hep B

m*w

74.20%

sum(m*w)

m*w

87.90%
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Table B4
continues
Arkansas

Standard
population

United
States

Standard
population

2008
PCABC

2010 Census

2008 NIS

2010 Census

Age

m

w

Age

m

w

m*w

13

0.774

0.16

0.124

13

0.903

0.16

0.144

14

0.778

0.162

0.126

14

0.918

0.162

0.149

15

0.778

0.165

0.128

15

0.901

0.165

0.149

16

0.778

0.168

0.13

16

0.862

0.168

0.145

17

0.778

0.171

0.133

17

0.881

0.171

0.15

18

0.777

0.175

0.136

18

0.893

0.175

0.156

MMR

sum(m*w)

MMR

m*w

77.70%

sum(m*w)

Arkansas

Standard
Population

2008
PCABC

2010 Census

Age

m

w

13

0.872

0.16

0.14

13

0.16

0

14

0.865

0.162

0.14

14

0.162

0

15

0.86

0.165

0.142

15

0.165

0

16

0.853

0.168

0.143

16

0.168

0

17

0.853

0.171

0.146

17

0.171

0

18

0.674

0.175

0.118

18

0.175

0

Polio

sum(m*w)
Arkansas

Standard
Population

2008
PCABC

2010 Census

Age

m

w

13

0.157

0.16

14

0.162

15

Polio

m*w

Age

United
States

Standard
Population

2008 NIS

2010 Census

m

w

89.30%

82.80%

sum(m*w)

m*w

0.00%

United
States

Standard
Population

2008 NIS

2010 Census

Age

m

w

0.025

13

0.94

0.16

0.15

0.162

0.026

14

0.926

0.162

0.15

0.172

0.165

0.028

15

0.926

0.165

0.153

16

0.188

0.168

0.032

16

0.925

0.168

0.155

17

0.188

0.171

0.032

17

0.92

0.171

0.157

18

0.83

0.175

0.145

18

0.927

0.175

0.162

Varicella

sum(m*w)

Varicella

m*w

28.80%

sum(m*w)

m*w

92.70%

Note. Adapted from PCABC 1990 Data Analysis, 2015; MMR = measles-mumps-rubella; PCABC =
Pulaski County, Arkansas, birth cohort; NIS = national immunization.
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Table B5
Individual Payoff Equation Estimated Payoff values Game Theory Comparison
Individual Equilibrium Equation Edel(p) = −r[ϕs(p)ds + ϕv(p)dv]*
Vaccine

ϕv(p)

ds

dv

p

peff

ϕs(p)

r

Td/Tdap

0.09

0.01692902

0.000001

0.831

0.83071

0.169290169 0.270034843

Pertussis

0.09

0.00846451

0.000001

0.831

0.83071

0.169290169 0.270034843
0.169290169 0.270034843

Tetanus

0.09

0.02200772

0.000001

0.831

0.83071

Hep B

0.09

0.30355509

0.000001

0.674

0.673597 0.326403326 0.01631913

Measles

0.09

0.00044609

0.000001

0.777

0.776953 0.223047223 0.002649007

Mumps

0.09

4.46E−05

0.000001

0.777

0.776953 0.223047223 0.002649007

Rubella

0.09

0.11152361

0.000001

0.777

0.776953 0.223047223 0.002649007

OPV/IPV 0.09

0.00775171

0.000001

0.845

0.844966 0.155034155 0.000297

Varicella

0.24101574

0.000001

0.197

0.196614 0.803385803 0.018456995

0.09

Individual Equilibrium Equation Estimated Payoff Calculations. *
Vaccine

ϕs(p)ds

ϕv(p)dv

[ϕs(p)ds + ϕv(p)dv]

Edel(p)

Cohort

Payoff Deaths

Td/Tdap

0.002866 0.00000009

0.002866006

0.0007739

3371

2.605793755

Pertussis

0.001433 0.00000009

0.001433048

0.000387

3371

1.302937792

Tetanus

0.003726 0.00000009

0.003725781

0.0010061

3371

3.387507333

Hep B

0.099081 0.00000009

0.099081482

0.0016169

3371

5.444181609

Measles

9.95E−05 0.00000009

9.96E−05

2.64E−07

3371

0.000888265

Mumps

9.95E−06 0.00000009

1.00E−05

2.66E−08

3371

8.95E−05

Rubella

0.024875 0.00000009

0.024875122

6.59E−05

3371

0.221866319

OPV/IPV 0.001202 0.00000009

0.001201869

3.57E−07

3371

0.001201868

VAR
0.193629 0.00000009 0.193628715 0.0035738
3371 12.03299894
Note. Td/Tdap = tetanus-diphtheria/tetanus-diphtheria-acellular pertussis; Hep B = hepatitis B; MMR =
measles-mumps-rubella; OPV/IPV = poliomyelitis; VAR = varicella; Pulaski County Arkansas 1990 Birth
Cohort Data Analysis. * All equation parameters are defined in Table B7.
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Table B6
Group Optimum Equation Estimated Payoff Values Game Theory Comparison
Group Optimum Equation C(p) = pdv + r(1 − p)[(ds − dv)ϕs(p) + dv]*
Vaccine

ϕv(p)

ds

dv

P

ϕs(p)

r

Td/Tdap

0.09

0.016929

0.000001

0.831

0.83071 0.16929

0.27

8.31E−07 0.169

Pertussis

0.09

0.008465

0.000001

0.831

0.83071 0.16929

0.27

8.31E−07 0.169

Tetanus

0.09

0.022008

0.000001

0.831

0.83071 0.16929

0.27

8.31E−07 0.169

Hep B

0.09

0.303555

0.000001

0.674

0.6736

0.0163 6.74E−07 0.326

Measles

0.09

0.000446

0.000001

0.777

0.77695 0.22305

0.0027 7.77E−07 0.223

Mumps

0.09

4.46E−05

0.000001

0.777

0.77695 0.22305

0.0027 7.77E−07 0.223

Rubella

0.09

0.111524

0.000001

0.777

0.77695 0.22305

0.0027 7.77E−07 0.223

OPV/IPV

0.09

0.007752

0.000001

0.845

0.84497 0.15503

0.0003 8.45E−07 0.155

VAR

0.09

0.241016

0.000001

0.197

0.19661 0.80339

0.0185 1.97E−07 0.803

peff

0.3264

pdv

1−p

Group Optimum Equation Estimated Payoff Calculations*
Vaccine

r (1−p)

(ds−dv)

(ds−dv)ϕs(p) [(ds−dv)ϕs(p)+dv] pdv+r(1−p)

C(p)

Cohort C(p) Cohort

Td/Tdap

0.045636 0.016928

0.002866

0.0029

0.04564 0.00013

Pertussis

0.045636 0.008464

0.001433

0.0014

0.04564 6.54E−05 3371 0.220315

3371 0.440503

Tetanus

0.045636 0.022007

0.003726

0.0037

0.04564 0.00017

3371 0.572615

Hep B

0.00532 0.303554

0.099081

0.0991

0.00532 0.00053

3371 1.775147

Measles

0.000591 0.000445

9.93E−05

0.0001

0.00059 5.93E−08 3371 0.0002

Mumps

0.000591 4.36E−05

9.73E−06

1E−05

0.00059 6.35E−09 3371 2.14E−05

Rubella

0.000591 0.111523

0.024875

0.0249

0.00059 1.47E−05 3371 0.049561

OPV/IPV

4.60E−05 0.007751

0.001202

0.0012

4.7E−05 5.66E−08 3371 0.00019

VAR

0.014821 0.241015

0.193628

0.1936

0.01482 0.00287

3371 9.663155

Note. Td/Tdap = tetanus-diphtheria/tetanus-diphtheria-acellular pertussis; Hep B = hepatitis B; MMR =
measles-mumps-rubella; OPV/IPV = poliomyelitis; VAR = varicella.
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Table B7
Vaccination Theory of Game Parameters Definition and Calculation
Parameter

Definition

Edel(p)

Individual Payoff

Individual equilibrium

Edel(p) = −r[ϕs(p)ds + ϕv(p)dv]

Group optimum

C(p) = pdv + r(1 − p)[(ds − dv)ϕs(p) + dv]

C(p)

Group optimum Payoff

p

Proportion of individuals preemptively vaccinated
[Number vaccinated before a disease attack]

r

Attack rate of the disease
[Number infected from no vaccine divided by population at risk]

ϕs(p)

Probability an individual delayer becomes infected after an outbreak
[Number unvaccinated divided by number vaccinated]

ds

Probability of death from vaccine preventable disease
[Death among unvaccinated divided by total population at risk]

ϕv(p)

Probability an individual delayer is successfully vaccinated after an outbreak
[Number of vaccinated delayers divided by delayers who received the vaccine]

pdv

Probability of death from vaccine

dv

Probability of death from vaccine defined as vaccine efficacy
[Number of vaccine deaths divided by number vaccinated ]

Note. Pulaski County Arkansas Birth Cohort 1990 Data Analysis.
.
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Appendix C: Immunization Acronyms
Table C1
Immunization Acronyms
Acronym
1990 Birth Cohort
ACIP 4:3:1:3:3:1
AIRR 4:3:2:3:3:2
ACIP
ADH
ADHS
AIL
AIR
AIRD
AIRR
AIRR
ALB
ARKIDS
CDC
CHRIS
DTP
DTaP
EHR
FCA
FVSE
Healthstyles
Hep B
Hib
HOR
IAC
IOM
IPV
IRB
MCV
MMR
NHA
NIS-Teen
NVAC
NVDD
OPV
PCA

Description
Children Born In Pulaski County, Arkansas
4+DTP, 3+Polio, 1+MMR, 3+Hib, 3+Hep B, 1+Varicella
4+DTP, 3+Polio, 2+MMR, 3+Hep B, 2+Varicella Vaccine Dose Series
Advisory Committee on Immunization Practices
Arkansas Department of Health
Arkansas Department of Human Services
Arkansas Immunization Laws
Arkansas Immunization Registry
Arkansas Immunization Registry Database
Arkansas Immunization Rules and Regulations
4:3:2:3:3:2 Vaccine Dose Series
Arkansas Legislative Branch
Medicaid and Supplemental Children’s Insurance
Centers for Disease Control and Prevention
Children’s Reporting and Information System
Diphtheria, Tetanus and Pertussis
Diphtheria toxoid Tetanus toxoid acellular Pertussis
Electronic Health Records
Foster Care Adolescents
Five Vaccines For School Entry
National Healthstyles Survey [CDC focuses on health orientations and practices]
Hepatitis B Vaccine
Haemophilus influenza type b
home of residence
Immunization Action Committee
Institute of Medicine
Inactivated Poliomyelitis Vaccine
Institutional Review Board
Meningococcal Conjugate Vaccine
Measles-Mumps-Rubella Vaccine
Natural Home Adolescents
National Immunization Survey Teen
National Vaccine Advisory Committee
Number of Vaccine Doses Administered and Documented
Oral Poliomyelitis Vaccine
Pulaski County, Arkansas

214
Table C1 continues
PCABC
SAC
Td/Tdap

Pulaski County, AR birth cohort
Scientific Advisory Committee
Diphtheria/Tetanus-Diphtheria-Acellular Pertussis diphtheria/tetanus-diphtheriaacellular pertussis
Tdap
Diphtheria/tetanus-diphtheria-acellular pertussis
TOG
Theory of games
UTD
Up To Date Status
USDHHS
U.S. Department of Health and Human Services
Vaccine Dose Series A1 4:3:1:3:3:1 = 4+DTP, 3+Polio, 1+MMR, 3+Hib, 3+Hep B, 1+Varicella
Vaccine Dose Series A2 4:3:2:3:3:2 = 4+DTP, 3+Polio, 2+MMR, 3+Hep B, 2+Varicella
VAR
Varicella Vaccine
VCU
vaccination uptake
VFC
Vaccine For Children
VGT
vaccination game theory
VIS
Vaccine Information Statements
VPD
Vaccine Preventable Diseases
WHO
World Health Organization
WIC
Special Supplemental Nutrition Program for Women, Infants, and Children

